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1. General introduction 
 
1.1. Central regulation of energy metabolism 
In healthy humans, the amount of energy consumed matches the amount of energy 
expended over a long-term period, even though short-term mismatches in energy 
balance can occur (1). This phenomenon is called energy homeostasis and works to a 
surprisingly precise extend, considering that adult mammals, including humans, 
maintain a relatively stable body weight over long periods of time even when presented 
with unlimited access to food sources. A study conducted in rats demonstrated that an 
extended period of fasting accompanied by body weight loss results in an increase of 
energy intake once animals regain ad libitum access to food. This increase only lasted 
for a limited time though, until rats recovered baseline body weight (2). These data 
demonstrate a highly accurate regulatory system controlling energy homeostasis. 
Already in 1953 a mechanism was proposed that aimed to explain this phenomenon, 
postulating inhibitory signals that are secreted in proportion to fat depots, acting in the 
hypothalamus to reduce energy intake (3). Decades later, this hypothesis turned out to 
be very precise, when the adiposity signal leptin was discovered (4). 
 
1.1.1. Leptin and its role in the development of obesity 
In 1994, a novel adipocyte-derived hormone was discovered by Jeffrey Friedman and 
colleagues (4). It was named leptin (from Greek leptos, meaning ‘thin’) for its 
anorexigenic and catabolic effects observed in mice (5). The absence of leptin results in 
hyperphagia, decreased energy expenditure and severe obesity, as observed in the 
Lepob/ob mouse, which is leptin deficient due to a mutation in the obese gene (4). After 
this discovery, leptin was believed to have great potential as an ‘obesity drug’ for the 
growing obesity problem of our modern society. However, this initial euphoria soon 
abated, after leptin was shown to be secreted by white adipose tissue and to circulate in 
proportion to body fat mass (6). In fact, most obese individuals have elevated leptin 
levels, whereas monogenetic defects as described for Lepob/ob mice are extremely rare 
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in humans, although they result in extreme cases of obesity if present (7). In both 
leptin-deficient humans as well as mice, leptin administration leads to rapid decrease in 
food intake, increase in energy expenditure and weight loss, demonstrating that these 
subjects are highly leptin sensitive (7-10), whereas this does not apply to obese patients 
with elevated serum leptin concentrations (11). This diet-induced obesity (DIO) is 
characterized by hyperleptinemia and leptin resistance, the failure of leptin to mediate 
its catabolic effects. In mice, DIO can be induced by feeding mice a high-fat diet 
(HFD) enriched in saturated fatty acids. These mice become obese and develop 
hypothalamic leptin resistance (12). The molecular cause for hypothalamic leptin 
resistance is still not fully understood. 
The main target tissue for leptin resides in the brain, specifically the mediobasal 
hypothalamus, which forms the regulatory centre of hunger and satiety and plays a key 
role in energy balance regulation (13, 14). Intracerebroventricular (icv) leptin injections 
were shown to decrease food intake and body weight, in both wild-type and leptin-
deficient Lepob/ob mice (15). Leptin crosses the blood-brain-barrier via the short isoform 
of the leptin receptor (LepRa) and enters the brain in proportion to its serum 
concentration (16-18). In the mediobasal hypothalamus, the long form of the leptin 
receptor (LepRb) is expressed particularly in the arcuate nucleus (ARC), ventromedial 
hypothalamus (VMH), dorsomedial hypothalamus (DMH) and lateral hypothalamic 
area (LHA) (19, 20). Of particular interest is the ARC, due to its crucial role in the 
regulation of energy metabolism and other homeostatic systems (21-24). 
Leptin conveys its weight-reducing effects by binding to LepRb, causing a 
conformational change and activating the associated Janus kinase 2 (JAK2), a tyrosine 
kinase. This results in phosphorylation of three intracellular receptor tyrosine residues; 
these are tyrosine 985, tyrosine 1077 and tyrosine 1138 (25, 26). Tyrosine 985 and 
tyrosine 1077 are involved in signal transduction via extracellular-regulated kinase 
(ERK) and Src homology 2-containing tyrosine phosphatase (SHP2) and will not be 
further discussed in this thesis. Phosphorylation of tyrosine 1138, on the other hand, 
leads to recruitment of signal transducer and activator of transcription 3 (STAT3), 
which then gets phosphorylated at its phosphorylation site tyrosine 705 by JAK2. 
Phosphorylated STAT3 (pSTAT3) homodimerises and translocates into the nucleus, 
where it acts as a transcription factor and activates target gene expression (26, 27). 
Among those are effector molecules that cause satiety and increased energy 
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expenditure as well as the suppressor of cytokine signalling 3 (SOCS3). Through 
negative feedback regulation, SOCS3 binds to LepRb and inhibits JAK2 activity, 
making SOCS3 an effective inhibitor of leptin signal transduction via JAK2/STAT3 
signalling (28, 29) (Figure 1). 
Two distinct populations of neurons in the ARC co-express LepRb. These are 
neuropeptide Y/agouti-related peptide (NPY/AgRP)-expressing neurons, which are 
inhibited by leptin (30, 31), as well as pro-opiomelanocortin/cocaine- and 
amphetamine-regulated transcript (POMC/CART)-expressing neurons, which are 
activated by leptin (32-34). Icv injections of NPY as well as AgRP cause hyperphagia, 
decreased energy expenditure and obesity (35-39), identifying both neuropeptides as 
anabolic signals. In contrast, catabolic effects were demonstrated for both α-
melanocyte-stimulating hormone (α-MSH), which is cleaved from the POMC precursor 
molecule, and CART (40-42). These ARC-located neurons are first-order neurons in 
the hypothalamic response to circulating hormones and send projections to other nuclei, 
such as the LHA, paraventricular nucleus (PVN) and perifornical area (PA), which are 
locations of second-order neurons involved in energy metabolism (43, 44). Stimulation 
of LHA and the adjacent PA provokes feeding, whereas PVN stimulation inhibits food 
intake (23, 45).  
In wildtype mice, leptin injections increase pSTAT3 levels, which serve as a marker for 
activated intracellular leptin signal transduction. In mice that are obese due to HFD 
feeding, this response to exogenous leptin is deteriorated, particularly in the ARC (12). 
Impaired leptin transport via the blood-brain-barrier into the brain potentially plays a 
role in the manifestation of leptin resistance. In healthy mice with normal circulating 
leptin levels the transport mechanism via LepRa processes linearly. However, during 
obesity accompanied by hyperleptinemia this system is saturated, suggesting that the 
hypothalamus receives misinformation about the peripheral energy state and integrates 
these signals into an inapt neural response (46, 47). Furthermore, expression of Socs3 
has been shown to be upregulated and lead to impairment of leptin signalling in obese 
mice as well as other rodent models of leptin resistance (28, 48). Notably, Socs3 is a 
target gene of different pro-inflammatory pathways (49). Our laboratory provided 
evidence that chronic low-grade hypothalamic inflammation, which has been 
associated with the development of metabolic disorders (50), plays a crucial role in the 
disruption of normal energy and glucose metabolism and the development of obesity 
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(51, 52). To date, the molecular mechanisms underlying the manifestation of 
hypothalamic leptin resistance and the development of obesity are still not entirely 
understood and have to be further determined.  
 
1.1.2. Insulin and its central control of energy metabolism 
Insulin is a peptide hormone produced by β-cells of the pancreatic islets of Langerhans 
and was the first hormone to be implicated in the control of glucose homeostasis. 
Circulating insulin concentrations are proportional to body fat mass (53). Since its 
discovery in the early 1920s insulin injections in type 1 diabetic patients proved to 
normalise their blood glucose concentrations and eliminate glycosuria. The blood 
glucose-lowering actions of insulin had long been regarded as solely peripheral, even 
though as early as in 1854, the French physiologist Claude Bernard discovered that 
lesions in the base of the fourth ventricle led to glycosuria in rabbits, demonstrating a 
crucial role of the central nervous system (CNS) in glucose homeostasis (54). Since 
then, icv injections of insulin have been shown to lead to body weight loss and reduced 
food intake in both monkeys and rats (55, 56). Additionally, neuron-specific insulin 
receptor knockout mice exhibit increased food intake, body fat, plasma leptin and 
insulin levels as well as mild insulin resistance (57), demonstrating that the brain is a 
key target tissue for insulin to mediate its catabolic and anorexigenic effects on energy 
metabolism. 
Circulating insulin from the periphery passes the blood-brain-barrier and binds to 
insulin receptors (IR) that are expressed throughout the brain and in particular 
abundance in the hypothalamic ARC (58, 59). As described for leptin, insulin acts on 
NPY/AgRP- and POMC/CART-expressing neurons in the ARC (23). Upon insulin 
binding to IR, the intrinsic tyrosine kinase domain of the receptor activates insulin 
receptor substrate (IRS) through phosphorylation at tyrosine residues, which in turn 
activates phosphatidylinositol 3-kinase (PI3K). This leads to downstream 
phosphorylation of AKT (protein kinase B) at its positive phosphorylation sites serine 
473 and threonine 308. AKT is a serine/threonine-specific protein kinase and in turn 
activates multiple insulin-sensitive metabolic pathways and gene expression, thereby 
controlling energy and glucose metabolism (23, 60). The enzyme glycogen synthase 
kinase-3β (GSK-3β) plays a crucial role in this signal transduction. Upon stimulation of 
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the insulin pathway GSK-3β gets phosphorylated at its negative phosphorylation site 
serine 9, thereby being inhibited (61-63). Furthermore, inhibition of GSK-3β has been 
demonstrated to improve glucose homeostasis in glucose-intolerant rodent models (64-
66), presenting GSK-3β as a potential modulator of insulin sensitivity (Figure 1). 
 
1.1.3. The connection of obesity and type 2 diabetes  
During obesity, circulating insulin concentrations are elevated, but insulin is unable to 
mediate its catabolic effects, as already described for leptin. Obesity is regarded as one 
of the major risk factors for the development of type 2 diabetes (67). During early 
stages of type 2 diabetes insulin sensitivity is attenuated. This leads to elevated insulin 
secretion from the pancreas in order to counteract this condition (68). During the 
further manifestation of type 2 diabetes this mechanism loses its ability to compensate 
for the disrupted insulin sensitivity and leads to deteriorated glucose tolerance, 
eventually resulting in the destruction of insulin-producing β-cells in the pancreas and 
insulin deficiency. At this stage, glucose homeostasis is fully disrupted and other 
physiological disorders can develop in the long-term, including nephropathy, 
retinopathy and cardiovascular disorders (69).  
In obese rats icv insulin injections fail to decrease food intake and body weight (56), 
thereby demonstrating a close relationship between obesity and insulin insensitivity and 
providing evidence for the importance of central insulin signalling for normal energy 
homeostasis. Both leptin-deficient Lepob/ob mice as well as leptin resistant subjects 
develop obesity accompanied by glucose intolerance and reduced hypothalamic insulin 
sensitivity (4, 70). Our laboratory and others showed that intact leptin signalling is 
necessary to sensitise insulin signal transduction, through modulation of IRS and 
subsequent activation of PI3K by leptin (71, 72) (Figure 1). These results reveal the 
potential connection between obesity and the related metabolic disorder type 2 
diabetes. 
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Figure 1: Central regulation of energy metabolism via leptin and insulin. Pancreatic insulin 
and adipose tissue-derived leptin cross the blood-brain-barrier and bind to their respective 
receptors in the hypothalamus. Upon binding, leptin leads to activation of the intracellular 
JAK2/STAT3 signalling cascade and the translocation of pSTAT3 homodimers into the nucleus. 
There, they activate the expression of target genes such as SOCS3, which in turn initiates a 
negative feedback loop and thereby decreases leptin action. Binding of insulin to IR leads to 
activation of the intracellular IRS-PI3K-AKT pathway and inhibition of GSK-3β, thereby 
regulating glucose homeostasis. Furthermore, leptin results in the sensitisation of insulin 
signalling by modulation of IRS. Glycogen synthase kinase-3β (GSK-3β), Insulin receptor (IR), 
Insulin receptor substrate (IRS), Janus kinase 2 (JAK2), Leptin receptor (LepRb), 
Phosphatidylinositol 3-kinase (PI3K), Protein kinase B (AKT), Signal transducer and activator of 
transcription 3 (STAT3), Suppressor of cytokine signalling 3 (SOCS3). 
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1.1.4. Adiponectin and its effects on energy metabolism 
The cytokine adiponectin is secreted by adipocytes and has been described to possess 
anti-inflammatory and insulin-sensitizing effects (73, 74). Due to the inversely 
correlated levels of circulating adiponectin and the amount of adipose tissue, a 
causative link between obesity and type 2 diabetes based on adiponectin has been 
proposed (75-77). Qi and colleagues observed rising adiponectin levels in the 
cerebrospinal fluid of mice after intravenous injections (78). Despite these findings, 
whether adiponectin is in fact able to cross the blood-brain-barrier or whether it is also 
expressed in the brain has long been a matter of debate, with some evidence indicating 
central expression of the hormone (79-81).  
Adiponectin has been shown to have very contradictory effects on metabolism, 
depending on its route of application. While peripherally administered adiponectin had 
orexigenic and anabolic effects, central administration revealed anorexigenic and 
catabolic effects on energy metabolism (78, 82, 83). Adiponectin mediates its effects by 
binding to one of the two adiponectin receptors, AdipoR1 and AdipoR2, both of which 
are seven-transmembrane domain receptors. Studies conducted in peripheral tissues 
demonstrated that adiponectin leads to an increase in adenosine monophosphate-
activated protein kinase (AMPK) activity, mainly mediated through the interaction with 
AdiopR1 (83, 84). After adiponectin binds to AdipoR1, the adapter protein 
phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1) is activated, 
leading to phosphorylation of AMPK at the positive phosphorylation site threonine 
172. AMPK monitors the energy status of the cell and phosphorylation at threonine 172 
results in an increase in food intake (85).  
Notably, both AdipoR1 and AdipoR2 were found to be expressed in the hypothalamus 
and are located on NPY/AgRP as well as POMC/CART neurons in the ARC (84, 86, 
87). Furthermore, APPL1 was shown to phosphorylate and activate JAK2 and IRS1-4, 
thereby suggesting a crosstalk between adiponectin and insulin as well as leptin signal 
transduction (73). Most of our knowledge about the effects and the mechanisms 
underlying adiponectin signal transduction derives from peripheral studies. However, 
whether central adiponectin signalling is mediated similarly and how it affects glucose 
and energy metabolism remains to be further determined. 
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1.1.5. WNT/β-catenin signalling pathway 
The WNT pathway is a highly conserved signal transduction pathway that is present in 
species throughout all of animal kingdom, from sponges and worms to insects and 
mammals. It regulates numerous cellular processes, such as stem cell differentiation 
and proliferation and has been well characterized in tumorigenesis and embryogenesis 
(88-90). Much of our early knowledge about the WNT pathway derived from 
developmental studies conducted in the fruit fly Drosophila melanogaster. The term 
WNT is composed of the gene names wg (wingless), characterized in D. melanogaster, 
and int-1 (integration-1), characterized in mice (91, 92). Both described the same 
highly conserved ligand, therefore later named WNT-1.  
As of today, three different WNT pathways have been identified, which are classified 
as either non-canonical or canonical. The non-canonical pathways are β-catenin-
independent. Of those, the WNT/planar cell polarity (PCP) pathway regulates 
cytoskeletal rearrangements as well as cell migration and tissue polarity during 
development (93, 94). The WNT/Ca2+ pathway, on the other hand, regulates 
intracellular Ca2+ concentrations and activates various kinases, such as the protein 
kinase-C (94-96). The canonical, β-catenin-dependent WNT pathway is most 
prominently involved in proliferation, differentiation and cell survival during 
development, whereas aberrant pathway activation is linked to carcinogenesis and the 
pathogenesis of other diseases, such as Alzheimer’s disease (97, 98). In the last decade, 
intriguing evidence was provided, linking the WNT/β-catenin pathway to the 
pathogenesis of type 2 diabetes and other metabolic risk factors. Polymorphisms in the 
genes encoding for T-cell factor-7 (TCF-7) and low-density lipoprotein receptor-related 
protein-6 (LRP-6) were shown to be associated with a higher risk of developing type 2 
diabetes in humans (99-102). 
While both canonical and non-canonical WNT pathways include the G protein-coupled, 
seven-transmembrane domain receptor Frizzled (Fz) (103-105), the co-receptor family 
LRP-5/6 is specific for the canonical, β-catenin-dependent WNT pathway (106-108). In 
mammals, the WNT protein family consists of 19 different WNT ligands (WNTs). The 
WNT pathway involves several regulatory steps for its activation. While in steady-
state, receptors are intracellularly phosphorylated and thereby inhibited. Additionally, 
there are several classes of extracellular antagonists, such as Dickkopf-related protein-1 
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(DKK-1) and secreted Frizzled-related proteins (SFRP). While DKK-1 exclusively 
targets the canonical WNT/β-catenin pathway by binding and blocking LRP-5/6 
receptors (109), members of the SFRP family act on WNT signalling in general by 
binding to WNTs, due to their close sequence homology to the WNT-binding domain 
of Fz receptors (110, 111).  
In the absence of WNT stimulation, which represents the steady-state of the canonical 
WNT/β-catenin pathway, a β-catenin destruction complex lingers in the cytoplasm, 
which contains the pathway’s key regulatory enzyme GSK-3β, casein kinase-1α (CK-
1α), adenomatous polyposis coli (APC), dishevelled (Dsh), as well as the scaffolding 
protein Axin (112-114). Cytoplasmic β-catenin is bound by this destruction complex 
and phosphorylated by GSK-3β, thereby targeting β-catenin for ubiquitination and 
proteasomal degradation (115, 116).  
The WNT/β-catenin pathway is activated when extracellular WNTs bind to Fz 
receptors, leading to heterodimerisation between those and the co-receptor LRP-5/6 and 
resulting in the recruitment of Dsh to the receptor complex. In the next stage, the 
destruction complex is recruited and CK-1α phosphorylates and thereby activates LRP-
5/6 at its phosphorylation site serine 1490 (106). Phosphorylated LRP-5/6 inhibits the 
destruction complex and GSK-3β is targeted for negative phosphorylation at serine 9 
and is thereby inhibited (117). As a consequence of this inhibition, hypophosphorylated 
β-catenin is stabilized and accumulates in the cytoplasm, before it translocates into the 
nucleus. Here, it acts as a co-transcriptional factor by activating the transcription 
factors TCF-7 and lymphoid enhancer factor (LEF). This leads to the transcription of 
WNT target genes, such as Cyclin-D1 and Axin-2 (118) (Figure 2). 
Recently, we provided strong evidence suggesting that hypothalamic WNT signalling is 
involved in the neuroendocrine control of energy metabolism in genetically obese and 
diabetic Lepob/ob mice (119, 120). Other studies further supported the role of the WNT 
pathway in energy homeostasis as well as an implication of WNT and leptin signalling 
in peripheral tissues (121-123). Furthermore, hypothalamic WNT signalling was shown 
to play a crucial role in adult neurogenesis as well as the cellular and structural 
remodelling of the hypothalamus (124, 125). Interestingly, alterations in the central 
WNT signal transduction seem to be at least partially regulated by photoperiod in 
photoperiod-responsive rats, suggesting an important role of the WNT pathway in the 
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control of seasonal biology in rats (125-127). However, whether this also applies to 
other seasonal species and whether hypothalamic WNT signalling is regulated by 
temporal rhythms remains to be determined. 
 
 
 
Figure 2: WNT/β-catenin signalling pathway in the presence of WNT ligands. Upon binding of 
WNT ligands to their receptors Frizzled and LRP-5/6, CK-1 phosphorylates LRP-5/6, which in 
turn results in the inhibition of GSK-3β. As a result, β-catenin is stabilized and translocates into 
the nucleus, where it activates the transcription factors TCF-7 and LEF, leading to the 
expression of WNT target genes such as Axin-2 and Cyclin-D1. Adenomatous polyposis coli 
(APC), Casein kinase 1 (CK-1), Dishevelled (Dsh), Glycogen synthase kinase-3β (GSK-3β), 
Lymphoid enhancer factor (LEF), Low-density lipoprotein receptor-related protein 5/6 (LRP-
5/6), T-cell factor 7 (TCF-7). 
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1.2. Biological rhythms in life on Earth 
All living organisms are exposed to ever-changing environmental conditions. Daily 
rotations of the earth around its axis generate distinct differences in the amount of light, 
temperature, humidity and various other environmental factors between day and night. 
The annual orbit of the earth around the sun results in the origin of seasons, due to 
Earth’s axial tilt relative to its ecliptic plane. This leads to seasonal periodicity of day 
length (photoperiod), the intensity of light, weather conditions, temperature and food 
availability. In temperate and polar climate zones, these changes are specifically 
pronounced. Warm summers accompanied by a long photoperiod and plenty of food 
alternate with cold winters accompanied by a short photoperiod and limited food 
supplies. To survive in these varying conditions, organisms must be able to anticipate 
these changes and optimize their metabolism and behaviour accordingly. Animals have 
evolved to be either diurnal or nocturnal, depending on factors such as their source of 
food and the presence of predators. Seasonal adaptations involve numerous 
behavioural, morphological and physiological modifications, including, amongst other 
things, reproduction, energy metabolism, body weight and pelage. To ensure these 
adaptations are accomplished in time, animals need a reliable environmental cue that 
notifies them of upcoming seasonal changes. While temperature and weather conditions 
can be rather variable, the photoperiod is always precise and is therefore used by a large 
variety of organisms to predict environmental changes. However, these daily and 
seasonal phenotypic oscillations are not merely passive responses to environmental 
changes. Instead, they are generated endogenously. The mechanisms that underlie both 
adaptive systems are closely interlinked and will be discussed in the next chapters.  
 
1.2.1. Circadian rhythmicity 
The notion of an internal timekeeping system that runs independent from external cues 
was first documented in the early 18th century, when French astronomer Jean-Jacques 
d’Ortous de Mairan observed the daily rhythm of leave movement of a Mimosa plant. 
De Mairan reported that the rhythmic opening and closing of the plant’s leaves 
persisted even in constant darkness (128). About a century later, the French-Swiss 
botanist Alphonse de Candolle repeated de Mairan’s experiment and recorded that 
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while in constant darkness, the rhythmic opening of leaves occurred not every 24 hours, 
but one hour earlier each day (129). This observation sparked further research in the 
field of chronobiology and eventually led to the introduction of the term circadian 
(derived from the Latin circa diem, meaning ‘about a day’), referring to endogenously 
generated rhythms of approximately 24-hour cycles (130). Today we know that all 
organisms depict circadian rhythms in physiology and behaviour, from simple 
cyanobacteria to mammals (131). Without external entrainment, the free-running period 
of circadian rhythms deviates slightly from 24 hours. Generally, in nocturnal animals it 
is slightly shorter than 24 hours, whereas diurnal animals show a slightly longer free-
running period.  
 
1.2.1.1. The suprachiasmatic nuclei as the master circadian clock 
In 1972, two independent research groups found evidence that the master pacemaker of 
circadian rhythms in mammals is located in the anterior hypothalamus, directly above 
the optic tract. Lesions in this brain region, later named the suprachiasmatic nucleus 
(SCN), resulted in the complete loss of circadian rhythms (132, 133). The SCN was 
fully verified as the central master pacemaker by an elegant study performed in 1990 in 
hamsters. Wildtype hamsters were SCN-lesioned and received SCN transplants from 
hamsters with a clock gene mutation, which displayed circadian rhythms with a shorter 
free-running period than wildtypes. Intriguingly, wildtype hamsters with mutant SCN 
transplants now displayed the same shortened free-running period, confirming that the 
SCN dictates peripheral circadian rhythms (134).  
As the central circadian clock, the SCN controls various local clocks, both in other 
brain areas and the periphery (135-137). To distinguish between those two different 
clock systems, the term 'peripheral clocks' was introduced for the latter, in opposition to 
the central clock. Interestingly, local outputs from peripheral clocks remain rhythmic 
even without a functional input from the SCN. However, all these peripheral circadian 
rhythms then desynchronize from each other (138-143), suggesting that the main role 
of the SCN is to align peripheral clocks and ensure a smooth coordination between an 
organism’s physiology and behaviour. 
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Circadian clocks feature three basic components: 1) they are endogenously generating 
circadian rhythms that have a free-running period of approximately 24 hours, meaning 
that they persist under constant conditions; 2) they receive input signals and are 
entrainable by these external cues, called Zeitgebers, of which light is the primary 
entrainment signal (144, 145); and 3) they generate output signals that mediate 
physiological and behavioural rhythms, which display a 24-hour oscillation (146).  
 
1.2.1.2. Molecular clockwork of biological clocks 
On a molecular level, the mechanism of the circadian clock is driven by a cell-
autonomous rhythmic transcriptional-translational feedback loop that is present in 
virtually all cells. The first clock gene was discovered in 1971 in Drosophila and 
named Period (147). Since then, the clock gene machinery has been largely unravelled. 
Joseph Takahashi and colleagues identified the first mammalian clock gene responsible 
for circadian rhythms in behaviour in 1994 and named it circadian locomotor output 
cycles kaput (Clock) (148). The positive arm of the mammalian feedback loop consists 
of the proteins CLOCK and brain and muscle ARNT-like protein 1 (BMAL-1) (135), 
which heterodimerise and bind to E-box regions in promotors of the clock genes Period 
(Per1 – 3) and Cryptochrome (Cry1/2), thereby inducing their transcription (149, 150). 
The protein products PER and CRY represent the negative arm of the feedback loop. 
PER/CRY heterodimers translocate into the nucleus and inhibit the activity of 
CLOCK/BMAL-1 heterodimers, thereby inhibiting their own transcription (151). PER 
and CRY are post-translationally targeted for degradation by casein kinases (CK-1ε/δ) 
and GSK-3β (151-153). The degradation of PER and CRY subsequently leads to the 
initiation of a new cycle. This feedback loop takes roughly 24 hours to completion, 
thereby defining the near-24-hour period of circadian rhythms. Additionally, 
CLOCK/BMAL-1 initiates transcription of Rev-erbα (reverse erythoblastoma) and 
Rorα/β (retinoid orphan receptor) nuclear receptors. Their protein products in turn 
either inhibit (REV-ERBα) or activate (RORα/β) Bmal-1 transcription (Figure 3).  
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Figure 3: Cell-autonomous regulation of the circadian clock in mammals. The central 
circadian clock, which resides in the SCN of the hypothalamus, receives light input via the RHT 
and synchronises peripheral circadian clocks that are present in virtually all tissues. On the 
molecular level, the transcription factors CLOCK and BMAL-1 activate gene expression of Per, 
Cry, Rev-erbα and Rorα/β as well as a variety of other target genes that are clock outputs. 
PER/CRY heterodimers in turn inhibit the transcriptional activity of CLOCK/BMAL-1, thereby 
preventing their own transcription. Additionally, Bmal-1 expression is initiated by RORα/β, but 
repressed by REV-ERBα. In the cytoplasm, CK-1 and GSK-3β target PER and CRY for 
degradation, thereby initiating the start of a new transcriptional-translational cycle. Brain and 
muscle ARNT-like protein 1 (BMAL-1), Casein kinase 1 (CK-1), Circadian locomotor output 
cycles kaput (CLOCK), Cryptochrome (CRY), Glycogen synthase kinase 3β (GSK-3β), Period 
(PER), Retinohypothalamic tract (RHT), Reverse erythoblastoma (REV-ERBα), Retinoid orphan 
receptor (RORα/β), Suprachiasmatic nucleus (SCN).  
 
 
1.2.1.3. Entrainment signals in circadian clocks 
The SCN receives light input directly from melanopsin-containing ganglion cells in the 
retina of the eyes via the retinohypothalamic tract (RHT) and ultimately synchronises 
peripheral clocks via circulating humoral factors and autonomic innervation (154-157). 
Apart from light, other external cues have been proposed to be able to entrain circadian 
clocks, such as social interactions, exercise and feeding patterns. Interestingly, HFD 
consumption leads to a disruption of circadian rhythms in the liver and in eating 
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behaviour of mice after just one week. However, at this point neither the central 
circadian clock in the SCN nor other peripheral clocks were compromised (158), 
showing that not only the time of food intake, but also the diet composition affects 
circadian clocks. Furthermore, these results demonstrated that not all circadian clocks 
are affected by the same external factors to the same extent and that the brain areas 
mediating the disruptions in eating behaviour caused by HFD must be located 
downstream of the SCN. Food intake had already been identified as a powerful SCN-
independent entrainment signal for circadian rhythms more than 40 years ago (159, 
160). More recently, the existence of a food-entrainable oscillator involving 
AgRP/NPY neurons in the hypothalamus has been proposed (161). Notably, as 
discussed in chapter 1.1.1, AgRP/NPY neurons play an important role in the leptin-
mediated control of body weight and metabolism.  
 
1.2.1.4. Circadian clock and metabolism 
Over the last 15 years, a close link of the circadian clock and metabolism has been 
demonstrated in numerous studies (162-167). In mice, SCN lesions as well as various 
clock gene mutations were shown to cause metabolic disorders, including obesity, 
hyperlipidaemia, hyperglycaemia and an impairment of glucose homeostasis and 
insulin signalling (163, 168-171). The research group of Joseph Takahashi discovered 
that a missense mutation in the murine Clock gene results in the loss of rhythmic 
expression of metabolic genes in liver, pancreas and muscle as well as a disruption of 
glucose and lipid homeostasis, ultimately leading to the development of obesity (170, 
171). Similar metabolic syndrome phenotypes occur after mutations in other clock 
genes, such as Bmal-1 and Per2 (164, 172-176). In humans, circadian disruptions such 
as continuous shift-work and social jet lag have been shown to result in symptoms of 
the metabolic syndrome. These include impaired glucose tolerance, serving as an 
indicator for prediabetes, as well as decreased insulin sensitivity, increased body mass 
index (BMI) and increased mean arterial blood pressure, indicating cardiovascular 
complications (177, 178). Results from our laboratory and from others demonstrate that 
chronic circadian misalignment, evoked by continuous exposure to jet lags, causes 
reduced hypothalamic leptin sensitivity and elevated body weight in mice [(179) and 
our own unpublished observations]. This offers a potential explanation for the 
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prominent correlation between circadian misalignment and obesity as observed in 
humans (177). While circadian misalignment was shown to cause metabolic 
dysfunctions in both rodents and humans, HFD feeding was in return shown to disrupt 
behavioural and molecular circadian rhythms. Consumption of HFD leads to 
arrhythmic feeding patterns, locomotor activity and expression of circadian clock genes 
(158, 180, 181). As mentioned above, AgRP/NPY-expressing neurons in the 
hypothalamus were shown to play an important role as a component of a food-
entrainable oscillator (161). These neurons express leptin receptors and are crucial for 
the maintenance of metabolism and body weight. Interestingly, ARC-targeted ablation 
of leptin-sensitive neurons in rats leads not only to the development of obesity, but also 
to an attenuation of feeding rhythms. Ablation of leptin-sensitive neurons in other 
nuclei of the hypothalamus, on the other hand, did not cause arrhythmic feeding (182). 
This suggests a unique involvement of the ARC in generating feeding rhythms over 
other hypothalamic areas involved in metabolic control. Whether leptin signal 
transduction in the ARC is controlled by a circadian rhythm and how HFD feeding 
interferes with central leptin sensitivity at different times throughout the day has not 
been investigated to date.  
 
1.2.2. Time-restricted food intake has beneficial effects on metabolic health 
Time-restricted feeding (TRF) is a new diet strategy with apparent efficacy in 
promoting weight loss and preventing metabolic diseases in both fruit flies and rodents 
(183, 184). In many organisms, including bacteria, yeast, nematodes, fruit flies and 
mice, temporary caloric restrictions lead to an extension of lifespan (185). TRF limits 
energy intake to certain times each day, followed by an extended period of food 
deprivation. This feeding regimen has been shown to attenuate peripheral inflammation 
by reducing circulating levels of pro-inflammatory cytokines in mice (185, 186). Two 
recent studies suggested that the beneficial effects of TRF on health seem to depend on 
the time of food access throughout the day. Time-restricted access to HFD exclusively 
during the inactive phase of mice (light phase) leads to increased body weight 
compared with mice that have access to HFD exclusively during their active phase 
(dark phase), even though both groups have the same overall caloric intake (181). In 
line with these results, access to HFD exclusively during their active phase prevents 
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mice from developing symptoms of metabolic disease, such as obesity, 
hyperinsulinemia, glucose intolerance and inflammation compared with mice with ad 
libitum access to HFD, while both groups consume a similar amount of calories (184). 
In humans, restriction of food intake to a maximum of 12 hours per day leads to weight 
loss in overweight individuals (187). Notably, in this study food access was only 
restricted to a certain amount of time each day, but not strictly to the participants’ 
active (light) phase. Additionally, while body weight was monitored during this study, 
caloric intake was not and the observed weight loss might be due to reduced caloric 
intake instead of a sole effect of circadian timing of food intake. The importance of 
circadian timing of TRF has so far mainly distinguished between the active and inactive 
phase in rodent studies. To what extent beneficial effects of TRF on metabolic health 
depend on circadian timing and during which specific periods throughout the 24-hour 
cycle TRF can reverse detrimental effects of HFD remains to be examined further.   
 
1.2.3. Seasonal rhythmicity 
Many organisms use the annual progression of day length as a cue to anticipate 
upcoming seasonal changes in environmental factors. This ability to adapt their 
phenotype accordingly is called photoperiodism and has first been described in 
conjunction with the seasonal flowering of tobacco plants and was since discovered in a 
wide variety of species (188). Not all animals are influenced by photoperiod to the 
same extent. Therefore, only species whose phenotype significantly depends on the 
photoperiod are considered as photoperiodic, or seasonal. In humans, mice and rats, for 
instance, reproduction and other physiological processes are less dictated by seasons 
and therefore those are not considered as photoperiodic species. In animals such as 
sheep and Djungarian hamsters, on the other hand, reproduction is highly seasonal.  
 
1.2.3.1. Seasonal encoding via circadian oscillation 
Melatonin is a crucial hormone for the regulation of circadian rhythmicity of sleep and 
wakefulness and other physiological functions (189). It is produced exclusively during 
the dark phase by the pineal gland and its secretion is controlled by a neural pathway 
originating from the SCN (190). At night, the SCN stimulates norepinephrine release in 
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the pineal gland, resulting in increased activity of the melatonin synthesis enzyme 
arylalkylamine N-acetyltransferase (AANAT) (191, 192). The duration of melatonin 
production during night-time is dependent on the photoperiod, with gradually 
prolonged production from summer to winter and shortening production from winter to 
summer. This led to the assumption that changes in photoperiod are mediated through 
the circadian oscillation of melatonin production (192-194). Furthermore, the electrical 
activity pattern of the SCN is compressed during short day photoperiod (resembles 
winter) and extended during long day photoperiod (resembles summer), resulting in 
changes in the duration of behavioural activity and other physiological processes 
between those photoperiods (195, 196).  
 
1.2.3.2. Seasonal adaptation of Phodopus sungorus 
Seasonal mammals have developed different adaptive mechanisms to survive in a 
seasonally changing environment. Winter-specific strategies include accumulation of 
large fat deposits or hibernation, methods that are mainly used by larger mammals. 
Small mammals, on the other hand, decrease their body weight in order to reduce their 
energy requirements (197). Since a reduction in body mass leads to a relatively larger 
surface area and increased heat loss (198), this strategy has to be accompanied by other 
morphological and physiological adaptations. The Djungarian hamster, Phodopus 
sungorus, is a powerful model organism to study seasonal adaptations in mammals. 
Originating from the steppes of Siberia and the region of Djungaria, this small rodent 
reduces its body weight by up to 40% during winter. This reduction of body mass is 
mainly due to a loss of white adipose tissue (199-201). During winter, male hamsters 
undergo testicular regression and become infertile. To compensate for the loss of body 
mass and thereby the increased heat loss, hamsters grow a more thermally insulated 
winter pelage, which turns white compared with their grey-tinged summer pelage and 
thereby also improves their camouflage (202, 203). Additionally, the cold tolerance of 
winter-adapted hamsters is improved due to nonshivering thermogenesis in brown 
adipose tissue (203). The annual cycle of body weight is accompanied by a seasonal, 
reversible switch in hypothalamic leptin sensitivity. Under laboratory conditions, the 
summer-like photoperiod is mimicked by an exposure to 16 hours of light and 8 hours 
of dark (long day, LD), whereas the winter-like photoperiod is mimicked by an 
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exposure to 8 hours of light and 16 hours of dark (short day, SD). During LD, hamsters 
have high circulating concentrations of leptin, but are resistant to the central effects of 
the hormone, whereas they have lower circulating concentrations and are highly leptin 
sensitive during SD (201, 204, 205). The expression of Socs-3 in the ARC of hamsters 
seems to play a crucial role in this cyclic leptin sensitivity (48, 206). After a switch 
from LD to SD, Socs-3 gene expression decreases promptly, long before the amount of 
white adipose tissue and circulating concentrations of leptin change (48). This leads to 
an increase in leptin sensitivity during SD and due to the yet high leptin levels results in 
the mediation of anorexigenic and catabolic effects.   
20 
 
1.3. Aims and objectives 
Development of hypothalamic leptin resistance is a key event in the manifestation of 
obesity and related metabolic diseases, such as type 2 diabetes. Over the last decades, 
significant process has been made in uncovering the neuroendocrine mechanisms that 
link these metabolic disorders. However, the environmental incitements of our modern 
age that trigger the disruption of molecular mechanisms underlying leptin resistance are 
still not entirely understood. The aim of this doctoral research study was to gain new 
insights into regulatory processes that lead to the development of leptin resistance and 
the disruption of energy metabolism. In this regard, the main objectives were to 
determine: 
 
1. Whether other adipocyte-derived hormones, beside leptin, are involved in the 
neuroendocrine control of energy metabolism.  
 
2. Whether WNT signalling is involved in the neuroendocrine control of energy 
metabolism in the seasonal rodent Phodopus sungorus.  
 
3. Whether hypothalamic leptin signalling and whole body metabolism are 
modulated by a 24-hour rhythm. 
 
4. How DIO interferes with hypothalamic leptin signalling and whole body 
metabolism throughout the course of the day. 
 
5. Whether TRF can reverse the detrimental effects of DIO on metabolic health. 
 
1. To examine whether other adipocyte-derived hormones, beside leptin, are 
involved in the neuroendocrine control of energy metabolism, the adipokine 
adiponectin was investigated. Therefore, its hypothalamic expression profile was 
examined and the effects of central adiponectin on glucose homeostasis as well as its 
implication in other neuroendocrine signalling pathways in lean wildtype and obese 
mice were analysed (207).  
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2. To determine whether WNT signalling is involved in the neuroendocrine 
control of energy metabolism in the seasonal rodent Phodopus sungorus, the 
hypothalamic expression profile of WNT pathway-related genes was examined at 
specific times throughout the 24-hour cycle in adult LD and SD acclimated hamsters. 
Next, the effect of leptin on hypothalamic WNT pathway activation was analysed 
(208). 
3. To determine whether hypothalamic leptin signalling and whole body 
metabolism are modulated by a 24-hour rhythm, the activation of the leptin signal 
transduction marker STAT3 was analysed every 3 hours throughout the 24-hour cycle 
in wildtype mice. Furthermore, circulating metabolic markers were examined at these 
time points.  
4. To investigate how DIO interferes with hypothalamic leptin signalling and 
whole body metabolism throughout the course of the 24-hour cycle, the same markers 
as described above were analysed every 3 hours throughout the day in DIO mice that 
received HFD. 
5. To determine whether TRF has beneficial effects on metabolic health and can 
reverse the detrimental impairment of normal energy metabolism caused by DIO, mice 
received ad libitum access to low-fat diet (LFD) or HFD (control groups) or time-
restricted access to HFD during different 6-hour periods throughout the 24-hour cycle. 
Metabolic measurements of energy metabolism and behaviour were examined and 
circulating metabolic markers were analysed. 
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2. General methods 
 
2.1. Animals 
All experimental protocols involving animals were performed in accordance with the 
German animal ethics legislation or the New Zealand Animal Welfare Act and 
associated guidelines, as appropriate, and received approval by the respective 
authorities for animal ethics.  
 
2.1.1. Djungarian hamsters, Phodopus sungorus 
Adult female Djungarian hamsters were used for the experiments described in chapter 
4.2. Hamsters were bred within the Department of Biology at the Philipps University of 
Marburg in Germany and were randomised and housed individually at an ambient 
temperature of 21 ± 1˚C with ad libitum access to a hamster-specific standard chow diet 
and water. Hamsters were maintained either under LD (16:8 hours light/dark cycle) or 
SD (8:16 hours light/dark cycle) conditions for eight weeks prior to experiments to 
ensure full adaptation to the respective photoperiods.  
 
2.1.2. Mice 
For experiments described in chapter 4.1, adult male C57BL/6J wild-type (Lep+/+) and 
leptin-deficient Lepob/ob mice were purchased from Janvier (France). They were 
randomised and housed individually under a 12:12 hours light/dark cycle at an ambient 
temperature of 22 ± 1˚C with ad libitum access to food and water. Mice received either 
LFD with 10% energy from fat (kcal), moderate HFD (mHFD) with 45% energy from 
fat (kcal) or HFD with 60% energy from fat (kcal). 
Adult male C57BL/6J mice bred at the University of Otago Taieri Resource Unit were 
used for experiments described in chapter 4.3. Animals were randomised and housed 
individually under a 12:12 hours light/dark cycle at an ambient temperature of 22 ± 1˚C 
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with ad libitum access to food and water, aside from mice that received time-restricted 
access to food during the TRF regimen, as described in chapter 4.3. The time periods 
for TRF were based on our findings about the circadian rhythmicity of leptin sensitivity 
in lean and DIO mice, as presented in chapter 4.3. Four groups received access to HFD 
for 6 hours per day, each group during a different period. Thereby, one group had 
access to food solely during the light (inactive) phase from Zeitgeber time (ZT) 3 – 
ZT9, one group solely during the dark (active) phase from ZT15 – ZT21 and two 
groups each during equal times of light and dark (both inactive and active) phase. In 
those activity-independent groups, mice received HFD either during their relative leptin 
sensitive phase from ZT9 – ZT15 or their relative leptin resistant phase from ZT21 – 
ZT3. Mice received either LFD with 10% energy from fat (kcal) or HFD with 60% 
energy from fat (kcal).  
 
 
2.2. Immunohistochemistry 
2.2.1. Collection of brain tissue for immunohistochemistry 
Treatment of animals prior to transcardial perfusions is described in the respective 
subchapters in chapter 4. Animals were deeply anaesthetised with an overdosed 
intraperitoneal (ip) injection of sodium pentobarbital (200 mg/kg body weight) with 
heparin to prevent blood clotting. Upon confirmation of deep anaesthesia by testing the 
pedal withdrawal reflex animals were transcardially perfused. Therefore, the chest 
cavity was opened, a needle was inserted into the left ventricle of the heart and the right 
atrium was cut open. Animals were perfused with saline, followed by perfusion with 
~20 mL of 4% paraformaldehyde in 0.1 M phosphate buffer (PFA; pH 7.5). Brains 
were dissected and post-fixed in 4% PFA for 4 hours, followed by 48 hours storage in 
30% sucrose solution in 0.1 M phosphate buffer at 4˚C for osmotic dehydration of 
brains. Brains were then rapidly frozen in 2-methylbutane at -40˚C and stored at -80˚C. 
Coronal brain sections (30 μm) were collected throughout the extent of the ARC, 
spanning the hypothalamic region from approximately -2.7 to -0.8 mm relative to 
Bregma according to the atlas of the mouse brain (209). Sections were stored in 
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cryoprotectant (30% sucrose, 30% ethylene glycol, 1% polyvinylpyrrolidone, in 0.2 M 
phosphate-buffered saline) at -20˚C.  
 
2.2.2. Antigen retrieval immunohistochemistry 
Antigen retrieval steps were performed to break aldehyde bonds between proteins that 
were formed in the fixation process during perfusion. This increases immunoreactivity 
of the brain tissue. Unless stated otherwise, all reagents were diluted in 0.1 M Tris-
buffered saline (TBS) and incubation steps were performed at room temperature. 
Free-floating brain sections were rinsed three times in 0.1 M TBS to remove 
cryoprotectant. This step was carried out between all subsequent incubations. For 
antigen retrieval and blocking of endogenous peroxidase activity, sections were treated 
with 10% methanol, 1% sodium hydroxide and 1% hydrogen peroxide in water for 20 
minutes, followed by incubation in 0.3% glycine for 10 minutes as well as 0.03% 
sodium dodecyl sulphate for 10 minutes. Next, brain sections were incubated for 1 hour 
in blocking solution consisting of 1% normal goat serum and 5% bovine serum albumin 
in TBS with 0.5% Triton-X (TBS-TX) to prevent non-specific binding of the antibody 
to tissue, followed by incubation in the respective primary antibody (diluted in blocking 
solution) for 16 hours at 4˚C. Triton-X is used to increase cell membrane permeability 
and improve the penetration of the primary antibody into the cytoplasm. On the next 
day, sections were incubated for 1 hour with the biotinylated secondary antibody 
(diluted in blocking solution), which was targeted against the primary antibody host 
species. This was followed by 1 hour of incubation in avidin-biotin complex solution. 
Finally, the signal was developed with diaminobenzidine solution, giving a grey 
precipitate. Stained brain sections were mounted onto gelatinised object slides and 
dehydrated in a series of ethanol solutions of increasing concentrations (50% - 100% 
ethanol), followed by a final wash in xylene. Sections were then coverslipped, using 
DPX mounting medium. 
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2.3. Analysis of hypothalamic gene expression 
2.3.1. Collection of brain tissue for in situ hybridization 
Treatment of animals prior to tissue collection is described in the respective 
subchapters in chapter 4. For in situ hybridization, animals were decapitated and brains 
were rapidly frozen on dry ice. Coronal brain sections (16 μm) were collected 
throughout the extent of the ARC, spanning the hypothalamic region from 
approximately -2.7 to -0.8 mm relative to Bregma according to the atlas of the mouse 
brain (209). Sections were mounted onto object slides and stored at -80˚C.  
 
2.3.2. Preparation of riboprobes 
To create riboprobes specific for the genes of interest, the hypothalamus of a hamster or 
mouse, respectively, was homogenised and ribonucleic acid (RNA) was extracted. 
Using reverse transcriptase, an enzyme functioning as a RNA-dependent 
deoxyribonucleic acid (DNA) polymerase, hypothalamic RNA was transcribed into 
complementary DNA (cDNA). In the next step, polymerase chain reaction (PCR) was 
performed to amplify cDNA fragments of interest. Therefore, specific primers were 
used, resulting in the amplification of specific genes sections. The primers used for 
each study are listed in the respective subchapters in chapter 4. Amplified cDNA 
fragments were purified and extracted with an agarose gel and via ligation into 
pGEM®-T Easy vector (Promega Corp.) and subsequent transformation into competent 
DH5-α Escherichia coli cells, cDNA was replicated to a great extent. The replicated 
DNA of interest was separated from the cells’ own structures by minipreparation, 
followed by sequencing and linearization of the plasmid DNA. To create radioactive 
RNA that is able to bind to its complementary messenger RNA (mRNA) in tissue, the 
generated cDNA was used as a template and in vitro transcription was performed, using 
a DNA-dependent RNA polymerase. This polymerase synthesises RNA with provided 
ribonucleoside triphosphates, including (35S)-radiolabelled uracil triphosphates.  
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2.3.3. In situ hybridization 
Brain sections were fixed in 4% PFA for 20 minutes followed by acetylation in 0.1 M 
triethanolamine and acetic anhydride in order to block non-specific binding sites. Next, 
sections were dehydrated in a series of ethanol solutions of increasing concentrations. 
This was followed by a 16-hour hybridization reaction at 58˚C. Therefore, object slides 
were covered with a hybridization solution containing radiolabelled riboprobes. On the 
next day, sections were treated with ribonuclease A, leading to the degradation of 
unbound radiolabelled RNA fragments and preventing false positive detection of 
tissue-specific mRNA. Subsequently, brain sections were desalted, dehydrated and 
exposed to an X-ray film sensitive to decay emissions, giving a black precipitation on 
the radiograph.  
 
 
2.4. Respirometry 
Metabolic measurements were performed using a multichannel respirometry system 
(Promethion, Sable Systems International), allowing synchronised monitoring of 
energy metabolism and behaviour. The Promethion system used in this study is an 
open-flow multiplexed system, with up to eight cages sharing one gas analyser. This 
allows the gas analyser to take brief metabolic measurements of the animal in each cage 
at intervals of a few minutes. To accurately determine the effect each animal has on air 
analysed from its cage relative to background air around the cage, continuous baseline 
measurements of the surrounding air are required (210). Energy expenditure was 
determined by indirect calorimetry, a method by which oxygen consumption and 
carbon dioxide production are synchronously measured, thereby accurately evaluating 
an endothermic animal’s metabolic rate. The air flow rate was adjusted to 
2000 mL/min, guaranteeing complete air exchange of 15 times per hour in compliance 
with Institutional Animal Care and Use Committee mouse calorimetry standards. The 
system synchronously measured oxygen consumption, carbon dioxide production, 
energy expenditure, food intake, body weight and locomotor activity. Access to food 
was restricted to defined 6-hour periods each day (specified in chapter 2.1.2) by 
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programming the food hopper doors in each individual cage to open and close at 
specific times. To compare metabolic parameters specific for the different feeding 
periods of the TRF groups, raw data were binned into the defined 6-hour periods using 
a customized automated analysis script kindly created and provided by Sable Systems 
International. The average of each of the four 6-hour periods recorded over three 
consecutive days was then assessed and compared between the different animal groups. 
 
 
2.5. Analysis of blood-borne metabolic signals 
Circulating levels of leptin, insulin and glucose were measured using enzyme-linked 
immunosorbent assays (ELISA) and glucose assays. Therefore, animals were 
decapitated; blood was collected and immediately placed on ice to allow coagulation, 
followed by centrifugation for 20 minutes at 4 °C and 13000 rpm. Extracted serum and 
plasma were stored at -80˚C. Assays were carried out using 96 well microplates and all 
samples were assayed in duplicate.  
 
2.5.1. Leptin ELISA 
Because circulating leptin levels of mice fed HFD were expected to be above the 
sensitivity range of the leptin ELISA (0.2 to 12.8 ng/mL), serum and plasma samples of 
those mice were diluted using sample diluent provided within the ELISA kit prior to 
performing the assay. To measure circulating leptin concentrations, a sandwich ELISA 
was performed. Here, two sets of antibodies are used to detect mouse leptin in the 
samples. Mouse serum or plasma samples as well as predefined mouse leptin standards 
were dispensed into wells together with sample diluent and guinea pig anti-leptin serum 
and incubated for 20 hours at 4˚C. During this first reaction, mouse leptin in the serum 
or plasma samples is simultaneously bound to the rabbit anti-leptin antibody coated on 
the microplate well and the anti-leptin antibody of the guinea pig serum. On the next 
day, wells were washed using washing buffer to remove unbound material. This step 
was carried out between all subsequent incubations. For the next step, horseradish 
28 
 
peroxidase (HRP)-conjugated anti-guinea pig antibody was added and incubated for 3 
hours at 4˚C to allow binding of the HRP-conjugated antibody to the immobilized 
complex on the microplate well. This was followed by 30 minutes of incubation with 
tetramethylbenzidine (TMB) enzyme substrate solution to chromogenically detect the 
HRP-conjugated antibody. Finally, the enzyme reaction was stopped with sulfuric acid 
and absorbance was measured using a plate reader. Leptin concentrations in the 
samples were interpolated using the standard curve and mean absorbance values for 
each sample.  
 
2.5.2. Insulin ELISA 
To determine circulating insulin concentrations, a sandwich ELISA was performed. 
Mouse serum or plasma samples as well as predefined mouse insulin standards were 
dispensed into wells together with sample diluent and incubated for 2 hours at 4˚C. 
During this first reaction, mouse insulin in the serum or plasma samples binds to the 
guinea pig anti-insulin antibody coated on the microplate well. Subsequently, wells 
were washed using washing buffer to remove unbound material. This step was carried 
out between all subsequent incubations. Next, HRP-conjugated anti-insulin antibody 
was dispensed into the wells and incubated for 30 minutes at room temperature to allow 
binding of the HRP-conjugated antibody to the immobilized complex on the microplate 
well. This was followed by 40 minutes of incubation with TMB enzyme substrate 
solution. Finally, the enzyme reaction was stopped with sulfuric acid and absorbance 
was measured using a plate reader. Insulin concentrations in the samples were 
determined by interpolation using the standard curve and mean absorbance values for 
each sample. 
 
2.5.3. Glucose assay 
Serum glucose concentrations were measured performing a multi-step glucose assay. 
Therefore, mouse serum samples as well as predefined glucose standards were 
incubated with an enzyme solution containing mutarotase for 5 minutes at 37˚C, 
leading to the rapid conversion of α-D-glucose to β-D-glucose. The β-D-glucose is then 
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oxidised and releases hydrogen peroxide, which reacts with the enzyme solution to 
yield a red dye. Absorbance was measured and serum glucose concentrations were 
determined by interpolation using the standard curve and mean absorbance values for 
each sample. 
 
 
2.6. Analysis of glucose metabolism 
To measure glucose tolerance and insulin sensitivity in mice, intraperitoneal glucose 
tolerance tests (ipGTT) were performed. For respective treatments prior to the ipGTT, 
see chapter 4.1. Fasted animals received an ip injection of glucose solution (0.75 – 
1.0 g glucose/kg body weight) and blood glucose concentration was measured at 
defined time points (0, 15, 30, 60, 90, 120, 150 and 180 minutes after glucose injection) 
using a glucometer. Blood was collected by puncturing the facial vein. 
Furthermore, hepatic glucose production was analysed by performing an ip pyruvate 
tolerance test (ipPTT). Pyruvate is an intermediate of gluconeogenesis and the 
conversion of pyruvate to glucose reflects hepatic glucose production. Mice received an 
ip pyruvate injection (1.5 g/kg) and blood glucose concentration was detected at 
defined time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes after pyruvate 
injection) as described above.  
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3. General results and discussion 
 
3.1. The role of adiponectin in the central regulation of energy 
metabolism 
Peripheral effects of adiponectin on energy metabolism have been demonstrated to 
possess anabolic and orexigenic properties (83), whereas the opposite appears to apply 
to its central effects (78, 82). Adiponectin receptors have been found to be expressed on 
energy homeostasis-regulating neurons in the ARC (84, 86, 87). However, the role of 
central adiponectin has been insufficiently studied to date.  
 
3.1.1. Central expression profile of genes involved in adiponectin signal 
transduction 
Whether adiponectin is expressed in the CNS and whether it is able to cross the blood-
brain-barrier has so far been discussed controversially. While some studies suggest that 
adiponectin is expressed in brain tissue (79), others rebut that adiponectin has any 
direct central effect at all (81).  
By performing in situ hybridization, we found central expression of adiponectin, 
APPL1, AdipoR1 and AdipoR2 in the mediobasal hypothalamus of mice, specifically in 
the ARC (chapter 4.1, figure 1). The gene expression of all investigated genes was 
dependent on the nutritional state of mice. We detected markedly reduced adiponectin 
mRNA levels in the ARC after 16 hours of food deprivation compared with ad libitum 
fed mice. This regulatory mechanism might compensate for the catabolic and 
anorexigenic properties described for central adiponectin (78, 82), in order to prevent 
further body weight loss. In the periphery, on the other hand, circulating adiponectin 
concentrations are inversely correlated with adipose tissue mass and food deprivation 
leads to elevated adiponectin secretion (75-77). Regarding the anti-inflammatory and 
insulin-sensitizing effects described for peripheral adiponectin (73, 74), this increase 
might be a potential explanation for the beneficial effects of periodic fasting on 
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metabolic health. Furthermore, due to the anabolic and orexigenic effects of peripheral 
adiponectin the up-regulation of adiponectin secretion might be a mechanism to 
antagonize further body weight loss during food deprivation. The down-regulation of 
adiponectin gene expression during fasting might also explain contradictory results 
from prior studies regarding adiponectin action in the CNS (79, 81). Spranger and 
colleagues reported that adiponectin does not cross the brain-blood-barrier in either 
mice or humans, nor did they detect adiponectin gene expression in the brain. 
However, in their study, cerebrospinal fluid (CSF) was sampled from human subjects 
that had fasted overnight prior to the surgical intervention. Unfortunately, no 
information about the nutritional state of mice used in those experiments was provided 
(81).  
Interestingly, we found increased APPL1 and AdipoR1 gene expression in the ARC of 
food deprived compared with ad libitum fed mice. This might be an adaptive 
mechanism to ensure sufficient hypothalamic adiponectin signal transduction to 
compensate for decreased levels of adiponectin. AdipoR2 showed a trend towards lower 
gene expression after fasting, although this decrease did not reach significance. 
However, in both ad libitum fed and fasted mice, AdipoR2 gene expression in the ARC 
was considerably low suggesting that adiponectin signal transduction via this receptor 
plays only a minor role in central regulation of metabolism. Furthermore, AdipoR1 
gene expression was increased in mice that received mHFD and HFD, whereas 
AdipoR2 gene expression was only elevated in mHFD mice. Leptin-deficient Lepob/ob 
mice showed no change in gene expression of both receptors (chapter 4.1, figure 2). 
These results suggest that hypothalamic adiponectin signal transduction is 
compromised by DIO, but is independent of functional leptin signal transduction.  
 
3.1.2. Central adiponectin has insulin-sensitizing and anti-inflammatory effects 
By performing ipGTTs, we next analysed the effects of centrally administered 
adiponectin on glucose homeostasis in mice with genetically or diet-induced obesity. 
Central adiponectin proved to have the same blood glucose-lowering effects as 
described for peripherally administered adiponectin (74). This was not only the case in 
leptin-deficient Lepob/ob mice on LFD and DIO mice that received HFD, but even in 
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Lepob/ob mice on HFD, an extremely severe model of obesity (chapter 4.1, figure 3). To 
determine via which neuroendocrine pathways these beneficial effects on metabolic 
health are mediated, we measured the activation of several signalling markers of 
hormone pathways in the hypothalamus (chapter 4.1, figures 4 and 5c, d). Central 
adiponectin led to an activation of insulin signal transduction as demonstrated by 
activated pAKT in the VMH of Lepob/ob mice, while the increase in pAKT 
immunoreactivity in the ARC only showed a trend towards elevated insulin signalling 
activation. Inhibition of the negative insulin signalling modulator GSK-3β was also 
increased in both ARC and VMH after adiponectin administration during DIO. 
Additionally, central adiponectin led to a decrease in pAMPK immunoreactivity in both 
ARC and VMH, whereas no effect was observed for the activation of leptin signal 
transduction in either ARC or VMH after icv adiponectin administration in leptin 
deficient Lepob/ob mice. These results suggest that adiponectin mediates its glucose-
lowering effects by interacting with hypothalamic insulin signal transduction, without 
affecting leptin signalling in the hypothalamus as observed in both leptin deficient 
Lepob/ob mice and leptin resistant DIO mice. Furthermore, we confirmed the catabolic 
and anorexigenic properties of central adiponectin (78, 82), as shown by the decrease of 
AMPK activation, since phosphorylation of AMPK leads to increased food intake (85). 
Anti-inflammatory effects have previously been described for peripheral adiponectin 
(73). By measuring the activation of pro-inflammatory markers in DIO mice, which 
have been demonstrated to have increased hypothalamic inflammation (211), we found 
ameliorated hypothalamic inflammation after central adiponectin administration 
(chapter 4.1, figure 5). These results provide evidence for anti-inflammatory properties 
of central adiponectin. 
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3.2. Central WNT signal transduction and its role in the 
neuroendocrine control of seasonal energy metabolism 
The evolutionary highly conserved WNT signalling pathway is best studied for its role 
in embryogenesis and tumorigenesis (88-90). Recent findings suggest an important role 
of this pathway in adult neurogenesis and the neuroendocrine control of energy 
metabolism, in particular in hypothalamic leptin signalling in obese mice (119, 120, 
124, 125). Furthermore, hypothalamic WNT signalling is involved in seasonal 
physiology in photoperiod-responsive rats (125-127). Here, we examined the 
implication of WNT signalling in the neuroendocrine control of seasonal body weight 
regulation and annual changes in leptin sensitivity exhibited by Phodopus sungorus. 
Furthermore, we examined whether hypothalamic WNT signalling is regulated by a 24-
hour rhythm. 
 
3.2.1. Central expression profile of WNT genes and the effect of photoperiod and 
time of day on WNT signal transduction in adult Phodopus sungorus 
We first characterised the hypothalamic expression profile of genes encoding 
components involved in the WNT pathway by performing in situ hybridization. We 
found gene expression of the WNT pathway ligands WNT-4, SFRP-2 and DKK-3, the 
key enzyme GSK-3β and the WNT pathway target genes Axin-2 and Cyclin-D1 in the 
mediobasal hypothalamus of adult Djungarian hamsters, specifically in the ARC 
(chapter 4.2, figure 1). Interestingly, gene expression of all investigated ligands as well 
as target genes was dependent on the photoperiod (chapter 4.2, figures 2 and 3a, b). The 
up-regulation of WNT-4, a WNT/β-catenin pathway agonist (212), together with 
increased levels of Axin-2 and Cyclin-D1 mRNA in the hypothalami of LD compared 
with SD hamsters, indicates enhanced activation of the canonical WNT/β-catenin 
pathway during LD conditions. Nonetheless, these data solely stem from observations 
of WNT signalling on a transcriptional level.  
To provide further evidence for increased hypothalamic WNT/β-catenin signalling in 
LD relative to SD hamsters, we next examined the canonical WNT/β-catenin pathway 
on a posttranslational level. Indeed, by performing immunohistochemistry we found 
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elevated phosphorylation of the WNT co-receptor LRP-6 at serine 1490 in the ARC of 
LD hamsters in comparison with SD hamsters (chapter 4.2, figure 4). Phosphorylation 
at this serine residue leads to activation of LRP-6, which is required for the initiation of 
canonical WNT/β-catenin signal transduction (106, 107). These data provide strong 
evidence for elevated WNT/β-catenin signalling in the ARC of Djungarian hamsters 
during LD relative to SD conditions. 
Additionally, SFRP-2 mRNA levels were increased in LD hamsters. In light of the 
proposed increased WNT/β-catenin pathway activation during LD this appears 
paradoxical at first, due to the general antagonizing effect on both canonical and non-
canonical WNT signalling described for members of the SFRP family (110, 111). 
However, SFRP-2 has been demonstrated to particularly facilitate the activity of WNT-
4 during kidney development (213). Thereby, the increase in SFRP-2 mRNA observed 
in our study might illustrate a regulatory mechanism to prevent aberrant activation of 
non-canonical WNT signalling, while at the same time allowing enhanced activation of 
canonical WNT/β-catenin signalling via WNT-4 in the ARC of LD hamsters.  
A key regulatory enzyme of the WNT/β-catenin pathway is GSK-3β, being responsible 
for the phosphorylation and subsequent proteasomal degradation of the co-transcription 
factor β-catenin (115, 116). In the present study, GSK-3β gene expression was 
regulated by neither photoperiod nor time of day (chapter 4.2, figure 3c). The WNT/β-
catenin pathway-inhibiting activity of GSK-3β is, however, altered by phosphorylation 
at serine 9, which results in the inhibition of this kinase (117). We performed 
immunohistochemistry to evaluate the number of pGSK-3β (serine 9)-immunoreactive 
cells in the ARC of hamsters from LD or SD and at different times throughout the 24-
hour period. Unfortunately, commercially available antibodies used in this study did 
not cross-react with hamster tissue. Therefore, no definite prediction can be made as to 
how GSK-3β activity is regulated by seasonal adaptations or during day and night in 
Djungarian hamsters. However, in light of our findings regarding increased WNT/β-
catenin pathway activation and elevated target gene expression during LD relative to 
SD, a probable reduction in GSK-3β activity in the ARC of LD hamsters can be 
proposed. Interestingly, SD compared with LD photoperiod was shown to induce 
deteriorated insulin signalling in the ARC of Djungarian hamsters (214). GSK-3β is a 
potent inhibitor of insulin signal transduction. The reduction in hypothalamic insulin 
signalling detected in SD hamsters may therefore result from ameliorated GSK-3β 
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activity as a consequence of reduced WNT/β-catenin pathway activation during SD 
compared with LD. In line with this, Benzler et al. demonstrated that blockade of 
canonical WNT/β-catenin signalling in diabetic Lepob/ob mice inhibits the glucose-
lowering effects of exogenous leptin (119). This suggests that WNT/β-catenin 
signalling is an important mediator of leptin-induced attenuation of glucose 
homeostasis and provides further evidence for a crucial role of hypothalamic WNT/β-
catenin signal transduction in the neuroendocrine control of metabolism.  
Furthermore, we investigated the 24-hour profile of hypothalamic WNT component 
gene expression. Overall, the effects of time of day on gene expression were limited, 
with no rhythmic regulation for WNT-4, SFRP-2 and GSK-3β (chapter 4.2, figure 3). 
On the other hand, DKK-3, Axin-2 and Cyclin-D1 revealed rhythmic regulation of 
hypothalamic gene expression throughout the 24-hour cycle (chapter 4.2, figure 2). In 
both LD and SD hamsters, expression of the two WNT target genes Axin-2 and Cyclin-
D1 appeared to decline throughout the light phase and increase throughout the dark 
phase. In LD hamsters, this was accompanied by increasing expression of the WNT/β-
catenin signalling antagonist DKK-3 throughout the light phase and decreasing 
expression throughout the dark phase, potentially resulting in the reciprocal expression 
profile of WNT target genes that we observed in the present study. Other than in LD 
hamsters, the 24-hour expression profile of DKK-3 did not justify the rhythmic 
regulation of Axin-2 and Cyclin-D1 mRNA in SD hamsters. Interestingly, several WNT 
gene promotors were shown to exhibit BMAL-1 occupancy, suggesting direct circadian 
regulation of expression of genes encoding components involved in the WNT pathway. 
Guo and colleagues demonstrated that overexpression of BMAL-1 resulted in enhanced 
WNT/β-catenin signal activity. Disruption of BMAL-1 function, on the other hand, led 
to down-regulation of genes involved in the canonical WNT/β-catenin pathway, 
accompanied by increased adipogenesis and the development of obesity in mice (215). 
Furthermore, BMAL-1 has been shown to be a prominent transcription factor for genes 
encoding central regulators of metabolism (216). These results, together with our 
findings in the Djungarian hamster, support an important role of canonical WNT/β-
catenin signalling in the seasonal as well as 24-hour-rhythmic hypothalamic regulation 
of cell differentiation as well as energy metabolism, as further discussed below. 
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3.2.2. The potential role of canonical WNT/β-catenin signalling in cell 
differentiation processes in Phodopus sungorus 
WNT/β-catenin signalling has been shown to control adipogenesis; it prevents 
differentiation of preadipocytes by inhibition of adipogenic transcription factors, 
namely CCAAT-enhancer binding protein α (C/EBPα) and peroxisome proliferator-
activated receptor γ (PPARγ), whereas disruption of WNT signal transduction in 
preadipocytes causes these cells to differentiate into adipocytes (217, 218). 
Interestingly, C/EBPα disruption in knockout mice causes a major reduction in lipid 
content and adipose cell size, while adipocyte differentiation still occurs (219). We 
found elevated WNT/β-catenin pathway activity during LD compared with SD, 
pointing to reduced adipogenesis in LD hamsters. However, LD hamsters possess 
larger body fat stores than SD hamsters (199, 200). This is primarily due to increased 
adipose hypertrophy, but not adipose hyperplasia (220). Therefore, the adipogenesis-
inhibiting role of canonical WNT/β-catenin signalling appears to play only a minor role 
in the seasonal regulation of fat pad mass in Djungarian hamsters. However, it is 
important to consider that we examined WNT/β-catenin signal transduction only in 
brain tissue, but not in the periphery. In peripheral tissues it might be regulated 
conversely depending on photoperiodic background and still contribute to the seasonal 
changes in adipose mass observed in Djungarian hamsters. 
The importance of neural WNT signalling has been extensively described in embryonic 
development. For a long time, neurogenesis in the adult mammalian brain was 
considered to be restricted to two distinct regions: the dentate gyrus in the hippocampus 
and the subventricular zone of the lateral ventricles in the forebrain, linked to learning, 
memory formation, olfaction and mood modulation (221-225). In these brain regions, 
canonical WNT signalling promotes neurogenesis (226). Recently, accumulating 
evidence suggests that adult neurogenesis also appears in other brain regions, such as 
the hypothalamus (227, 228). It was demonstrated that WNT signalling is required in 
the developed hypothalamus of both zebrafish and mice (227). Furthermore, there is a 
large body of evidence showing photoperiodic control of hypothalamic WNT signalling 
in photoperiod-sensitive F344 rats (125, 126, 229), and various members of the 
canonical WNT/β-catenin pathway were up-regulated in LD-acclimated F344 rats 
(127). In line with these findings, we demonstrated elevated canonical WNT pathway 
activity in the Djungarian hamster during LD. It is tempting to speculate that this 
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increased pathway activation in LD hamsters entails increased neurogenesis. However, 
a study conducted in another hamster species, the adult Syrian hamster (Mesocricetus 
auratus), found contradictory results. There, higher numbers of newly incorporated 
neurons were detected in the hypothalamus of SD hamsters. It was unclear whether this 
was due to increased cell birth or reduced cell death, but the authors concluded that 
LD-acclimated Syrian hamsters exhibit reduced neuronal cell proliferation compared 
with SD hamsters (230). Whether this is regulated similarly in Djungarian hamsters is 
unclear. While both hamster species are long day-breeders, there are numerous 
differences in regards to their photoperiodic adaptations. While Djungarian hamsters 
exhibit an increase in body weight, adipose tissue mass and circulating leptin levels 
during LD compared with SD, these effects are absent or very limited in Syrian 
hamsters (231-233). Additionally, Djungarian hamsters exhibit increased Socs-3 
mRNA levels during LD relative to SD conditions, accompanied by deteriorated 
hypothalamic leptin sensitivity (48). In Syrian hamsters, on the other hand, photoperiod 
had no effect on Socs-3 gene expression (206). Therefore, neurogenesis might also be 
regulated differently in these two hamster species.  
Studies conducted in photoperiod-responsive hamsters as well as sheep suggest 
photoperiod-induced alterations in the morphology of the mediobasal hypothalamus 
(230, 234-236). Neurogenesis in the adult murine hypothalamus has been demonstrated 
to play an important role in the regulation of neuroendocrine pathways that are in 
control of energy metabolism (237, 238). The increase in WNT/β-catenin signalling in 
the ARC of LD hamsters demonstrated in the present study potentially represents a 
mechanism for cellular and structural remodelling of neurocircuits that mediate 
photoperiodic alterations in energy balance in the Djungarian hamster. Further 
investigation into the effects of photoperiod on neurogenesis and morphological 
remodelling of the adult Djungarian hamster’s hypothalamus with a focus on signalling 
pathways regulating energy homeostasis is required. 
 
38 
 
3.2.3. Leptin activates the canonical WNT/β-catenin signalling pathway in 
Phodopus sungorus 
Recently, our group demonstrated that hypothalamic WNT/β-catenin signalling is 
disrupted in obese leptin-deficient Lepob/ob mice and is reinstated by leptin 
administration (119). Therefore, we next wanted to investigate whether leptin 
administration in Djungarian hamsters leads to an activation of the canonical WNT 
pathway and whether this effect is photoperiod-dependent. By using 
immunohistochemistry to determine the number of pLRP-6 (serine 1490)-
immunoreactive cells, we found increased activation of the canonical WNT co-receptor 
LRP-6 in the ARC of hamsters that were challenged with leptin compared with vehicle-
treated control animals (chapter 4.2, figure 4). Interestingly, leptin led to activation of 
the WNT/β-catenin pathway in Djungarian hamsters from LD as well as SD. This 
finding was surprising, since LD hamsters are leptin resistant relative to SD hamsters 
(201, 204, 205, 239). In Djungarian hamsters, hypothalamic leptin resistance during LD 
was shown to be mediated by reduced translocation of activated STAT3 into the 
nucleus and as a consequence of up-regulated Socs-3 expression, leading to an 
inhibition of intracellular signal transduction via JAK2/STAT3 signalling (28, 29, 48, 
206, 240). Therefore, it is probable that the leptin-induced activation of the WNT/β-
catenin pathway is independent of the JAK2/STAT3 pathway. Instead, signal 
transduction via an indirect mechanism could be possible. However, the rapid 
activation of the WNT/β-catenin co-receptor LRP-6 only 15 minutes after 
intraperitoneal leptin administration suggests a direct effect of leptin. Therefore, the 
exact mechanism via which leptin mediates its WNT pathway-activating effects in the 
hypothalamus remains to be further investigated. A very recent study conducted in 
Xenopus laevis tadpoles confirmed our finding that leptin is able to activate WNT/β-
catenin signalling in the hypothalamus of yet another species (241), indicating that this 
particular effect of leptin is conserved throughout several taxonomic classes of the 
animal kingdom. 
Intriguingly, Ellis et al. reported a time of day-dependent effect on LepRb gene 
expression in the ARC of Djungarian hamsters acclimated to LD, but this rhythm was 
not present in SD animals (242). In LD hamsters, LepRb mRNA levels are elevated 
during the dark phase relative to the light phase. It is interesting to note that LepRb 
gene expression in LD hamsters peaks in the middle of the dark phase at ZT21 (242). 
39 
 
We found that at this exact time mRNA levels of the WNT target genes Axin-2 and 
Cyclin-D1 reach their nadir in LD hamsters, followed by an abrupt increase in gene 
expression. This may be a consequence of enhanced leptin signalling due to increased 
leptin receptor levels. It appears that the 24-hour rhythm in LepRb gene expression and, 
as a potential consequence, leptin sensitivity is revealed under conditions of leptin 
resistance and high levels of the hormone during LD, whereas this does not apply to 
leptin sensitive SD hamsters with low hormone levels (242). Furthermore, these data 
suggest that hypothalamic leptin resistance does not persist throughout the entire day 
once it is established, but may be subject to daily variations. 
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3.3. Influence of the time of day on the control of energy metabolism 
It is well established that circadian clocks play an important role in the maintenance of 
energy metabolism. Disruptions of circadian rhythms lead to metabolic disorders in 
both rodents and humans (177-179) and HFD feeding has been shown to interfere with 
circadian rhythms (158, 180, 181). However, whether leptin signal transduction in the 
ARC, a key region in neuronal control of body weight and overall energy metabolism, 
is rhythmically regulated throughout the day has not yet been examined. Furthermore, 
the suggestion that physiological leptin resistance in LD-acclimated Djungarian 
hamsters may underlie a 24-hour rhythm, as discussed above (chapter 3.2.3), brings 
about the question as to whether this also applies to the pathological model of leptin 
resistance during DIO. In the present study, we therefore investigated how activation of 
the leptin signalling pathway is modulated over the course of the day per se and 
whether HFD-induced obesity interferes with this. We also examined the effects of 
time-restricted access to HFD on metabolic markers and whether the time of TRF has 
an influence on the amelioration of metabolic health. For an overview of the 
experimental designs of this study, see chapter 4.3, supplementary figure 1.  
 
3.3.1. Time of day-dependent action of hypothalamic leptin signalling 
3.3.1.1. Rhythmic regulation of basal leptin signal transduction is disrupted by 
HFD feeding 
By performing immunohistochemistry, we examined the activation of the transcription 
factor STAT3 at its phosphorylation site tyrosine 705 as a marker for leptin’s 
intracellular signalling action over the course of an entire day in mice that had been 
fasted for 24 hours prior to perfusion (chapter 4.3, figure 1a, b). We discovered a 24-
hour rhythm of leptin pathway activation, as demonstrated by the number of pSTAT3 
(tyrosine 705)-immunoreactive cells, in the ARC of vehicle-treated mice that were fed 
with LFD, as well as both mice fed with LFD and HFD after leptin treatment. Although 
three-way ANOVA detected an overall rhythmicity of basal pSTAT3 immunoreactivity 
in vehicle-treated mice fed HFD, the subsequent post hoc test did not reveal significant 
differences between the individual time points. Instead, these mice showed a consistent 
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number of basal pSTAT3-immunoreactive cells throughout the entire 24-hour cycle. 
We therefore concluded that no physiologically relevant 24-hour rhythm of endogenous 
leptin pathway activation is present in mice fed HFD, showing that HFD feeding leads 
to a disruption of the rhythmic regulation of basal leptin pathway activity. 
In vehicle-treated mice fed LFD, basal leptin pathway activity was at a maximum at the 
beginning of the light phase at ZT0 and at a minimum at ZT6 with continuously 
increasing pSTAT3 activation from the middle of the light phase to the end of the dark 
phase. This rhythmic regulation of basal leptin pathway activity occurred despite an 
extended fasting period of 24 hours prior to tissue sampling and therefore indicates a 
physiological role that is independent of preceding food intake. Furthermore, this 
rhythmic oscillation of basal pSTAT3 activation is also independent of variations in 
serum leptin concentrations, which revealed no rhythmic regulation over 24 hours in 
fasted vehicle-treated mice fed LFD (chapter 4.3, figure 2a). These results indicate that 
the elevated number of pSTAT3-immunoreactive cells during the dark compared with 
the light phase is due to enhanced leptin sensitivity caused by mechanisms independent 
of the short-term factors food intake and circulating leptin levels. 
The majority of studies that investigated the effect of HFD feeding on leptin sensitivity 
in the ARC so far reported similar numbers of basal pSTAT3-immunoreactive cells in 
wild-type mice as well as in rats fed either LFD or HFD (12, 243, 244). By rigorous 
tissue sampling every 3 hours throughout the 24-hour cycle, we discovered that the 
effect of the diet on pSTAT3 activation is dependent on the time of day. Mice fed LFD 
compared with HFD had similar levels of pSTAT3 activation exclusively during the 
second part of the dark phase and the first part of the light phase from ZT21 – ZT3. 
However, HFD feeding led to an increase in pSTAT3 activation during the second part 
of the light phase and the first part of the dark phase from ZT6 – ZT18 (chapter 4.3, 
figure 1b). The discrepant results between our and the above-mentioned studies can be 
explained by the time of tissue sampling, which is typically performed in the early 
morning as has been specified in at least one of these studies (243). To our knowledge, 
there is only one other study that demonstrates elevated basal pSTAT3 activation 
during DIO. This study was conducted in rats that were fed either chow or HFD and 
received an icv injection of artificial cerebrospinal fluid (ACSF) and pSTAT3 
immunoreactivity was measured in the entire hypothalamus (245). Unfortunately, the 
authors did not indicate at what time of day brains were harvested. 
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A plausible explanation for this HFD-induced activation of pSTAT3 at specific times 
during the day compared with basal pathway activation in mice on LFD might be 
hypothalamic inflammation. Obesity is associated with chronic low-grade systemic and 
central inflammation (50, 246, 247). Pro-inflammatory cytokines such as interleukin 6 
(IL-6) and tumour necrosis factor α (TNFα) are secreted by white adipose and brain 
tissue, amongst a variety of other cell types, and circulating levels of IL-6 as well as 
TNFα were shown to be elevated during obesity (248-250). Interestingly, the role of 
IL-6 in inflammatory responses is complex and appears to be tissue-dependent. While 
myocyte-derived IL-6 has been shown to improve glucose metabolism and to have anti-
inflammatory functions (251, 252), these effects appear to be specific for its role as a 
myokine. Pro-inflammatory effects have been demonstrated for IL-6 in the majority of 
other tissues. Both IL-6 and TNFα mediate their effects via actions in the CNS, 
specifically the hypothalamus (253, 254), and hypothalamic inflammation via these 
cytokines has been implicated in the development of leptin as well as insulin resistance 
and type 2 diabetes (50, 248, 255, 256). Both cytokines have been shown to be able to 
mediate their pro-inflammatory effects via activation of the intracellular JAK2/STAT3 
pathway (257, 258). In line with this, our research group recently demonstrated that 
pSTAT3 is equally activated in leptin-deficient Lepob/ob mice fed HFD and treated with 
vehicle and mice fed LFD and treated with leptin (51). Since these mice lack 
endogenous leptin, the activation of pSTAT3 observed in vehicle-treated mice on HFD 
must be due to mechanisms other than leptin signalling. Furthermore, inhibition of the 
pro-inflammatory c-Jun N-terminal kinase (JNK) pathway in the hypothalamus of 
Lepob/ob mice reversed the HFD-induced resistance to the glucose-lowering effects of 
leptin (51). These results suggest that hypothalamic inflammation due to HFD-induced 
elevation of pro-inflammatory cytokine levels, but not the occurrence of 
hyperleptinemia, causes leptin resistance in leptin-deficient Lepob/ob mice. Therefore, it 
is possible that the increase in pSTAT3 activation in vehicle-treated wild-type mice fed 
HFD compared with LFD at particular times of the day demonstrated in the current 
study is a direct effect of pro-inflammatory cytokines leading to pSTAT3 activation. 
Notably, in the current study we used a mouse model of DIO typically associated with 
high circulating levels of leptin. Nonetheless, hypothalamic inflammation has been 
shown to interfere with leptin signalling in this mouse model and is causative for the 
development of HFD-induced obesity and related metabolic disorders (246, 259). 
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Hypothalamic inflammation is already altered within just hours of HFD consumption 
(247). By central inhibition of pro-inflammatory inhibitor of nuclear factor-κB kinase β 
(IKKβ)/nuclear factor-κ-light-chain-enhancer of B-cells (NF-κB) signal transduction in 
mice fed HFD, our research group recently confirmed that this pathway is involved in 
the development of DIO (52). Mice subjected to ARC-directed genetic inhibition of 
IKKβ/NF-κB signalling experienced an amelioration of the detrimental effects of HFD 
on body weight gain, body fat mass, energy expenditure, Socs3 gene expression in the 
ARC, as well as glucose tolerance. Since all of these factors are regulated by 
hypothalamic leptin signalling, these results provide evidence that the central pro-
inflammatory IKKβ/NF-κB pathway is involved in the development of arcuate leptin 
resistance during DIO (52). Indeed, a prominent target of the IKKβ/NF-κB signalling 
cascade is the expression of SOCS3, a potent inhibitor of leptin signalling (49). Gao 
and colleagues demonstrated similar effects for the JNK pathway. They found 
enhanced hypothalamic leptin signalling as well as decreased body weight gain and 
food intake in DIO mice after pharmacological inhibition of JNK signal transduction 
(260). Based on these findings, the elevated activation of pSTAT3 in HFD-induced 
obese mice at specific times, as observed in the current study, might result from a 
rhythmic occurrence of hypothalamic inflammation and thus rhythmic appearance and 
abatement of leptin signal transduction-inhibiting inflammatory effects, rather than 
from a direct effect of pro-inflammatory cytokines.  
 
3.3.1.2. Rhythmic regulation of leptin-induced leptin signal transduction is 
disrupted by HFD feeding 
This phenomenon would also explain our findings of leptin-induced pSTAT3 activation 
over the course of a day in mice that were fasted for 24 hours prior to leptin injections. 
Mice fed LFD displayed a 24-hour rhythm in arcuate pSTAT3 levels, with maximum 
activation at ZT0 and declining levels throughout the light phase, reaching a minimum 
at ZT9 (chapter 4.3, figure 1a, b). These findings suggest rhythmic regulation of leptin 
signal transduction in the hypothalamic ARC of mice independent of food intake, with 
highest leptin sensitivity at the end of their active phase and lowest sensitivity before 
the onset of their active phase. Interestingly, basal pSTAT3 activation in vehicle-treated 
mice fed LFD follows the same daily pattern, even though baseline levels are 
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significantly lower at all investigated time points compared with leptin-induced 
pSTAT3 activation (chapter 4.3, figure 1a, b). 
On the other hand, HFD feeding led to a disruption of the 24-hour rhythm of leptin-
induced pSTAT3 activation that we observed in mice fed LFD. Leptin-treated mice fed 
HFD showed pSTAT3 levels that were at a minimum at ZT0 and continuously 
increasing throughout the light as well as the first half of the dark phase, reaching 
maximum levels at ZT18. Intriguingly, mice fed HFD showed lower levels of leptin-
induced pSTAT3 activation only during the second part of the dark and the first part of 
the light phase from ZT21 – ZT6 compared with mice fed LFD. At all other time 
points, pSTAT3 levels were similar between mice fed HFD and LFD (chapter 4.3, 
figure 1a, b). To our knowledge, this is the first description of this time of day-
dependent occurrence of leptin resistance in response to HFD feeding. Other studies so 
far reported decreased leptin-induced pSTAT3 activation and thus impaired leptin 
sensitivity in rodents fed HFD as a temporally omnipresent phenomenon (12, 243, 
244). As discussed above for basal pSTAT3 activation, this discrepancy most likely 
arises from the limited number of time points of tissue sampling in those studies. 
Taken together, our results demonstrate that DIO leads to a disruption of the 24-hour 
rhythm in the control of both basal as well as leptin-induced leptin signalling and 
furthermore suggest that DIO-induced leptin resistance is restricted to specific times of 
the day. In vehicle-treated mice fed HFD, which have higher circulating leptin 
concentrations relative to LFD throughout the entire day (chapter 4.3, figure 2a), we 
report increased leptin pathway activity, exemplified by the number of pSTAT3-
immunoreactive cells, exclusively from ZT6 – ZT18. In line with this, leptin-treated 
mice fed HFD show leptin sensitivity similar to mice fed LFD exclusively from ZT9 – 
ZT18, whereas pSTAT3 activation is deteriorated at all other times. A DIO-induced 
increase in hypothalamic inflammatory activity during the second half of the dark 
(active) and the first half of the light (inactive) phase, evoking impaired leptin 
signalling, might be causative for this time of day-dependent impairment of leptin 
signal transduction as observed in both vehicle- and leptin-treated mice fed HFD 
compared with LFD. 
Although a large body of evidence demonstrates circadian regulation of central 
inflammation in rodents, only few of these studies concentrated on the hypothalamus 
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and results are contradictory. Some studies report that Tnfα gene expression in the 
hypothalamus is increased in the light phase compared with the dark phase (261), with 
peak mRNA levels at ZT0 and lowest levels at ZT18 (262), while others found 
relatively low Tnfα gene expression during the light phase and highest mRNA levels 
during the middle of the dark phase (263). Notably, only the latter study was conducted 
in mice, whereas all other studies used rats. These discrepancies could be due to 
differences between species or to different experimental conditions. Cytokines and 
other immune mediators have been shown to be directly influenced by circadian 
timekeeping processes in various tissues (264). For example, CLOCK can directly 
interact with the pro-inflammatory transcription factor NF-κB, leading to elevated 
transcriptional activity, whereas the heterodimerisation of CLOCK and BMAL-1 
results in rhythmic repression of inflammatory genes (265). Furthermore, REV-ERBα 
represses a distinct subset of inflammatory genes in macrophages (266) and loss of 
CRY proteins results in constitutive NF-κB activation (267). These studies show that 
the rhythmic regulation of inflammatory responses is intricately arranged. 
Characteristically, a peak in circulating cytokines during the onset of an animal’s active 
phase has been described for humans as well as mice (268, 269). Of great importance is 
that all above-mentioned studies examining rhythmic regulation of inflammatory 
activity focused on non-obese subjects (261-263, 268, 269). Therefore, it is rather 
possible that the daily rhythm of hypothalamic inflammation in DIO mice, which show 
an increase in pro-inflammatory markers, is regulated differently. Unfortunately, 
commercially available ELISA kits for the analysis of circulating cytokines required 
too large serum sample volumes and we were therefore unable to measure circulating 
levels of IL-6 and TNFα throughout the 24-hour cycle in mice used in our study. 
 
3.3.1.3. Leptin sensitivity on a behavioural level is dependent on the time of day 
After we had established that arcuate leptin sensitivity on a molecular level exhibits a 
24-hour rhythm in mice, we next analysed whether this rhythmicity also applies to the 
behavioural response to exogenous leptin. Mice fed either LFD or HFD were injected 
at either ZT0, when leptin sensitivity on a molecular level was at a maximum in LFD 
mice, or at ZT12. Subsequently, accumulated caloric intake was measured 4 hours and 
24 hours post injections to assess the anorexigenic effects of the hormone (chapter 4.3, 
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figure 1b, c). Compared with their vehicle-treated counterparts, mice fed LFD showed a 
significant reduction in caloric intake after both 4 hours and 24 hours when leptin was 
administered at ZT0, whereas injections at ZT12 had no effect on caloric intake. In 
mice fed HFD, on the other hand, exogenous leptin at either time point did not result in 
decreased caloric intake, suggesting that on a behavioural level these mice are resistant 
to the anorexigenic effects of leptin throughout the entire 24-hour cycle.  
 
3.3.1.4. 24-hour profile of blood-borne metabolic markers 
To further investigate the impact of DIO on physiological rhythms, we next analysed 
circulating metabolic markers throughout the 24-hour cycle. Vehicle-treated mice fed 
LFD showed consistently low levels of circulating leptin. The absence of a 24-hour 
rhythm in these mice is most likely due to the extended fasting period prior to blood 
sampling. Non-fasted male mice on a control diet have been shown to exhibit a 24-hour 
rhythm of endogenous leptin, with elevated levels during the dark and reduced levels 
during the light phase (270). Intriguingly, vehicle-treated mice fed HFD displayed a 
prominent rhythm in serum leptin concentrations, despite the preceding 24-hour fasting 
period (chapter 4.3, figure 2a). Leptin concentrations were elevated during the light 
phase, reaching a maximum at ZT6, and reduced during the dark phase. This peak in 
endogenous leptin levels coincides with reduced pSTAT3 activation in mice fed HFD 
on a molecular level, indicating an inhibitory effect of leptin on leptin pathway 
activation during DIO. This finding furthermore corroborates that hyperleptinemia is 
required for the development of hypothalamic leptin resistance (271).  
Indeed, in a series of elegant studies, Scarpace and colleagues demonstrated that 
elevated central leptin levels are causative for hypothalamic leptin resistance. Rats 
received a chronic virus-mediated leptin transgene overexpression directly into the 
third ventricle of the brain, resulting in elevated hypothalamic but not systemic leptin 
levels (272). These rats developed impaired leptin responsiveness despite lower body 
mass and serum leptin levels compared with control rats, demonstrating hypothalamic 
leptin-induced leptin resistance independent of other detrimental effects typically 
associated with DIO, such as elevated hypothalamic inflammation (272). In a follow-up 
study, hypothalamic leptin resistance was induced as described above and rats received 
a HFD after hypothalamic leptin resistance was established (273). Leptin-vector-treated 
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rats fed HFD consumed significantly more calories and gained more body weight and 
fat mass than rats that were treated with a control virus and fed HFD. These results 
indicate that hypothalamic leptin resistance provokes increased susceptibility to DIO, 
proposing the fascinating notion that leptin resistance is both a cause and a 
consequence of obesity (273). As discussed above, the involvement of hypothalamic 
inflammation has also been shown to contribute to the development of leptin resistance 
and obesity (52, 260). Taken together, these findings provide evidence that not one 
single cause underlies these metabolic derangements, but rather the conjoined 
occurrence of both hyperleptinemia and elevated hypothalamic inflammation is 
causative for their development.  
To further examine the hypothesis that leptin has an inhibitory effect on hypothalamic 
leptin signal transduction in states of DIO, we conducted another study with the same 
experimental setup as described above in which mice were injected at either ZT0 or 
ZT12. This time mice received an ip injection of a potent short-acting leptin antagonist 
(LAN; 1.0 mg/kg in PBS; Protein Laboratories Rehovot Ltd.) with the same half-life as 
recombinant mouse leptin, to assess whether acute targeted inhibition of leptin action at 
specific time points leads to an increased anorexigenic response on a behavioural level 
in mice fed HFD. Unfortunately, we found no effect of acute LAN administration on 
caloric intake in either mice fed LFD or HFD, potentially because the applied dose was 
insufficient to entirely antagonise leptin binding to its receptor and activating 
downstream pathway signalling.  
Circulating insulin concentrations displayed no rhythmic oscillation over the 24-hour 
cycle in either mice fed LFD or HFD, but three-way ANOVA revealed an overall 
increase of serum insulin levels in mice fed HFD compared with LFD, independent of 
leptin administration (chapter 4.3, figure 2b). Increased insulin levels during DIO have 
been reported previously and are an indicator for disrupted insulin signal transduction, 
eventually resulting in the manifestation of type 2 diabetes (23). 
In line with the consistently low levels of leptin and insulin, mice that were fed LFD 
and fasted for 24 hours prior to blood sampling showed no rhythmic regulation of 
serum glucose levels throughout the day. In contrast, mice fed HFD displayed rhythmic 
levels of circulating glucose with concentrations similar to those observed in mice fed 
LFD during the light phase and elevated levels during the dark phase (chapter 4.3, 
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figure 2c). Notably, this peak occurs independently of food intake, but simultaneously 
with reduced levels of serum leptin, suggesting a correlation between circulating leptin 
and glucose levels. Indeed, obese leptin-deficient Lepob/ob mice display severe 
hyperglycaemia despite increased levels of circulating insulin. In these mice, even low 
doses of exogenous leptin restore normal glucose homeostasis without leptin eliciting 
its anorexigenic properties on food intake and body weight, demonstrating a profound 
blood glucose-lowering effect of the hormone and highlighting the importance of leptin 
signalling on functional insulin signal transduction (271). On a molecular level, leptin 
injections lead to increased activation of IRS1 (71). This is most likely achieved by 
leptin activating the WNT/β-catenin pathway and subsequent inhibition of GSK3β 
[chapter 3.2 and (119)]. Since GSK3β is a potent inhibitor of insulin signalling, this 
decrease in GSK3β activity might be causative for the leptin-mediated sensitisation of 
insulin pathway activation. 
Taken together, our and the above-mentioned studies suggest that leptin in more 
efficient in regulating glucose homeostasis than in mediating its anorexigenic effects on 
food intake and body weight. Furthermore, no difference in serum glucose levels 
throughout the day was observed between vehicle- and leptin-treated mice in either 
mice fed LFD or HFD. This indicates that in mice fed LFD, glucose homeostasis is 
fully functional and additional leptin administration does not improve glucose tolerance 
any further. On the other hand, in mice fed HFD that exhibit responsiveness to the 
glucose-lowering effects of endogenous leptin during the light phase, exogenous leptin 
seems unable to counteract the deteriorated glucose homeostasis displayed during the 
dark phase. These findings suggest an intricately regulated mechanism discriminating 
between effects of endogenous versus exogenous leptin. Indeed, Ottaway et al. reported 
that repeated administration of high doses of a long-acting leptin antagonist leads to an 
increase in caloric intake in mice fed HFD relative to vehicle-treated animals, 
suggesting that on a behavioural level DIO mice are still responsive to endogenous 
leptin to some extent, despite impaired leptin signalling and resistance to exogenous 
leptin (274). 
In conclusion, we demonstrate a time of day-dependent regulation of leptin action that 
is disrupted by the consumption of HFD. Physiologically, the elevated responsiveness 
to leptin on both the molecular and behavioural level at the beginning of the light phase 
as observed in mice fed LFD might present a regulatory mechanism that inhibits the 
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drive to eat and ultimately prevents food seeking behaviour during the animals’ 
inactive phase. The disruption of this physiological rhythm during DIO might be 
causative for the arrhythmic behavioural patterns observed during obesity. Mice 
subjected to HFD were shown to have increased relative locomotor activity and food 
intake during the light phase (158, 181), coinciding with decreased leptin sensitivity as 
demonstrated in our study. 
 
3.3.2. Effects of time-restricted feeding on energy metabolism 
We next examined whether the beneficial effects on metabolic health that have been 
described for TRF regimens depend on the rhythmic control of hypothalamic leptin 
sensitivity. Based on our observations about the DIO-induced disruption of this rhythm 
on a molecular level, we restricted access to HFD to four defined 6-hour intervals each 
day, thereby covering the entire 24-hour cycle. One group of mice subjected to the TRF 
regimen received HFD during the interval when mice fed HFD displayed leptin 
resistance on a molecular level compared with mice fed LFD (ZT21 – ZT3). A second 
group received HFD during the interval when both mice fed LFD and HFD showed 
identical responsiveness to exogenous leptin (ZT9 – ZT15). Because these two groups 
had access to HFD for 3 hours during both the light and the dark phase, effects 
observed between these groups can be regarded as activity-independent. Two more 
groups had access to HFD during either the light (resting) phase (ZT3 – ZT9) or the 
dark (active) phase (ZT15 – ZT21). 
 
3.3.2.1. Effect of time-restricted feeding on body weight and behaviour 
Mice showed increased body weight as early as nine days after the start of HFD feeding 
relative to mice fed LFD (chapter 4.3, figure 3). After four weeks of ad libitum HFD 
feeding, these mice were separated into five groups of which one continued to receive 
ad libitum HFD and the other animals were subjected to the TRF regimen as described 
above. By the end of the experiment, all TRF mice had significantly reduced body 
weight as well as circulating leptin concentrations (chapter 4.3, figure 5a) relative to 
mice fed HFD ad libitum, with values similar to those detected in mice fed LFD. We 
observed no differences of these parameters between the TRF groups. The reduction in 
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body weight of TRF mice can be accounted for by reduced daily caloric intake 
compared with mice fed HFD ad libitum (chapter 4.3, supplementary figure 2a), 
however, this was not accompanied by a reduction of daily locomotor activity (chapter 
4.3, supplementary figure 2b). Notably, since circulating leptin levels are proportional 
to body fat mass (275), the reduction in body weight together with decreased plasma 
leptin levels observed in TRF mice relative to mice fed HFD ad libitum indicates a 
reduction in fat mass but not lean mass. Indeed, this effect on body fat content has 
recently been described for a TRF regimen (276). 
 
3.3.2.2. Effect of time-restricted feeding on markers of metabolic health 
We monitored parameters of energy metabolism and behaviour of mice from this study 
using a respirometry system. By analysing data that were binned into 6-hour intervals, 
we found that locomotor activity as well as average metabolic rate and energy 
expenditure followed a clear daily rhythm in mice fed LFD and HFD ad libitum 
(chapter 4.3, figure 4b, c, d). These parameters were lowest during the animals’ resting 
phase from ZT3 – ZT9 and highest during their active phase from ZT15 – ZT21, 
whereas they exhibited similar values during both activity-independent intervals (ZT9 – 
ZT15 and ZT21 – ZT3) that were situated medially between these two extremes. 
However, mice fed HFD showed a reduction in these parameters during one or more 6-
hour intervals compared with mice fed LFD (chapter 4.3, figure 4b, c, d). This is in 
accordance with previous studies revealing impaired locomotor activity and energy 
metabolism during DIO (181). Here, we demonstrate that these impairments occur 
during phases when mice are active, but not during their exclusive resting phase. 
Feeding behaviour exhibited a slight variation from this clear daily rhythm (chapter 4.3, 
figure 4a). In mice fed LFD, caloric intake was minimal during their inactive phase and 
maximal during their active phase. Concerning the two activity-independent intervals, 
caloric intake was significantly higher during ZT9 – ZT15 relative to ZT21 – ZT3. We 
found similar results in mice fed HFD. Here, caloric intake was lowest during their 
inactive phase and highest during the two following intervals. However, this was not 
followed by a reduction in caloric intake as observed in mice fed LFD, but remained 
significantly increased during ZT21 – ZT3. The caloric overconsumption exclusively 
during this interval was sufficient to result in the overall increase in daily caloric intake 
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relative to mice fed LFD (chapter 4.3, supplementary figure 2a). A relative increase in 
caloric intake during the light relative to the dark phase has been reported previously in 
mice fed HFD (181). Here, we show that this increase is linked to the animals’ 
responsiveness to leptin. Intriguingly, in mice fed LFD caloric intake is increased at 
times when leptin sensitivity on a molecular level is at a minimum, and decreases when 
leptin sensitivity is at a maximum. Moreover, mice fed HFD show abnormally elevated 
caloric intake exclusively at times when leptin sensitivity on a molecular level is 
impaired relative to control mice. These findings provide further evidence for an 
important impact of this 24-hour rhythm of leptin signal transduction on physiological 
and behavioural responses. 
In TRF mice, access to HFD during either the inactive (ZT3 – ZT9) or active (ZT15 – 
ZT21) phase resulted in a slight dampening of the daily rhythm of locomotor activity, 
whereas mice with access to HFD exclusively during their leptin sensitive interval from 
ZT9 – ZT15 retained a robust locomotor activity rhythm relative to mice fed LFD ad 
libitum. In contrast, while mice that consumed HFD exclusively during their relative 
leptin resistant interval from ZT21 – ZT3 still showed lowest activity during the light 
phase, these animals lost the daily rhythm in locomotor activity observed in mice fed 
LFD and HFD ad libitum and displayed no variations between any of the subsequent 
intervals (chapter 4.3, figure 4b). 
The daily rhythms in average metabolic rate as well as energy expenditure that were 
displayed by ad libitum fed mice were affected in all TRF mice. To account for the 
differences in body mass between the experimental groups, we evaluated these 
parameters based on body weight. Mice with access to HFD during either their leptin 
sensitive or active phase retained the most robust rhythm relative to animals with ad 
libitum access to food, even though mice with access to food exclusively during their 
leptin sensitive phase showed no differences in both metabolic rate and energy 
expenditure between the feeding phase and the subsequent active phase. Notably, an 
animals’ metabolic rate is elevated during times of food intake and this finding can 
therefore be accounted for by the food intake-mediated increase in oxygen 
consumption. HFD feeding during either the animals’ inactive or leptin resistant phase, 
on the other hand, led to a loss of the daily rhythms in metabolic rate as well as energy 
expenditure, with energy expenditure being most severely impaired in mice that had 
food during the leptin resistant phase (chapter 4.3, figure 4c, d). 
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Furthermore, mice fed during the leptin resistant interval displayed elevated circulating 
insulin concentrations compared with mice fed LFD, independent of leptin treatment 
prior to blood sampling (chapter 4.3, figure 5b). Unfortunately, we were unable to 
analyse blood glucose concentrations in these mice, which could have revealed the 
severity of the metabolic derailment. Nonetheless, the increase in plasma insulin levels 
suggests disrupted insulin signal transduction that may eventually result in the 
manifestation of type 2 diabetes (23). 
Taken together, we demonstrate that the detrimental effects of HFD on metabolic 
health are dependent on when throughout the day the diet is consumed. HFD feeding at 
times when mice are unresponsive to the anorexigenic effects of leptin leads to 
symptoms of metabolic disease, whereas HFD at times when mice are sensitive to 
leptin protects from these detrimental health outcomes (Figure 4). 
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Figure 4: Effects of time-restricted feeding on metabolic health are dependent on the time 
of day. In mice, restricted access to HFD exclusively from ZT21 – ZT3, coinciding with their 
relative leptin resistant interval, leads to the manifestation of symptoms of metabolic disease 
such as compromised daily rhythms of locomotor activity, metabolic rate, and energy 
expenditure as well as increased circulating insulin levels. On the other hand, restricted access 
to HFD exclusively from ZT9 – ZT15, coinciding with their relative leptin sensitive interval, 
protects from the manifestation of these metabolic impairments. These effects on metabolic 
health are independent of activity states, since both TRF regimens allowed access to HFD for 3 
hours during the light and 3 hours during the dark phase each day. High-fat diet (HFD), Time-
restricted feeding (TRF), Zeitgeber time (ZT).  
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3.4. Future perspectives 
In this thesis, we revealed a 24-hour rhythm of hypothalamic leptin sensitivity that 
plays a crucial role in the regulation of whole body energy homeostasis. We 
furthermore demonstrated that HFD-induced obesity leads to a disruption of this 
rhythm, which in turn underlies the metabolic derangements observed in obese mice. 
The underlying molecular mechanism, by which obesity leads to this breakdown of 
physiological rhythmicity, is yet to be determined. Alterations in the secretion of 
circulating inflammatory cytokines or expression patterns of other leptin pathway-
inhibiting signals could be a plausible explanation for this phenomenon. Therefore, the 
investigation of 24-hour rhythms in hypothalamic gene expression of leptin inhibitors 
such as SOCS3 and the effect of HFD feeding on these patterns are to be considered in 
future experiments, as well as a potential rhythmic regulation of circulating pro-
inflammatory cytokines such as TNFα and IL-6.  
To assess whether elevated hypothalamic inflammation causes the disruption of leptin 
sensitivity at specific times during the day as observed in DIO mice, it would be of 
great interest to examine how inhibition of inflammation at defined times affects this 
phenomenon. Administration of short-acting pharmacological inhibitors of the pro-
inflammatory NFκB and JNK pathways in the middle of the dark phase, when reduced 
responsiveness to leptin in mice fed HFD first appears, and a potential reversal of HFD-
induced disruptions of metabolic rhythms on the molecular as well as behavioural level 
would determine the implication of hypothalamic inflammation in this metabolic 
derangement. 
Additionally, a closer investigation of the long-term effects of TRF on metabolic health 
could help develop better strategies for therapeutic interventions on a behavioural level, 
which could circumvent the side effects that often accompany pharmacological 
interventions. For example, it needs to be determined whether TRF at defined times 
during the day maintains its beneficial effects on metabolic health independent of the 
patients’ age and baseline health status, and how these positive health outcomes are 
affected by prolonged periods of unrestricted food consumption after periods of TRF.  
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3.5. Abstract 
3.5.1. Abstract (English) 
Obesity and related metabolic disorders such as type 2 diabetes are a major health issue 
of our modern society. The brain has been identified to play an essential role in the 
pathogenesis of these diseases. Disruptions of the neuroendocrine system, such as the 
development of hypothalamic leptin resistance, are strongly correlated with the 
manifestation of diet-induced obesity (DIO). To date, the molecular mechanisms 
underlying these metabolic derangements are incompletely understood. Over the last 
decade, a close connection of energy metabolism and the circadian clock has been 
established, but the link between DIO and disruptions of physiological rhythms still 
needs further investigation. Therefore, the aim of this thesis was to gain new insights 
into neuroendocrine mechanisms that lead to the development of leptin resistance and 
the role of physiological rhythms in the disruption of energy metabolism. 
In this study, we investigated the implication of the adipocyte-derived hormone 
adiponectin in neuroendocrine control of energy metabolism. We detected expression 
of all investigated genes involved in the adiponectin signalling pathway in the 
hypothalamus of mice. Expression levels of adiponectin were reduced during states of 
food deprivation, potentially presenting a regulatory mechanism to counteract the 
anorexigenic traits that had been previously described for central adiponectin signalling 
and that were confirmed by us in this study, in order to prevent further reduction in 
body weight. In both fasted control mice as well as DIO mice, gene expression of the 
adiponectin receptor AdipoR1 was elevated, suggesting multiple regulatory 
mechanisms to maintain sufficient adiponectin signal transduction. The upregulation of 
AdipoR1 during DIO might be an attempt to support the beneficial effects of the 
hormone on metabolic health that have been reported for peripheral adiponectin. In line 
with this, we demonstrated that adiponectin holds insulin-sensitising, blood glucose-
lowering and anti-inflammatory properties in control as well as DIO mice and that 
these effects are mediated via central signal transduction. 
We furthermore investigated the role of the WNT/β-catenin pathway in the 
neuroendocrine control of energy metabolism. Here, we found gene expression of 
members of the WNT pathway on all regulatory levels (ligands, intracellular pathway 
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enzymes, target genes) in the hypothalamus of adult Djungarian hamsters, Phodopus 
sungorus, a seasonal rodent that exhibits profound annual changes in body weight and 
leptin sensitivity. Expression of all ligands as well as target genes was upregulated in 
hamsters acclimated to long day (LD) relative to short day (SD) conditions. Confirming 
our results from these transcriptional studies, we furthermore found increased 
phosphorylation of the WNT pathway co-receptor LRP-6, demonstrating elevated 
activation of canonical WNT signalling, in LD hamsters. These findings provide strong 
evidence for increased WNT signalling during LD compared with SD photoperiod. We 
found a 24-hour rhythm in the hypothalamic expression of WNT target genes, with 
decreasing levels during the light and increasing levels during the dark phase in both 
LD and SD hamsters. Moreover, leptin administration led to a further increase in LRP-
6 activation in hamsters from both photoperiods. Taken together, we demonstrate a 
novel integration site for the leptin signal in the hypothalamus, potentially linking the 
WNT pathway to body weight regulation. Furthermore, our results suggest an 
important role of canonical WNT signalling in the seasonal as well as daily 
neuroendocrine control of energy metabolism in Djungarian hamsters. 
By examining whether hypothalamic leptin signalling and whole body metabolism are 
modulated by a daily rhythm, we detected a 24-hour rhythm of STAT3 
phosphorylation, a marker for activated leptin signalling on a molecular level, in the 
hypothalamus of wild-type mice. Both basal as well as leptin-induced leptin sensitivity 
were highest at the end of the dark (active) phase and lowest at the end of the light 
(inactive) phase. Furthermore, we found that leptin sensitivity on a behavioural level 
followed the same rhythm, with mice showing a greater response to exogenous leptin at 
the end of the dark phase at Zeitgeber time (ZT) 0 compared with the end of the light 
phase at ZT12. Throughout the 24-hour cycle, mice displayed a robust rhythm in food 
intake, locomotor activity as well as oxygen consumption and energy expenditure, with 
reduced whole body metabolism during their inactive and increased metabolic rate 
during their active phase. In DIO mice that were subjected to high-fat diet (HFD) 
feeding, we found a disruption of the 24-hour rhythmic regulation of leptin pathway 
activation on a molecular level for both basal and leptin-induced leptin sensitivity. 
Intriguingly, we demonstrated that this hypothalamic leptin resistance is a temporary 
phenomenon that persists only at specific times during the day. Responsiveness to 
leptin was deteriorated during the second part of the dark and the first half of the light 
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phase (ZT21 – ZT6), but identical to mice fed low-fat diet (LFD) at all other times on 
both the molecular and behavioural level. Furthermore, DIO mice displayed a 
disruption of the daily rhythms in food intake, locomotor activity, oxygen consumption 
and energy expenditure. We found that the daily caloric overconsumption observed in 
mice fed HFD was restricted to the phase when DIO mice were leptin resistant relative 
to mice fed LFD. In conclusion, these findings provide strong evidence for a crucial 
role of the 24-hour rhythm of leptin sensitivity in the control of energy metabolism.  
We furthermore demonstrated that mice with access to HFD exclusively during their 
leptin resistant phase (ZT21 – ZT3) displayed impairments in a variety of parameters 
that indicate metabolic health, such as compromised rhythms of locomotor activity, 
metabolic rate, and energy expenditure as well as increased circulating insulin levels. 
Restricting HFD exclusively to the leptin sensitive phase (ZT9 – ZT15), on the other 
hand, protected mice from the development of these severe metabolic impairments. To 
date it is still largely unknown whether HFD-induced development of metabolic 
diseases results from an increase in body fat content, diet composition or disrupted 
circadian rhythms. We observed these differences between TRF groups despite an 
identical reduction in body weight and plasma leptin levels in all TRF mice, suggesting 
that they are based on the time of food intake during the 24-hour rhythm of leptin 
sensitivity, but independent from factors such as body composition or HFD content. 
Nonetheless, all mice fed HFD displayed a reduction in the absolute values of average 
metabolic rate and energy expenditure relative to mice fed LFD, demonstrating that 
also the HFD itself affects energy metabolism. In conclusion, these results demonstrate 
that TRF is efficient in the reduction of body weight and the amelioration of metabolic 
health. However, our findings also highlight the importance of synchronising food 
intake with daily physiological rhythms to maintain metabolic health. 
Taken together, this thesis identifies novel pathways that are involved in the 
neuroendocrine regulation of energy metabolism and provides new insights into the 
connection between physiological rhythms and the development of metabolic diseases.  
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3.5.2. Zusammenfassung (Deutsch) 
Adipositas und damit einhergehende Folgeerkrankungen, wie zum Beispiel Diabetes 
mellitus Typ 2, stellen ein enormes Gesundheitsproblem in unserer modernen 
Wohlstandsgesellschaft dar. Dem zentralen Nervensystem wurde dabei eine 
wesentliche Rolle in der Pathogenese dieser Erkrankungen nachgewiesen. Stӧrungen 
des neuroendokrinen Systems, im Besonderen die Entstehung von hypothalamischer 
Leptinresistenz, korrelieren stark mit dem Auftreten von diӓtinduzierter Adipositas. Die 
molekularen Mechanismen, die diesen metabolischen Stӧrungen zugrunde liegen, sind 
noch immer unzureichend erforscht. Zudem wurde gezeigt, dass die Regulierung des 
Energiemetabolismus eng mit der circadianen Uhr in Verbindung steht. Der 
Zusammenhang zwischen Adipositas und der Stӧrung physiologischer Rhythmen 
bedarf jedoch noch weiterer Untersuchungen, um ausreichend verstanden zu werden. 
Das Ziel der vorliegenden Arbeit war es daher, sowohl neue Einblicke in die 
neuroendokrinen Mechanismen zu erlangen, die zur Entstehung von Leptinresistenz 
führen, als auch die Rolle physiologischer Rhythmen in der Entgleisung des 
Energiemetabolismus zu entschlüsseln. 
In dieser Arbeit konnte die Expression von Genen des Adiponektinsignalweges im 
Hypothalamus von Mӓusen sowie eine Reduktion der adiponektin-Konzentration bei 
gefasteten Tieren nachgewiesen werden. Dies dient mӧglicherweise dazu, den 
katabolen Eigenschaften von Adiponektin entgegenzuwirken und verhindert somit 
einen weiteren Verlust an Kӧrpergewicht. Die Erhӧhung der Genexpression des 
Adiponektinrezeptors, die wir in adipӧsen Mӓusen nachweisen konnten, kӧnnte einen 
Regulationsmechanismus darstellen, um den gesundheitsschӓdlichen Auswirkungen 
von Adipositas entgegenzuwirken. Dazu passen unsere Ergebnisse, die zeigen, dass 
zentral appliziertes Adiponektin zu einer Sensitisierung des Insulinsignalweges, einer 
Verbesserung der Glucosehomӧostase sowie einem antiinflammatorischen Effekt führt. 
Des Weiteren wurde die Rolle des WNT/β-catenin-Signalweges in der neuroendokrinen 
Regulation des Energiemetabolismus untersucht. Hierbei konnten wir die Expression 
aller untersuchten Gene des WNT-Signalweges im Gehirn von adulten Dsungarischen 
Zwerghamstern, deren Kӧrpergewicht und Leptinsensitivitӓt einer strengen 
jahreszeitlichen Regulation unterliegen, nachweisen. Zudem zeigten Zielgene des 
WNT-Signalweges eine tagesrhythmische Oszillation mit abfallenden Konzentrationen 
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wӓhrend des Tages und ansteigenden Konzentrationen wӓhrend der Nacht. Dies traf 
sowohl auf Langtag- (LT)- als auch auf Kurztag- (KT)-akklimatisierte Hamster zu. Die 
Genexpression bei LT-Hamstern war im Vergleich zu der bei KT-Hamstern ebenso 
erhӧht wie die Phosphorylierung des WNT-Korezeptors LRP-6, ein Zeichen für die 
Aktivierung des WNT-Signalweges. Diese Ergebnisse deuten auf eine erhӧhte WNT-
Signaltransduktion in LT-Hamstern hin. Zudem führte die Gabe von Leptin zu einer 
zusӓtzlichen Aktivierung des WNT-Signalweges in Hamstern aus beiden 
Photoperioden. Zusammenfassend legen diese Daten nahe, dass der WNT-Signalweg 
an der saisonalen sowie tagesrhythmischen Regulation des Energiestoffwechsels und 
des Kӧrpergewichts des Dsungarischen Zwerghamsters beteiligt ist. 
Zusӓtzlich konnten wir einen 24-Stunden-Rhythmus bei der Aktivierung des 
Leptinsignalweges im Hypothalamus von schlanken Kontrollmӓusen auf molekularer 
Ebene nachweisen. Sowohl die basale als auch die leptininduzierte Leptinsensitivitӓt 
waren am Ende der aktiven Phase (Zeitgeber time; ZT0) der Tiere am hӧchsten und am 
Ende der inaktiven Phase am niedrigsten. Auch auf der Verhaltensebene zeigten die 
Mӓuse zu ZT0 eine hӧhere Empfindlichkeit gegenüber Leptin als zu ZT12. 
Futteraufnahme, Bewegungsaktivitӓt, Stoffwechselrate und Energieverbrauch 
unterlagen ebenfalls einem tagesrhythmischen Verlauf und waren wӓhrend der 
inaktiven Phase reduziert und wӓhrend der aktiven Phase erhӧht. 
Adipӧse Mӓuse wiesen im Vergleich dazu eine Stӧrung des 24-Stunden-Rhythmus der 
Leptinsensitivitӓt auf molekularer Ebene auf. Überraschenderweise bestand diese 
Leptinresistenz allerdings nicht wӓhrend des gesamten Tagesverlaufs, sondern 
ausschließlich von ZT21 – ZT6. Zu allen anderen Zeitpunkten wiesen schlanke und 
adipӧse Mӓuse sowohl auf molekularer als auch auf Verhaltensebene die gleiche 
Sensitivitӓt gegenüber Leptin auf. Zudem waren die Tagesrhythmen von 
Futteraufnahme, Bewegungsaktivitӓt, Stoffwechselrate und Energieverbrauch bei 
Mӓusen auf hochkalorischer Diӓt gestӧrt. Die gesteigerte Kalorienaufnahme dieser 
Mӓuse im Vergleich zu der von Kontrollmӓusen fand ausschließlich wӓhrend deren 
leptinresistenter Phase statt. Diese Ergebnisse zeigen, dass die rhythmische Oszillation 
der hypothalamischen Leptinsensitivitӓt eine wichtige Rolle in der Regulation des 
Energiestoffwechsels spielt. 
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Des Weiteren konnten wir in dieser Arbeit nachweisen, dass der Verzehr einer 
hochkalorischen Diӓt ausschließlich wӓhrend der leptinresistenen Phase adipӧser 
Mӓuse (ZT21 – ZT3) zu einer Beeintrӓchtigung verschiedener Parameter führt, die 
einen gesunden Stoffwechsel anzeigen. Dies traf auf die Tagesrhythmik von 
Bewegungsaktivitӓt, Stoffwechselrate und Energieverbrauch sowie auf die 
zirkulierenden Insulinkonzentrationen zu. Mӓuse, deren Futteraufnahme ausschließlich 
wӓhrend ihrer leptinsensitiven Phase (ZT9 – ZT15) erfolgte, waren im Gegensatz dazu 
vor diesen negativen Auswirkungen auf den Energiemetabolismus geschützt. Ob die 
Entgleisung des Energiestoffwechsels, die durch den Konsum einer hochkalorischen 
Diӓt hervorgerufen wird, durch erhӧhte Kӧrperfettmasse, die Zusammensetzung der 
Diӓt oder Stӧrungen der circadianen Rhythmen bedingt ist, ist noch immer weitgehend 
unklar. Die Unterschiede im Energiestoffwechsel traten ungeachtet einer identischen 
Abnahme an Kӧrpergewicht sowie von zirkulierenden Leptinkonzentrationen bei allen 
Mӓusen auf, deren Zugang zu hochkalorischer Diӓt auf verschiedene Zeitrӓume 
wӓhrend des Tages (inaktive, leptinsensitive, aktive, leptinresistente Phase) beschrӓnkt 
war. Dies deutet darauf hin, dass der Einfluss der Futteraufnahme auf die metabolische 
Gesundheit hauptsӓchlich von der Tageszeit und dem Status der Leptinsensitivitӓt 
abhӓngt, weniger jedoch von anderen Faktoren wie Kӧrperfettgehalt oder 
Zusammensetzung der Diӓt. Trotzdessen wiesen alle Mӓuse, die eine hochkalorische 
Diӓt erhielten, im Vergleich zu Kontrollmӓusen eine Beeintrӓchtigung der absoluten 
Werte für Stoffwechselrate und Energieverbrauch auf, was zusӓtzlich auf einen 
metabolischen Effekt der hochkalorischen Diӓt selbst hindeutet. Zusammengefasst 
konnten wir mit dieser Studie nachweisen, dass Varianten des intermittierenden 
Fastens, in diesem Fall die sogenannte 16/8-Variante mit 16 Stunden Fasten und 8 
Stunden Nahrungsaufnahme pro Tag, bei einer Gewichtsabnahme und der 
Verbesserung der metabolischen Gesundheit helfen kӧnnen. Allerdings ist hierbei zu 
beachten, dass der Zeitraum der Nahrungsaufnahme kritisch ist, um die positiven 
Auswirkungen auf den Stoffwechsel zu garantieren. 
Mit der vorliegenden Arbeit konnten neue Einblicke in die neuroendokrine Regulation 
des Energiestoffwechsels gewonnen und weitere Signalwege identifiziert werden, die 
an dieser Regulation beteiligt sind. Zusӓtzlich konnten wir eine wichtige Rolle der 
rhythmischen Oszillation der hypothalamischen Leptinsensitivitӓt bei der Entstehung 
von Stoffwechselentgleisungen nachweisen.  
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Abstract 
Synchronisation between biological temporal clocks and metabolism is crucial for the 
survival of most species. It is unknown as to whether the circadian timing of time-
restricted feeding (TRF), a diet strategy with apparent efficacy in promoting weight 
loss, is important for maximising its beneficial effects. Here, we examined whether 
leptin signalling, important for the control of energy metabolism, is regulated by a 24-
hour rhythm in the hypothalamus of mice and whether diet-induced obesity (DIO) 
affects this rhythmicity. Furthermore, we investigated whether the beneficial effects of 
TRF depend on the timing of the feeding period. Therefore, we examined the ability of 
leptin to induce leptin signalling in the arcuate nucleus (ARC) of fasted mice 
throughout the 24-hour rhythm by immunohistochemistry. By measuring activated 
phospho-STAT3-immunoreactive cells after leptin injection, we found that leptin 
sensitivity was regulated in a 24-rhythmic manner in control mice. In these mice leptin 
sensitivity was highest in the early morning around Zeitgeber time (ZT) 0, after lights 
on, with sensitivity declining throughout the light phase and increasing throughout the 
dark phase. Surprisingly, leptin resistance in mice fed a high-fat diet (HFD) was only 
temporary and varied during the 24-hour rhythm, with deteriorated leptin signalling 
occurring only during the last half of the dark phase and the first half of the light phase 
compared with control animals. At all other time points, leptin sensitivity was similar to 
control mice. To investigate the physiological effect of this rhythmicity, we next 
injected leptin or vehicle in control and HFD mice either at ZT0 or ZT12 and compared 
their caloric intake. Surprisingly, control mice showed decreased caloric intake only 
when leptin injections occurred at ZT0, while HFD mice remained resistant to leptin at 
both ZT0 and ZT12, suggesting that control mice are sensitive to exogenous leptin on a 
behavioural level exclusively during the first part of the light phase. The daily rhythm 
of caloric intake between control and HFD mice was identical over the 24-hour rhythm, 
except for elevated caloric intake in HFD mice between ZT21-3 (3 hours of dark and 3 
hours of light period, the period when HFD mice were leptin resistant on a molecular 
level) independent of locomotor activity. TRF (a limitation of HFD to 6 hours each day 
continuously for 3 weeks) regardless of circadian timing led to a marked reduction in 
food intake and body weight, but not in locomotor activity or energy expenditure 
compared with ad libitum fed mice. Specifically when TRF occurred from ZT21-3, it 
led to a disruption in the daily rhythm of locomotor activity and energy expenditure, as 
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well as to increased plasma insulin levels compared with other TRF periods. These data 
provide evidence that the circadian clock plays a crucial role in the control of leptin 
action and whole body energy homeostasis. Furthermore, TRF may be a promising 
weight loss strategy and its beneficial effects depend on circadian timing. 
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Introduction 
Synchronisation between daily environmental alterations and biological processes is 
crucial for the survival of most living organisms. Endogenous circadian clocks adjust 
these processes to the most beneficial time of day in a broad range of species. In 
mammals, the master pacemaker resides in the suprachiasmatic nucleus (SCN) of the 
hypothalamus and is entrained by external cues (Zeitgebers), of which light is the 
primary entrainment signal. This central circadian clock controls local clocks in other 
brain regions as well as the periphery to orchestrate physiological and behavioural 
rhythms (1-3). 
In recent years, numerous studies have highlighted a close correlation of the circadian 
clock system and the maintenance of energy metabolism (4-9). In mice, SCN lesions as 
well as various clock gene mutations result in metabolic disorders, including obesity, 
hyperlipidemia, hyperglycemia and an impairment in glucose tolerance and insulin 
sensitivity (8, 10-13). In humans, circadian misalignments such as shift work and social 
jet lag have been shown to be associated with symptoms of the metabolic syndrome, 
including an increased BMI, impaired glucose tolerance and insulin sensitivity and an 
increase in mean arterial blood pressure (14, 15).  
The adipocyte-derived hormone leptin plays a crucial role in the control of metabolism 
by reducing food intake and increasing energy expenditure, ultimately leading to a 
decrease of body weight (BW) (16-18). Diet-induced obesity (DIO), the leading cause 
for obesity in humans and many rodent models, is accompanied by hyperleptinemia 
(19). Despite increased circulating leptin levels in most cases of obesity, leptin however 
fails to mediate its weight-reducing effects (20). Molecularly, this condition of leptin 
resistance is characterised by a disturbance in the ability of leptin to phosphorylate and 
activate the transcription factor signal transducer and activator of transcription 3 
(STAT3) in the hypothalamus, specifically the arcuate nucleus (ARC), a brain region 
where large numbers of leptin receptors are expressed and that is crucial for 
maintaining energy homeostasis (21-24). Recent findings from our laboratory as well 
as from others show that chronic circadian disruptions cause impaired hypothalamic 
leptin sensitivity and elevated BW gain (25)(own unpublished observations), providing 
a possible explanation for the association between circadian misalignment and obesity 
as seen in humans (14). 
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While circadian misalignment led to reduced hypothalamic leptin signal transduction 
(25)(own unpublished observations), high-fat diet (HFD) feeding was also shown to 
disrupt behavioural and molecular circadian rhythms, including eating behaviour, 
locomotor activity and expression of circadian clock genes (26-28). Interestingly, 
feeding of this diet for only one week already causes a disruption of circadian rhythms 
in the liver, whereas neither the SCN nor other peripheral clocks were impaired (26), 
suggesting the presence and involvement of an SCN-independent oscillator in this 
process. Aside from light, food intake has been identified as another Zeitgeber for 
circadian rhythms and the existence of a food-entrainable oscillator involving 
AgRP/NPY neurons of the hypothalamus was proposed (29-31).  
Kohsaka et al. showed that time-restricted feeding (TRF) of HFD during the inactive 
phase of mice results in increased BW, even though caloric intake is similar to mice 
that have access to HFD during their active phase (28). In line with this, access to HFD 
only during the active phase protects mice from metabolic disease compared with mice 
that have ad libitum access to HFD (32). 
To our knowledge it is still unknown as to whether hypothalamic leptin sensitivity is 
regulated by a circadian rhythm and how HFD feeding affects leptin signal transduction 
throughout the day. In the current study we therefore examined the ability of leptin to 
induce activation of the transcription factor STAT3 (pSTAT3) at different times 
throughout the 24 hour day in mice that were either fed HFD or low-fat diet (LFD). 
After identifying that the response to leptin differs throughout the day and depends on 
the type of diet, we measured the behavioural response to leptin at times when the 
ability of leptin to activate pSTAT3 was either maximal or minimal. By restricting the 
timing of food access to 6 hours per day (time-restricted feeding; TRF) at 4 different 
intervals throughout the 24 hour day we assessed to what extent the beneficial effects 
of TRF during HFD feeding on BW gain and metabolic health are dependent on the 
time of day. 
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Materials and methods 
Animals 
Adult male C57BL/6J mice were obtained from the University of Otago Taieri 
Resource Unit and housed individually under controlled conditions of temperature 
(22 °C ± 1 °C) and light (12 h:12 h light:dark cycle; lights on at Zeitgeber time (ZT) 0, 
lights off at ZT12) with ad libitum access to water and food, unless stated otherwise. 
Mice aged 3 – 6 months were fed either LFD, with 10% energy from fat (kcal) or HFD 
with 60% energy from fat (D12450B and D12492, respectively; Research Diets). All 
experimental protocols were approved by the University of Otago Animal Ethics 
Committee. 
 
Experiment 1: Daily rhythm in leptin sensitivity 
We investigated whether intracellular leptin signalling is modulated by a 24-hour 
rhythm in the hypothalamus of lean mice and to what extent the consumption of HFD 
affects this daily rhythm. Therefore, we examined the phosphorylation of STAT3 
(Tyr705), as a marker of leptin pathway activation, every 3 h throughout the 24-h day by 
immunohistochemistry. Mice were fed either LFD or HFD (n = 64 each) for four weeks 
and were food deprived for 24 h before transcardial perfusion. Animals were 
subdivided into weight-matched groups and received a single intraperitoneal (i.p.) 
injection of either recombinant mouse leptin (1.25 mg/kg in PBS; R&D Systems) or 
vehicle (PBS) every three hours throughout a day, with animals being treated at either 
ZT0, ZT3, ZT6, ZT9, ZT12, ZT15, ZT18 or ZT21 (n = 4 per group). Thirty minutes 
after injections, transcardial perfusion was performed and brains were treated as 
described elsewhere (33). A second cohort of mice was generated as described above, 
decapitated and trunk blood was collected from these animals, in order to measure 
serum levels of the adiposity hormones leptin and insulin as well as fasting glucose 
levels. Animals killed during the dark phase were handled under dim red light. 
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Experiment 2: Leptin-mediated anorexigenic effects at ZT0 vs ZT12 
To assess whether the ability of leptin to reduce food intake is affected by the circadian 
rhythm, we administered leptin at different times of the day. Mice were fed either LFD 
or HFD (n = 20 each) for four weeks and were food deprived for 24 h before the 
experiment. Half of each group was injected at ZT0, the other half at ZT12. Animals 
were weight-matched for each time point and received a single i.p. injection of either 
leptin (5.0 mg/kg in 20 mM TRIS-HCl) or vehicle (20 mM TRIS-HCl). Animals were 
re-fed with their respective diets directly after the injections and food intake was 
monitored 4 h and 24 h post-injection. For ethical reasons, the experiment was repeated 
after a recovery period of 3 days as described above and results are presented as pooled 
data points from both experiments. Animals treated with leptin or vehicle at ZT0 in the 
first experiment received the same treatment at ZT12 in the second experiment and vice 
versa (n = 6 – 10 per group). 
 
Experiment 3: Effects of time-restricted feeding on energy metabolism 
To investigate whether periodic reductions in caloric intake are able to reverse 
metabolic derangements induced by HFD, mice were put on a time-restricted feeding 
(TRF) schedule. Mice were fed either LFD (n = 8) or HFD (n = 40) ad libitum for 28 
days, followed by time-restricted access to HFD for a further 24 days. To examine 
whether potential beneficial effects of TRF are dependent on the timing of food intake 
throughout the 24-hour rhythm, mice were granted access to food at different intervals 
(n = 8 per group). Two control groups had ad libitum access to LFD (LFDal) and HFD 
(HFDal), respectively, whereas four TRF groups had access to HFD for a 6 h 
continuous interval each day, followed by 18 h of food deprivation, until the end of the 
experiment. The TRF groups were granted access to food during the following 
intervals: from ZT3 – ZT9 (group TRF3–9), ZT9 – ZT15 (TRF9–15), ZT15 – ZT21 
(TRF15–21) and ZT21 – ZT3 (TRF21–3), respectively (Supplementary figure 1). BW 
was monitored throughout the entire experiment. For mice fed LFDal and HFDal, these 
parameters were measured at ZT3, whereas for all TRF groups, they were measured 
before and after their respective feeding periods. On day 7 of TRF, mice were 
transferred to metabolic cages for 3 days, followed by a return to their normal housing 
conditions, as described above. At the end of the experiment, mice were fasted for 18 h; 
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each group was subdivided and received a single i.p. injection of either leptin 
(1.25 mg/kg in PBS) or vehicle (PBS) 30 minutes prior to transcardial perfusion (33). 
Both control groups were injected at ZT3, whereas TRF groups were injected at the 
start of their usual feeding periods (i.e. injection of TRF3–9 mice at ZT3, injection of 
TRF9–15 mice at ZT9 etc.). Blood was collected prior to perfusions from the inferior 
vena cava into heparinized tubes in order to measure plasma levels of leptin, insulin 
and fasting glucose levels. Animals killed during the dark phase were handled under 
dim red light. 
 
Metabolic measurements 
As part of experiment 3, we examined whether TRF causes changes in energy 
metabolism and behaviour. Therefore, mice were monitored in a multichannel 
respirometry system (3721 mouse cages, Promethion, Sable Systems International) for 
3 days. The air flow in the cages was adjusted to 2000 ml/min and monitored 
constantly. The system allowed synchronised analysis of O2 consumption (VO2), CO2 
production (VCO2), energy expenditure (EE), food intake, BW and locomotor activity. 
Running wheels were removed from the cages during the experiment. Data collected 
were analysed with the ExpeData data analysis software (Sable Systems Int.). To 
compare metabolic parameters specific for the different feeding intervals of the TRF 
groups, raw data for each day were binned into defined 6-hour intervals (ZT3 – ZT9, 
ZT9 – ZT15, ZT15 – ZT21, ZT21 – ZT3) using a customized automated analysis script 
(Sable Systems Int.). The average of each of the four 6-hour intervals over the 3 days of 
measurement was then calculated and compared between the six groups. Additionally, 
we compared these metabolic parameters over the 24-hour cycle, by combining the data 
from the 6-hour intervals. 
 
Immunohistochemistry 
Free-floating brain sections were pre-treated with 10% methanol, 1% NaOH and 1% 
H2O2 in H2O for 20 min, 0.3% glycine for 10 min and 0.03% sodium dodecyl sulphate 
for 10 min. Next, sections were blocked for 1 h with 1% normal goat serum and 5% 
bovine serum albumin in Tris-buffered saline (TBS)-Triton X-100 (0.5%), followed by 
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overnight incubation at 4 °C using a rabbit anti-phospho-STAT3 (Tyr705) antibody 
(1:1000 in blocking solution; catalogue no. 9131, Cell Signaling Technology, Inc.). On 
the next day, sections were rinsed and incubated for 1 h with biotinylated goat anti-
rabbit antibody (1:1000 in blocking solution), followed by 1 h in avidin-biotin complex 
solution (Vector Laboratories, Inc.). Then, the signal was developed by 
diaminobenzidine solution (Vector Laboratories, Inc.), giving a grey precipitate. 
Pictures were taken and immunoreactive (ir) cells in the ARC were counted in three 
sections per animal by two investigators who were blinded to the treatments. 
 
Enzyme-linked immunosorbent assays and Glucose assays 
To measure circulating levels of leptin, insulin and glucose, blood was collected from 
mice as described above. After collection, blood was immediately placed on ice and 
then centrifuged for 20 minutes at 4 °C and 13000 rpm. Serum and plasma were stored 
at -80 °C until assayed. Enzyme-linked immunosorbent assays and glucose assays 
(Mouse Leptin ELISA Kit, catalogue no. 90030; Ultra Sensitive Mouse Insulin ELISA 
Kit, catalogue no. 90080; Mouse Glucose Assay Kit, catalogue no. 81692; Crystal 
Chem Inc.) were performed in accordance with the kit instructions and all samples 
were assayed in duplicate. Because circulating leptin levels of mice fed HFD were 
expected to be above the sensitivity range of the leptin assay, serum and plasma 
samples of those mice were diluted 1:8 with the kits’ own sample diluent to allow the 
analysis of circulating leptin levels. 
 
Statistical analysis 
The 24-hour rhythmicity of leptin sensitivity was analysed by three-way ANOVA with 
diet (LFD or HFD), treatment (vehicle or leptin) and time (ZT) as variables, followed 
by a Tukey’s range post hoc test using SigmaStat statistical software (Systat Software, 
Inc.). To illustrate rhythmicity, a fourth order polynomial nonlinear regression curve 
was fitted with GraphPad Prism software (GraphPad Software, Inc.). Serum insulin 
levels were analysed by three-way ANOVA, as described above. All other data were 
analysed by either one- or two-way ANOVA, as appropriate, with diet and time as 
variables for serum leptin levels throughout the 24-hour cycle or time of food access 
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(LFDal, HFDal, TRF3–9, TRF9–15, TRF15–21 or TRF21–3) and period of day (ZT3 – 
ZT9, ZT9 – ZT15, ZT15 – ZT21, ZT21 – ZT3) for metabolic measurements or 
treatment for both leptin sensitivity and plasma insulin levels of TRF mice. BW 
trajectory of TRF mice was analysed by two-way repeated measures ANOVA. Where 
appropriate, this was followed by a Tukey’s range post hoc test using GraphPad Prism 
software. Results are presented as the mean ± SEM and P < 0.05 was considered 
statistically significant. 
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Results 
Experiment 1:  
Daily rhythm in the regulation of hypothalamic leptin sensitivity in mice on LFD 
and HFD 
To investigate how leptin sensitivity is regulated over the course of a day, we evaluated 
the number of pSTAT3 (Tyr705)-ir cells in the ARC of 24 h fasted mice on LFD or 
HFD every 3 h throughout the 24-hour cycle. We found a 24-hour rhythm of pSTAT3 
activation in both LFD and HFD-fed mice, with significant interactions between diet 
and time (P < 0.001), diet and treatment (P < 0.001) and diet, treatment and time 
(P = 0.005; Fig. 1, A and B), but not treatment and time (P = 0.692). In both LFD- and 
HFD-fed mice, leptin compared with vehicle treatment led to an increase of pSTAT3-ir 
cells in the ARC at all examined time points (LFD, P < 0.001; HFD, P ≤ 0.012).  
In vehicle-treated mice on LFD the number of pSTAT3-ir cells differed dependent on 
the time of day (P < 0.001) The highest number was detected at the beginning of the 
light phase at ZT0 (34 ± 3 cells), followed by declining levels throughout the light and 
increasing levels throughout the dark phase. Relative to ZT0, the number of pSTAT3-ir 
cells was reduced by about 65% at ZT3 (P = 0.016), 84% at ZT6 (P < 0.001), 78% at 
ZT9 (P = 0.001) and 66% at ZT12 (P = 0.008). For vehicle-treated mice on HFD an 
overall rhythmicity in basal pSTAT3-ir levels was detected (P = 0.027), however 
contrary to mice fed LFD, the subsequent Tukey’s multiple comparisons test did not 
reveal significant differences between any of the individual time points (48 ± 10 cells at 
ZT0).  
Leptin-treated mice fed LFD revealed a significant difference in the number of 
pSTAT3-ir cells over the 24-hour rhythm (P = 0.023) with levels peaking at the 
beginning of the light phase at ZT0 (198 ± 16 cells). Levels declined throughout the 
light phase and were reduced by about 26% at ZT9 compared with ZT0 (P = 0.015). 
This trough at the end of the light phase was followed by increasing levels of pSTAT3-
ir cells throughout the dark phase. Leptin treatment in mice fed HFD revealed a 24-
hour rhythm in the activation of STAT3 (P < 0.001), but this rhythm was inverted 
compared to mice fed LFD, revealing lowest levels at ZT0 (110 ± 15 cells). Levels then 
increased during the light phase, reaching peak values half-way throughout the dark 
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phase at ZT18 and subsequently decreased during the second half of the dark phase. 
Activation of STAT3 was elevated by about 46% at ZT9 (P = 0.049), 49% at ZT12 
(P = 0.032), 70% at ZT15 (P < 0.001) and 75% at ZT18 (P = 0.001). 
We found that the number of pSTAT3-ir cells, when compared between mice fed LFD 
vs HFD (in both vehicle- and leptin-treated groups), was not consistently different 
throughout the whole 24-hour cycle, but differences were dependent on the time of day. 
Vehicle-treated mice fed HFD compared with LFD showed an increased number of 
pSTAT3-ir cells at ZT6 (P = 0.023), ZT9 (P = 0.024), ZT12 (P = 0.003), ZT15 
(P < 0.001) and ZT18 (P < 0.001), whereas at ZT0, ZT3 and ZT21 no differences were 
revealed. Leptin treatment, by contrast, revealed reduced levels in mice fed HFD 
compared with LFD during the first half of the light phase at ZT0 (P < 0.001), ZT3 
(P < 0.001) and ZT6 (P < 0.001) and towards the end of the dark phase at 
ZT21(P = 0.018), whereas levels remained similar between LFD- and HFD-fed mice 
from ZT9 to ZT18. 
 
Daily rhythm of serum leptin levels in fasted mice on LFD and HFD 
We next investigated to what extent endogenous leptin levels vary throughout the 24-
hour rhythm in 24 h fasted mice on LFD and HFD. To reflect endogenous leptin levels 
only measurements of vehicle-injected mice were included whereas analysis of leptin-
injected mice was excluded from the study due to excessively high leptin 
concentrations. We found significant effects of diet and time (P < 0.001), as well as an 
interaction between diet and time on levels of circulating leptin (P < 0.001). Mice on 
LFD revealed no significant changes in serum leptin concentrations over the course of 
the day, with concentrations ranging between a maximum of 6.08 ± 0.59 ng/mL at ZT9 
and a minimum of 3.37 ± 1.48 ng/mL at ZT12 (P ≥ 0.997; Fig. 2, A). Mice on HFD on 
the other hand showed a daily rhythm of serum leptin levels with elevated levels during 
the first half of the light phase, reaching a peak at ZT6 with a concentration of 48.08 ± 
2.60 ng/mL, followed by reduced levels during the second half of the light phase and 
continuously low levels during the dark phase. Leptin levels reached a minimum of 
13.68 ± 2.57 ng/mL at ZT18. Leptin levels were elevated at ZT3 compared with ZT0, 
ZT12, ZT15, ZT18 and ZT21 (P < 0.05, each), at ZT6 compared with ZT0, ZT9, ZT12, 
ZT15, ZT18 and ZT21 (P < 0.05, each) and at ZT9 compared with ZT0, ZT12, ZT18 
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and ZT21 (P < 0.01, each). HFD feeding led to an overall increase of serum leptin 
levels across all examined time points compared with LFD feeding (LFD = 4.80 ± 0.94 
ng/mL on average; HFD = 26.65 ± 1.05 ng/mL on average; P < 0.05 for each ZT).  
Effects of diet, leptin injections and time on serum insulin levels in fasted mice 
We measured serum insulin levels over the 24-hour time course in fasted mice on LFD 
and HFD that were challenged with either vehicle or leptin injections. The 24-hour 
profile of circulating insulin levels revealed a significant effect of diet (P < 0.001; Fig. 
2, B), whereas neither leptin treatment nor time of day had a significant effect on 
insulin concentrations (P = 0.229 and P = 0.541, respectively). Mice on HFD as 
compared with LFD showed an overall increase in serum insulin concentrations 
(LFD = 0.49 ± 0.03 ng/mL on average; HFD = 0.69 ± 0.03 ng/mL on average) that was 
independent of both the treatment and the time of day.  
 
Effects of diet, leptin injections and time on fasting serum glucose levels in mice 
Fasting glucose concentrations were significantly affected by of both diet and time of 
day (P = 0.003 and P < 0.001, respectively), whereas leptin injections did not alter 
serum glucose levels (P = 0.845). The effect of different times throughout the day was 
dependent on which diet was present (ZT x Diet, P = 0.010). In LFD-fed animals, no 
significant changes in glucose levels over the 24-hour course were detected, with 
concentrations ranging from a minimum of 108.79 ± 16.23 mg/dL at ZT0 to a 
maximum of 152.18 ± 6.02 mg/dL at ZT21 in vehicle-treated mice and between 
143.74 ± 19.20 mg/dL at ZT 3 and 102.25 ± 8.90 mg/dL at ZT6 in leptin-treated mice 
(Fig. 2, C). HFD-fed mice on the other hand revealed a time-dependent rhythm in 
glucose levels with continuously low levels during the light phase, with vehicle-treated 
mice reaching a nadir at ZT9 (concentrations of 103.37 ± 2.58 mg/dL) and leptin-
treated mice revealing lowest levels at ZT6 with 108.67 ± 4.78 mg/dL. This was 
followed by increasing levels during the dark phase, with both vehicle- and leptin-
treated mice reaching a peak at ZT21 with concentrations of 166.25 ± 15.59 mg/dL and 
192.86 ± 11.77 mg/dL, respectively. Glucose levels in mice on HFD at ZT0, ZT3, ZT6 
and ZT9 were reduced compared with ZT21, as well as at ZT6 and ZT9 compared with 
both ZT15 and ZT18 (P < 0.05, for each time comparison). HFD feeding as compared 
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with LFD caused an increase in glucose concentrations at ZT15, ZT18 and ZT21 
(P = 0.017, P = 0.006 and P = 0.004, respectively), whereas at all other times glucose 
concentrations remained similar between the two diets.  
 
Experiment 2:  
Leptin’s anorexigenic effects are restricted to the relative leptin sensitive phase in 
mice fed LFD  
After we had established that leptin sensitivity on a molecular level in the ARC is 
altered depending on the time of day, we next investigated whether leptin 
responsiveness at a behavioural level is also rhythmically regulated. Therefore, caloric 
intake was measured following leptin injections at times when DIO mice were leptin 
resistant (ZT0) and sensitive (ZT12) compared with mice fed LFD. Two-way ANOVA 
revealed a significant effect of leptin treatment (P < 0.001), which was dependent on 
the time of the injections (interaction, P = 0.024). For further analysis, we next 
compared the accumulated caloric intake over 4 h (Fig. 1, C) and 24 h (Fig. 1, D) after 
injections between vehicle-treated mice and their respective leptin-treated counterparts. 
Therefore, we defined the average caloric intake of vehicle-treated mice as baseline and 
compared it with the deviant caloric intake of leptin-treated mice that were fed the same 
diet and injected at the same time point. We found that in mice fed LFD, leptin 
administration at ZT0 led to a decrease in accumulated caloric intake over 4 h (Δ 
1.97 ± 0.45 kcal, P = 0.013) as well as 24 h (Δ 2.07 ± 0.60 kcal; P = 0.024) after 
injections compared with vehicle-treated mice. In contrast, mice fed HFD and injected 
with leptin at ZT0 showed no differences in caloric intake after 4 h (Δ 0.77 ± 0.40 kcal) 
and 24 h (Δ 0.26 ± 0.86 kcal) compared with their vehicle-treated counterparts. Leptin 
injections at ZT12 did not lead to a decrease in caloric intake in mice fed either LFD 
(4 h: Δ 0.75 ± 0.22 kcal; 24 h: Δ 0.65 ± 0.55 kcal) or HFD (4 h: Δ 0.71 ± 0.63 kcal; 
24 h: Δ 0.45 ± 1.00 kcal).  
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Experiment 3:  
Body weight trajectory of TRF mice 
We established that HFD-induced leptin resistance on a molecular level is restricted to 
the period between ZT21 – ZT6 whereas mice fed HFD revealed an identical absolute 
increase in the number of pSTAT3-ir cells compared with mice fed LFD, suggesting 
molecular leptin sensitivity between ZT9 – ZT18. To investigate the potential impact of 
food restriction to these time periods, we restricted access to HFD to 6-hour intervals 
with TRF9–15 mice receiving HFD exclusively during their leptin sensitive interval 
and TRF21–3 mice exclusively during their leptin resistant interval. The BW of mice 
from experiment 3 was monitored every second day for the first 3 weeks while all mice 
had ad libitum access to their respective diets and then daily with the onset of TRF 
throughout the remainder of the experiment. By day 9 of exposure to their respective 
diets, mice fed HFD had a significantly increased BW compared with mice fed LFD 
(Fig. 3). This BW increase in HFDal mice persisted until the end of the experiment 
(P ≤ 0.023). After 28 days of ad libitum feeding, mice on HFD were transferred to the 
TRF regimen. While mice fed HFDal were still on a positive BW trajectory until the 
end of the experiment, TRF mice decreased their BW shortly after the start of TRF, but 
retained a higher BW compared with mice fed LFDal until all animals were transferred 
into the metabolic cages on day 35 of the experiment (P ≤ 0.027). By day 40, all TRF 
mice had reduced their BW to levels similar to LFDal mice. TRF3–9, TRF9–15 and 
TRF21–3 mice had a significantly lower BW after 16 days of restricted food access and 
TRF15–21 mice after 18 days compared with HFDal mice (P ≤ 0.034). There was no 
difference in BW between the four TRF groups throughout the whole experiment. At 
the end of the experiment, BW was 30.8 ± 0.7 g for mice on LFDal, 38.4 ± 1.3 g for 
mice on HFDal, 32.5 ± 0.8 g for TRF3–9 mice, 32.9 ± 0.9 g for TRF9–15 mice, 
33.6 ± 0.4 g for TRF15–21 mice and 33.4 ± 0.8 g for TRF21–3 mice. 
 
Mice on HFD were susceptible to caloric overconsumption exclusively during their 
relative leptin insensitive phase from ZT21 – ZT3 
Using metabolic cages, we assessed the average caloric intake during the four TRF 
intervals throughout the 24-hour time course. TRF mice with limited access to food 
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consumed their food allocations exclusively during their respective food access 
intervals (Fig. 4, A). Comparing caloric intake for each of the defined intervals 
throughout the day amongst mice fed LFDal and HFDal, we found a distinct daily 
rhythm that was present in mice fed LFD, but less pronounced in mice fed HFD (Fig. 4, 
A). With a caloric intake of 0.92 ± 0.20 kcal, mice fed LFD revealed the lowest caloric 
intake during the light phase from ZT3 – ZT9, coinciding with their inactive phase. 
Compared with the preceding interval, their caloric intake increased significantly 
during ZT9 – ZT15 (3.49 ± 0.33 kcal; P < 0.001) and remained high during the dark 
phase between ZT15 – ZT21 (3.85 ± 0.38 kcal; Vs ZT3 – ZT9, P < 0.001). This was 
followed by a significant reduction in caloric intake during ZT21 – ZT3 (2.24 ± 0.31 
kcal; P = 0.025, vs ZT15 – ZT21), with a return to levels that were statistically similar 
to ZT3 – ZT9. Caloric intake in mice fed HFD during ZT3 – ZT9 (1.54 ± 0.35 kcal), 
ZT9 – ZT15 (3.91 ± 0.48 kcal) and ZT15 – ZT21 (4.69 ± 0.42 kcal) was not 
significantly different from caloric intake in LFD during their respective intervals. 
Surprisingly, HFD feeding led to the consumption of more calories compared with LFD 
exclusively during the relative leptin insensitive interval of mice on HFD from ZT21 – 
ZT3 (4.04 ± 0.40 kcal; P = 0.011). While in mice on LFD food intake dropped 
distinctly after the dark period, it remained elevated in mice on HFD (ZT15 – ZT21 vs 
ZT21 – ZT3; LFD, P = 0.025; HFD, P = 0.912).  
Additionally, we evaluated the cumulative caloric intake over 24 hours for each group 
(Suppl Fig. 2, A). The overall daily caloric intake was 10.50 ± 0.61 kcal for mice that 
received LFDal, 14.17 ± 0.47 kcal for HFDal, 5.94 ± 0.72 kcal for TRF3–9, 7.09 ± 0.71 
kcal for TRF9–15, 7.70 ± 0.76 kcal for TRF15–21 and 8.07 ± 0.69 kcal for TRF21–3. 
One-way ANOVA revealed that mice on HFDal consumed significantly more calories 
than any other group (vs. LFDal, P = 0.003; vs. all other groups, P < 0.001). The daily 
caloric intake of mice from the TRF3–9 and TRF9–15 groups was significantly lower 
compared with mice on LFDal (P < 0.001 and P = 0.013, respectively), whereas it was 
similar to the TRF15–21 and TRF21–3 groups, which were also not different to mice 
on LFDal. 
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TRF21–3 mice lose their daily rhythm of locomotor activity 
We next investigated whether the rhythm that we observed in the feeding pattern is 
associated with alterations in locomotor activity. Two-way ANOVA revealed 
significant effects of both time of food access and the period of day, as well as a 
significant interaction between both parameters (P < 0.001, each; Fig. 4, B). Locomotor 
activity during the intervals ZT3 – ZT9, ZT9 – ZT15, ZT15 – ZT21 and ZT21 – ZT3 
was 16.65 ± 1.97 m, 45.32 ± 3.50 m, 83.00 ± 8.01 m, 47.91 ± 4.25 m in LFDal mice, 
16.54 ± 1.53 m, 34.04 ± 2.76 m, 52.16 ± 3.39 m, 34.59 ± 2.45 m in HFDal mice, 
15.83 ± 1.63 m, 56.46 ± 5.30 m, 63.38 ± 4.83 m, 35.98 ± 2.93 m in TRF3–9, 
18.05 ± 1.96 m, 51.34 ± 3.65 m, 70.82 ± 5.96 m, 43.28 ± 5.69 m in TRF9–15, 
15.43 ± 1.67 m, 47.00 ± 3.51 m, 63.11 ± 5.09 m, 51.30 ± 4.16 m in TRF15–21 and 
19.28 ± 1.84 m, 52.80 ± 2.98 m, 48.79 ± 3.14 m, 48.70 ± 3.69 m in TRF21–3 mice, 
respectively. Mice fed LFDal as well as HFDal demonstrated a circadian rhythm of 
locomotor activity, with lowest activity levels during their inactive phase from ZT3 – 
ZT9 and highest activity levels during their active phase from ZT15 – ZT21 (LFDal: 
P < 0.001; HFDal: P < 0.001). During ZT9 – ZT15 and ZT21 – ZT3, activity levels 
were halfway between those extremes in both groups. Locomotion in mice fed HFDal 
during ZT3 – ZT9, ZT9 – ZT15 and ZT21 – ZT3 was similar compared with mice fed 
LFDal during their respective periods. Notably, mice fed HFDal showed decreased 
locomotion relative to LFDal exclusively during ZT15 – ZT21 (P < 0.001). TRF9–15 
mice, which received HFD only during their relative leptin sensitive phase, showed the 
same circadian rhythm of locomotor activity compared with both LFDal and HFDal 
groups, with increased levels of activity solely during ZT9 – ZT15 compared with the 
respective interval in mice on HFDal (P < 0.001). In contrast, TRF21–3 mice, which 
received HFD exclusively during their relative leptin insensitive phase, showed a loss 
of the rhythmic pattern in locomotion with similar activity levels during ZT9 – ZT15, 
ZT15 – ZT21 and ZT21 – ZT3. Both TRF3–9 and TRF15–21 mice still revealed 
rhythmic variations in locomotion, even though less pronounced compared with LFDal, 
HFDal and TRF9–15 mice (Fig. 4, B). 
Summated over 24 hours, locomotion was 194.94 ± 18.30 m in LFDal, 137.09 ± 4.70 m 
in HFDal, 176.66 ± 13.86 m in TRF3–9, 179.57 ± 21.02 m in TRF9–15, 177.09 ± 12.17 
m in TRF15–21 and 169.58 ± 7.45 m in TRF21–3 mice (Suppl. Figure 2, B). One-way 
ANOVA revealed no significant differences between any of the groups, although 
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HFDal caused a trend towards a significant reduction of locomotion compared with 
LFDal feeding (P = 0.060). 
 
TRF21–3 mice lose their daily rhythm of VO2 
Next, we investigated whether the alterations in feeding and locomotor activity patterns 
are correlated with differences in average metabolic rate (VO2), defined by ml of 
oxygen consumption per minute. VO2 during the intervals ZT3 – ZT9, ZT9 – ZT15, 
ZT15 – ZT21 and ZT21 – ZT3 was 1.07 ± 0.03 ml O2/min, 1.30 ± 0.02 ml O2/min, 1.62 
± 0.04 ml O2/min, 1.30 ± 0.05 ml O2/min in LFDal mice, 1.24 ± 0.03 ml O2/min, 1.42 ± 
0.03 ml O2/min, 1.55 ± 0.03 ml O2/min, 1.42 ± 0.02 ml O2/min in HFDal, 1.20 ± 0.02 
ml O2/min, 1.39 ± 0.03 ml O2/min, 1.37 ± 0.02 ml O2/min, 1.26 ± 0.02 ml O2/min in 
TRF3–9, 1.00 ± 0.02 ml O2/min, 1.37 ± 0.02 ml O2/min, 1.41 ± 0.03 ml O2/min, 1.17 ± 
0.03 ml O2/min in TRF9–15, 1.20 ± 0.02 ml O2/min, 1.32 ± 0.03 ml O2/min, 1.56 ± 
0.02 ml O2/min, 1.42 ± 0.03 ml O2/min in TRF15–21 and 1.17 ± 0.03 ml O2/min, 1.29 
± 0.03 ml O2/min, 1.25 ± 0.05 ml O2/min, 1.41 ± 0.05 ml O2/min in TRF21–3 mice, 
respectively. Two-way ANOVA revealed significant effects of both time of food access 
and the period of day, as well as a significant interaction between both factors 
(P < 0.001, each; Suppl. Fig. 3, A). Mice on LFDal as well as HFDal showed a 
prominent circadian rhythm of VO2 with lowest rates during ZT3 – ZT9 and highest 
rates during ZT15 – ZT21 (LFDal: P < 0.001; HFDal: P < 0.001), while VO2 was 
situated between those extremes during ZT9 – ZT15 and ZT21 – ZT3. Interestingly, 
VO2 was increased during ZT3 – ZT9 and ZT9 – ZT15 in HFDal- compared with 
LFDal-fed mice (P < 0.001 and P < 0.001), but similar during ZT15 – ZT21 and ZT21 
– ZT3. The circadian rhythm of VO2 found in both ad libitum fed groups was altered in 
all TRF groups. Notably, VO2 appeared to be elevated during the respective intervals 
when TRF mice had access to food. Taking this food intake-related increase in VO2 
into account, TRF9–15 mice, which had access to food during their leptin sensitive 
phase, showed a circadian rhythm that is most similar to the LFDal and HFDal groups 
with lowest VO2 during ZT3 – ZT9 and highest rates during ZT15 – ZT21 (P < 0.001). 
In contrast, TRF21–3 mice, which had access to food during their relative leptin 
insensitive phase, showed no differences in VO2 between ZT3 – ZT9, ZT9 – ZT15 and 
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ZT15 – ZT21. Here, VO2 was highest during ZT21 – ZT3, when they had access to 
food (Suppl. Fig. 3, A).  
We corrected for the influence of BW by calculating VO2 per g BW. VO2 during the 
intervals ZT3 – ZT9, ZT9 – ZT15, ZT15 – ZT21 and ZT21 – ZT3 was 0.036 ± 0.001 
ml O2/g/min, 0.044 ± 0.001 ml O2/g/min, 0.053 ± 0.001 ml O2/g/min, 0.043 ± 0.001 ml 
O2/g/min in LFDal mice, 0.034 ± 0.001 ml O2/g/min, 0.039 ± 0.001 ml O2/g/min, 0.043 
± 0.001 ml O2/g/min, 0.039 ± 0.001 ml O2/g/min in HFDal, 0.035 ± 0.001 ml O2/g/min, 
0.040 ± 0.001 ml O2/g/min, 0.040 ± 0.001 ml O2/g/min, 0.037 ± 0.001 ml O2/g/min in 
TRF3–9, 0.029 ± 0.001 ml O2/g/min, 0.039 ± 0.001 ml O2/g/min, 0.040 ± 0.001 ml 
O2/g/min, 0.034 ± 0.001 ml O2/g/min in TRF9–15, 0.035 ± 0.001 ml O2/g/min, 0.038 ± 
0.001 ml O2/g/min, 0.045 ± 0.001 ml O2/g/min, 0.041 ± 0.001 ml O2/g/min in TRF15–
21 and 0.034 ± 0.001 ml O2/g/min, 0.039 ± 0.001 ml O2/g/min, 0.037 ± 0.001 ml 
O2/g/min, 0.042 ± 0.001 ml O2/g/min in TRF21–3 mice, respectively. Two-way 
ANOVA revealed significant effects of both time of food access and the period of day, 
as well as a significant interaction between both factors (P < 0.001, each; Fig. 4, C). As 
described for the non-BW-corrected values, mice on LFDal as well as HFDal showed a 
prominent circadian rhythm of VO2 with lowest rates during ZT3 – ZT9 and highest 
rates during ZT15 – ZT21 (LFDal: P < 0.001; HFDal: P < 0.001), while VO2 was 
situated between those extremes during ZT9 – ZT15 and ZT21 – ZT3. In the ad 
libitum-fed groups, mice fed LFD had increased VO2 during ZT9 – ZT15 and ZT15 – 
ZT21 compared with mice fed HFD (P = 0.007 and P < 0.001, respectively). The here 
observed rhythm was altered in all TRF groups. TRF9–15 mice, which had access to 
food during their leptin sensitive phase, as well as TRF15–21 showed a slightly 
dampened rhythm relative to LFDal and HFDal groups, whereas TRF3–9 as well as 
TRF21–3 mice, which had access to food during their relative leptin insensitive phase, 
showed no differences during the three intervals from ZT9–ZT3 (Fig. 4, C).  
Averaged over 24 hours, VO2 was 1.32 ± 0.04 ml O2/min in LFDal, 1.41 ± 0.04 ml 
O2/min in HFDal, 1.31 ± 0.03 ml O2/min in TRF3–9, 1.24 ± 0.03 ml O2/min in TRF9–
15, 1.37 ± 0.01 ml O2/min in TRF15–21 and 1.28 ± 0.06 ml O2/min in TRF21–3 mice 
(Suppl. Figure 2, C). One-way ANOVA revealed a significantly reduced VO2 in TRF9–
15 compared with HFDal-fed mice (P = 0.034), whereas there were no differences 
amongst the other groups.  
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However, the BW-corrected VO2 over the course of 24 hours revealed a reduction in 
VO2 in TRF9–15 of about 20% per day and in TRF21–3 of about 14% per day relative 
to LFDal mice (P = 0.003, P = 0.044, respectively). BW-corrected daily VO2 was 0.044 
± 0.001 ml O2/g/min in LFDal mice, 0.039 ± 0.001 ml O2/g/min in HFDal, 
0.038 ± 0.001 ml O2/g/min in TRF3–9, 0.036 ± 0.002 ml O2/g/min in TRF9–15, 
0.040 ± 0.001 ml O2/g/min in TRF15–21 and 0.038 ± 0.02 ml O2/g/min in TRF21–3 
(Suppl. Fig. 4, A).  
 
The daily rhythm of energy expenditure is disrupted in TRF21–3 mice 
Energy expenditure (EE) during the intervals ZT3 – ZT9, ZT9 – ZT15, ZT15 – ZT21 
and ZT21 – ZT3 was 1.93 ± 0.06 kcal, 2.40 ± 0.03 kcal, 3.03 ± 0.07 kcal, 2.39 ± 0.10 
kcal in LFDal mice, 2.21 ± 0.05 kcal, 2.53 ± 0.05 kcal, 2.77 ± 0.05 kcal, 2.51 ± 0.04 
kcal in HFDal, 2.14 ± 0.03 kcal, 2.47 ± 0.05 kcal, 2.41 ± 0.04 kcal, 2.23 ± 0.04 kcal in 
TRF3–9, 1.74 ± 0.04 kcal, 2.43 ± 0.03 kcal, 2.49 ± 0.05 kcal, 2.03 ± 0.06 kcal in 
TRF9–15, 2.11 ± 0.03 kcal, 2.33 ± 0.05 kcal, 2.78 ± 0.04 kcal, 2.52 ± 0.05 kcal in 
TRF15–21 and 2.05 ± 0.07 kcal, 2.28 ± 0.05 kcal, 2.18 ± 0.09 kcal, 2.50 ± 0.09 kcal in 
TRF21–3 mice, respectively. Two-way ANOVA revealed significant effects of both 
time of food access and the period of day, as well as a significant interaction between 
both factors (P < 0.001, each; Suppl. Fig. 3, B). Similar to VO2 as described above, EE 
was of a rhythmic pattern in mice on LFDal as well as HFDal with lowest EE during 
their inactive phase from ZT3 – ZT9 and highest EE during their active phase during 
ZT15 – ZT21, while EE was situated between those extremes during ZT9 – ZT15 and 
ZT21 – ZT3. In mice on HFDal EE was increased during ZT3 – ZT9 compared with 
mice on LFDal (P = 0.004), whereas it was similar between both groups during the 
other intervals. In all TRF groups, the rhythmic pattern of EE was identical to the one 
described for VO2, with TRF9–15 showing a rhythm that was most similar to that 
observed in both ad libitum fed groups and TRF21–3 mice showing the least 
pronounced rhythm once the food intake-related increase of EE was taken into account 
(Suppl. Fig. 3, B).  
BW-corrected EE during the intervals ZT3 – ZT9, ZT9 – ZT15, ZT15 – ZT21 and 
ZT21 – ZT3 was 0.065 ± 0.002 kcal/g, 0.080 ± 0.002 kcal/g, 0.103 ± 0.003 kcal/g, 
0.080 ± 0.002 kcal/g in LFDal mice, 0.061 ± 0.001 kcal/g, 0.070 ± 0.001 kcal/g, 0.080 
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± 0.003 kcal/g, 0.070 ± 0.001 kcal/g in HFDal, 0.063 ± 0.001 kcal/g, 0.071 ± 0.001 
kcal/g, 0.072 ± 0.002 kcal/g, 0.066 ± 0.002 kcal/g in TRF3–9, 0.050 ± 0.001 kcal/g, 
0.070 ± 0.002 kcal/g, 0.074 ± 0.003 kcal/g, 0.059 ± 0.002 kcal/g in TRF9–15, 0.061 ± 
0.001 kcal/g, 0.067 ± 0.001 kcal/g, 0.081 ± 0.002 kcal/g, 0.072 ± 0.003 kcal/g in 
TRF15–21 and 0.060 ± 0.002 kcal/g, 0.068 ± 0.002 kcal/g, 0.072 ± 0.004 kcal/g, 0.074 
± 0.003 kcal/g in TRF21–3 mice, respectively. Two-way ANOVA revealed significant 
effects of both time of food access and the period of day, as well as a significant 
interaction between both factors (P < 0.001, each; Fig. 4, D). In the ad libitum-fed 
groups, mice fed LFD had increased BW-corrected EE during ZT9 – ZT15 (P < 0.001), 
ZT15 – ZT21 (P < 0.001) and ZT21 – ZT3 (P = 0.037) compared with HFDal. As 
described for the non-BW-corrected values, mice on LFDal as well as HFDal showed a 
rhythm in EE with lowest rates during ZT3 – ZT9 and highest rates during ZT15 – 
ZT21 (LFDal: P < 0.001; HFDal: P < 0.001). This rhythm was altered in all TRF 
groups. TRF9–15 mice, which had access to food during their leptin sensitive phase, as 
well as TRF15–21 showed a slight dampening in their 24-hour rhythm relative to 
LFDal and HFDal groups, whereas TRF21–3 mice, which had access to food during 
their relative leptin insensitive phase, showed no differences during the three intervals 
from ZT9–ZT3 (Fig. 4, C).  
Summed over 24 hours, total energy expenditure was 9.72 ± 0.31 kcal in LFDal, 
10.07 ± 0.26 kcal in HFDal, 9.31 ± 0.23 kcal in TRF3–9, 8.71 ± 0.23 kcal in TRF9–15, 
9.72 ± 0.11 kcal in TRF15–21 and 9.03 ± 0.44 kcal in TRF21–3 mice (Suppl. Fig. 2, 
D). As shown with VO2, there was a statistically significant reduction of EE in TRF9–
15 compared with mice on HFDal (P = 0.035), but none of the other groups revealed 
significant differences between each other.  
The BW-corrected energy expenditure summed over 24 hours was 0.33 ± 0.01 kcal/g in 
LFDal, 0.28 ± 0.01 kcal/g in HFDal, 0.27 ± 0.01 kcal/g in TRF3–9, 0.25 ± 0.01 kcal/g 
in TRF9–15, 0.28 ± 0.01 kcal/g in TRF15–21 and 0.28 ± 0.01 kcal/g in TRF21–3 mice 
(Suppl. Fig. 4, B). Thus, LFDal mice had the highest energy expenditure per day 
compared with all other groups (P < 0.019 for all groups), but there were no significant 
differences amongst the other groups. 
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TRF decreases plasma leptin levels in mice fed HFD 
We next investigated whether time-restricted access to HFD alters circulating levels of 
leptin in the blood plasma of fasted mice that were treated with vehicle. As explained 
above, samples from animals that were injected with leptin were not included in this 
experiment due to the extensively high levels of circulating leptin. One-way ANOVA 
revealed a decrease of plasma leptin concentrations in all TRF groups compared with 
HFDal feeding, approximating levels found in mice fed LFDal (HFDal vs. LFDal, 
TRF3–9, TRF9–15, TRF15–21 and TRF21–3; P < 0.001, P = 0.005, P = 0.019, 
P = 0.032 and P = 0.003, respectively; Fig. 5, A). Mice fed HFDal showed the highest 
leptin levels of 49.87 ± 9.18 ng/mL, whereas mice fed LFDal revealed the lowest levels 
of 4.24 ± 0.19 ng/mL. TRF mice showed concentrations of 13.24 ± 1.31 ng/mL for 
TRF3–9, 21.43 ± 5.52 ng/mL for TRF9–15, 23.44 ± 6.09 ng/mL for TRF15–21 and 
13.68 ± 1.84 ng/mL for TRF21–3 mice. 
 
Access to HFD from ZT21 – ZT3 increases plasma insulin levels 
We examined plasma insulin levels in fasted mice from experiment 3 that were 
challenged with either vehicle or leptin injections. Two-way ANOVA revealed a 
significant effect of time of food access (P = 0.036), but neither an effect of treatment 
nor an interaction between the two factors. On average, mice on LFDal had plasma 
insulin levels of 0.21 ± 0.01 ng/mL, mice on HFDal of 0.41 ± 0.09 ng/mL, TRF3–9 of 
0.28 ± 0.05 ng/mL, TRF9–15 of 0.41 ± 0.07 ng/mL, TRF15–21 of 0.32 ± 0.04 ng/mL 
and TRF21–3 of 0.63 ± 0.14 ng/mL (Fig. 5, B). Plasma insulin concentrations of 
TRF21–3 mice were significantly increased compared with concentrations of mice fed 
LFDal (P = 0.021), whereas none of the other TRF groups revealed a difference in 
insulin concentrations compared with LFDal and HFDal groups. 
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Discussion 
We discovered a 24-h rhythm in the number of basal pSTAT3-ir cells in the ARC of 
vehicle-treated mice on LFD that were fasted for 24 hours, indicating rhythmic 
regulation of leptin sensitivity. With 34 ± 3 pSTAT3-ir cells the level of basal pathway 
activity was highest at the beginning of the light phase at ZT0 and lowest at ZT6 with 
as little as 5 ± 1 pSTAT3-ir cells. The very low number of pSTAT3-ir cells around the 
middle of the light phase suggests a limited physiological role of leptin signalling 
during this time, whereas leptin pathway activation was significantly higher during the 
dark phase. In mice on HFD, on the other hand, this 24-h rhythm was absent, with 
consistent numbers of basal pSTAT3-ir cells throughout the 24-h cycle. Interestingly, 
HFD vs LFD feeding led to an increase in the number of pSTAT3-ir cells from ZT6 – 
ZT18, whereas there was no difference from ZT21 – ZT3. To our knowledge this is the 
first description of HFD-induced activation of pSTAT3 during certain times of the day 
as well as the first description of rhythmic variations in basal pSTAT3 in wild-type 
mice fed LFD that suggest 24-h-rhythmic alterations in leptin signal transduction. 
Other studies so far reported similar numbers of pSTAT3-ir cells in the ARC between 
wild-type mice fed LFD and HFD (23, 34). This discrepancy might be explained by the 
time of sampling which is typically performed in the early morning and this was indeed 
described for at least one of these studies (34).  
Leptin-treated mice on both LFD and HFD revealed a 24-h rhythm of leptin-induced 
pSTAT3 activation in the ARC; however, this rhythm was inversely regulated 
dependent on the diet. At ZT0 compared with all other times, the number of pSTAT3-ir 
cells was maximal in mice on LFD, but minimal in mice on HFD. Leptin-treated mice 
on HFD showed a decreased response to exogenous leptin exemplified by the number 
of pSTAT3-ir cells compared with mice on LFD only in the first half of the light and 
the second half of the dark phase. This suggests that HFD-induced leptin resistance is a 
temporary phenomenon; it is restricted to these specific times of the day. To investigate 
the behavioural response to exogenous leptin, we injected mice on LFD as well as HFD 
with leptin at either ZT0 or ZT12 and compared their subsequent caloric intake with 
vehicle-treated mice. In this experiment, mice fed LFD reduced their caloric intake only 
when injected at ZT0, the time when relative leptin sensitivity was maximal, whereas in 
mice fed HFD leptin failed to reduce food intake at both ZT0 and ZT12. This suggests 
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that in mice fed LFD the behavioural response to the hormone reflects the pattern of 
molecular leptin sensitivity with leptin eliciting its anorexigenic effects at the beginning 
of the light phase, when leptin sensitivity at a molecular level was at a maximum. HFD 
feeding, however, leads to complete resistance to exogenous leptin on a behavioural 
level.  
We discovered that in mice fed LFD a 24-h rhythm in serum leptin concentrations was 
absent, which can be mostly attributed to the 24-h fasting period preceding blood 
sampling. Intriguingly, mice fed HFD showed a profound rhythmic regulation of 
endogenous leptin concentrations with maximal concentrations during the light phase 
compared with lower levels during the dark phase. Notably, this rhythm occurred 
despite a 24-h fasting period prior to sampling and is therefore independent of food 
intake. Intriguingly, the increase in serum leptin levels coincides with the time when 
leptin sensitivity in the ARC of mice fed HFD was minimal and the nadir in circulating 
leptin levels coincides with maximal stimulation of STAT3. This finding suggests an 
inhibitory effect of leptin on pSTAT3 activation in states of DIO and reinforces the 
notion that hyperleptinemia is a crucial factor in the development of hypothalamic 
leptin resistance and obesity (35). Neither mice on LFD nor HFD showed rhythmic 
regulation of serum insulin levels, but HFD feeding led to an overall increase of insulin 
levels relative to LFD feeding. This is in accordance with other studies, showing that 
insulin secretion is upregulated to counteract elevated blood glucose levels, 
representing an ultradian regulatory rhythm reflecting food intake. Chronic HFD 
feeding is associated with an overall increase of insulin secretion, reflecting the role of 
the hormone as an adipostat (36). These elevated insulin levels eventually give rise to 
the manifestation of type 2 diabetes during DIO. Unlike insulin, we found higher serum 
glucose concentrations in mice on HFD compared with LFD during the dark phase. At 
this time, serum leptin levels were minimal in mice fed HFD suggesting that increases 
in leptin levels during the light phase may contribute to glucose uptake. This could be 
mediated by leptin facilitating insulin action. Indeed, we and others have shown that 
leptin is required for the activation of the insulin pathway (33, 37-39). 
The above-mentioned peak in leptin signal transduction at the beginning of the light 
phase observed in both vehicle- and leptin-treated mice fed LFD and the behavioural 
response to leptin at ZT0 indicates a greater anorexigenic effect of leptin with the 
beginning of the light phase. Since mice are nocturnal this may prepare the animal for 
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the inhibition of the drive to eat during the inactive (light) phase. Mice fed HFD, on the 
other hand, show a disruption of the normal 24-h rhythm of leptin signal transduction, 
which offers an explanation for the development of arrhythmic feeding as well as 
disrupted expression patterns of leptin-induced hypothalamic genes, typically 
associated with DIO (26-28). Based on these findings, we conducted a study to 
examine whether restricting the access to HFD to these intervals of varying leptin 
sensitivity affects energy metabolism and behaviour.  
We exposed mice to HFD for an interval of six hours each day, in which they had 
access to food either during their relative leptin sensitive phase (ZT9 – ZT15), their 
relative leptin insensitive phase (ZT21 – ZT3) or during one of the remaining six hours 
in-between those intervals (ZT3 – ZT9 and ZT15 – ZT21). Intriguingly, we found that 
ad libitum-fed mice on HFD showed increased caloric intake compared with ad 
libitum-fed mice on LFD exclusively during the interval from ZT21 – ZT3, when mice 
on HFD have lower numbers of leptin-induced pSTAT3-ir cells compared with mice on 
LFD. The caloric overconsumption observed in mice on HFD during this interval was 
sufficient to lead to a significant increase in overall caloric intake displayed over the 
24-hour cycle. Similar behavioural results were reported by Kohsaka et al., showing 
that even though mice on HFD consume more food during the dark (active) compared 
with the light (inactive) phase, the relative caloric intake was increased by 
approximately 20% during the light phase (28). In accordance with other studies, all 
TRF groups consumed fewer calories over 24 hours and had reduced BW compared to 
ad libitum fed mice on HFD (40). Additionally, TRF of HFD led to a reduction of 
plasma leptin levels in all TRF groups. Since circulating leptin levels are proportional 
to adipose tissue mass (41), this suggests that the reduction of BW may be due to a 
reduction of adipose tissue mass. Indeed, a reduction of body weight due to loss of fat 
mass has been shown for mice on a TRF protocol (40). Despite the similar reduction of 
BW, we saw differences in other metabolic parameters between the different TRF 
groups. The ad libitum fed mice on LFD and HFD showed a clear rhythm of locomotor 
activity, average metabolic rate and energy expenditure, with lowest levels during their 
inactive phase and highest levels during their active phase. However, HFD feeding 
caused a dampening of these daily rhythms. For instance, locomotor activity in mice 
fed HFD was lower during their active phase relative to mice fed LFD. This effect has 
been demonstrated previously for mice fed HFD compared with control chow diet. 
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There, a non-significant but consistent increase in locomotion during the light phase 
relative to the dark phase has been reported for mice fed HFD (28). Interestingly, all 
metabolic parameters analysed in the current study were reduced by HFD compared 
with LFD feeding only when access to HFD was limited to specific intervals. For 
example, mice with access to HFD exclusively during their leptin sensitive interval 
from ZT9 – ZT15 maintained their rhythm of locomotor activity and showed the most 
robust rhythm of average metabolic rate and energy expenditure amongst all TRF 
groups when compared with ad libitum fed mice on LFD and HFD. Mice with access to 
HFD exclusively during their leptin resistant interval from ZT21 – ZT3 on the other 
hand experienced a disruption of the 24-h rhythms of locomotor activity as well as both 
average metabolic rate and energy expenditure. Furthermore, those mice had higher 
plasma insulin concentration compared with mice on LFD, indicating an impairment of 
insulin signalling that may result in the development of type 2 diabetes. Although all 
TRF groups had the same duration of food access and similar caloric intake, mice that 
received HFD during their relative leptin sensitive interval showed ameliorated 
parameters of metabolic health compared with mice that received HFD during their 
leptin insensitive interval, which showed evidence for impaired metabolic health. 
In conclusion, these data show that leptin sensitivity is controlled by a 24-h rhythm in 
wild-type mice and that DIO disrupts this rhythm, causing impaired regulation of 
energy metabolism. Furthermore, we provide strong evidence that HFD-induced leptin 
resistance is a temporary phenomenon and occurs only at specific intervals during the 
24-h cycle. These intervals seem to be decisive for the detrimental effects of HFD on 
metabolic health. 
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Figure legends 
Figure 1: Experiments 1 and 2. A) Representative coronal brain sections with highest 
and lowest pSTAT3-ir cell numbers for mice fed LFD or HFD and treated with i.p. 
vehicle or leptin and B) quantified pSTAT3-immunoreactive cells in the ARC of mice 
at the respective time points, representing the circadian rhythm of hypothalamic leptin 
sensitivity. Rhythmicity is represented by a fourth order polynomial nonlinear 
regression curve. C) Leptin-induced reduction in caloric intake after injections at ZT0 
and ZT12 after 4 hours and D) after 24 hours relative to vehicle-treated mice with the 
same dietary background (= baseline). *, P ≤ .05; **, P ≤ .01; ***, P ≤ .001 reveal 
significance between vehicle- and leptin-treated mice with the same dietary 
background. 
Figure 2: Experiment 1. 24-hour rhythms of circulating metabolic markers in mice fed 
LFD or HFD and treated with i.p. vehicle or leptin. A) serum leptin concentrations, B) 
serum insulin concentrations and C) serum glucose concentrations. Rhythmicity is 
represented by a fourth order polynomial nonlinear regression curve. *, P ≤ .05; **, 
P ≤ .01; ***, P ≤ .001 reveal significance between mice fed LFD and mice fed HFD, ] 
indicates significance at all time points. 
Figure 3: Experiment 3. Body weight trajectory of mice fed LFD and HFD ad libitum 
and TRF mice throughout the experiment. *, P ≤ .05 reveals significance between mice 
fed LFD ad libitum and HFD ad libitum; #, P ≤ .05 between LFD ad libitum and all 
TRF groups; %, P ≤ .05 between HFD ad libitum and TRF3–9, TRF15–21 and TRF21–
3; $, P ≤ .05 between HFD ad libitum and all TRF groups. 
Figure 4: Experiment 3. Metabolic measurements in mice fed LFD and HFD ad 
libitum and TRF mice binned into 6-hour intervals. A) Caloric intake, B) locomotor 
activity, C) oxygen consumption per g body weight and D) energy expenditure per g 
body weight. Statistical information shown with A, B, C, D depicts comparisons within 
each TRF group only, while comparisons between mice fed LFD ad libitum and HFD 
ad libitum are depicted by asterisk (*).*, P ≤ .05; **, P ≤ .01; ***, P ≤ .001. 
Figure 5: Experiment 3. Circulating metabolic markers in mice fed LFD and HFD ad 
libitum and TRF mice. A. Plasma leptin concentrations and B. plasma insulin 
concentrations. *, P ≤ .05. 
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Supplementary figure legends 
Suppl. Figure 1: Experimental designs of this study. A. Experiment 1. Mice received 
low fat-diet (LFD) or high fat-diet (HFD) for four weeks. They were then fasted for 24 
hours before being injected with either leptin or vehicle prior to perfusions. Mice were 
perfused at ZT0, ZT3, ZT6, ZT9, ZT12, ZT15, ZT18 or ZT21 (n = 4). Blood was 
collected to analyse circulating metabolic markers and immunohistochemistry was 
performed to assess the number of pSTAT3 (Tyr705)-ir cells at each time point. B. 
Experiment 2. Mice fed LFD and HFD were fasted for 24 hours and received a single 
ip injection of either leptin or vehicle at either ZT0 or ZT12. Mice were re-fed after 
injections and food intake as well as body weight change were monitored for 24 hours 
(n = 6–10). C. Experiment 3. Two groups of mice had ad libitum access to either LFD 
or HFD throughout the entire experiment, whereas four other groups had time-
restricted access to HFD for six hours each day, either from ZT3 – ZT9, ZT9 – ZT15, 
ZT15 – ZT21 or ZT21 – ZT3. Metabolic parameters were recorded using metabolic 
cages (n = 8). At the end of the experiment mice were fasted for 18 hours followed by 
i.p. injections of either leptin or vehicle prior to perfusions. Blood was collected to 
analyse circulating metabolic markers (n = 4). 
Suppl. Figure 2: Experiment 3. Metabolic measurements in mice fed LFD and HFD ad 
libitum and TRF mice summed over 24 hours. A) Caloric intake, B) locomotor activity, 
C) oxygen consumption and D) energy expenditure.  
Suppl. Figure 3: Experiment 3. Metabolic measurements in mice fed LFD and HFD ad 
libitum and TRF mice binned into 6-hour intervals. A) Oxygen consumption and B) 
energy expenditure. Statistical information shown with A, B, C, D depicts comparisons 
within each TRF group only, while comparisons between mice fed LFD ad libitum and 
HFD ad libitum are depicted by asterisk (*). *, P ≤ .05; **, P ≤ .01; ***, P ≤ .001.  
Suppl. Figure 4: Experiment 3. Body weight-corrected metabolic measurements in 
mice fed LFD and HFD ad libitum and TRF mice summed over 24 hours. A) Oxygen 
consumption per g body weight and B) energy expenditure per g body weight. 
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Abstract 
Metabolic syndrome and Alzheimer´s disease are two major health issues of our 
modern society causing an extraordinary financial burden for the world´s healthcare 
systems. In past decades a tight link between the pathologies of obesity and type 2 
diabetes and more recently between type 2 diabetes and Alzheimer’s disease was 
discovered. This review focuses on central insulin resistance, altered glycogen synthase 
kinase 3β signalling and central inflammation as common features of the three 
metabolic disorders and how pathological changes in one disease can contribute to the 
development of another.  Furthermore, we discuss the role of circadian disruptions in 
the development and progress of metabolic derangements and vice versa. Based on the 
shared features, combined therapeutic interventions will be discussed briefly.  
 
Metabolic Disorders and the Circadian Clock 
Since 1975, the worldwide prevalence of obesity has nearly trebled, accompanied by a 
dramatic increase of type 2 diabetes (T2D), which is predicted to affect 629 million 
people by 2045 [1, 2]. A large body of evidence links diet-induced obesity (DIO) to the 
development of other metabolic diseases such as T2D and Alzheimer’s disease (AD). 
Over the last decades, these disorders became more prevalent, causing a high financial 
burden for health systems and impacting quality of life. More recently, the essential 
role of the brain in the pathogenesis of these metabolic diseases has been highlighted. 
Common hallmarks of DIO, T2D and AD are central insulin resistance, altered 
glycogen synthase kinase 3β (GSK3β) (see Glossary) signalling as well as central 
inflammation. In this review, we discuss the shared molecular derangements that 
underlie these pathologies and focus on the connection between energy metabolism and 
circadian rhythms. In our modern society, these internal timekeeping systems become 
disrupted due to lifestyle changes and technological advances, including social jetlag, 
transmeridian travel, night shift work and constant exposure to bright artificial light 
sources. Here, we describe how circadian disruptions are associated with the 
development of metabolic derangements in both rodents and humans, as well as the 
efficacy of fasting regimens, such as time-restricted feeding (TRF), as a therapeutic 
intervention to reinstate metabolic health. Finally, we highlight future challenges and 
open questions in this field of research. 
153 
 
Obesity, Type 2 Diabetes and Alzheimer’s Disease: Three Distinct Diseases With 
Similar Aetiology? 
a) Neuroendocrine Pathways in the Regulation of Energy Homeostasis 
In both rodents and humans, DIO is characterised by a marked increase in circulating 
leptin levels, which are proportional to the amount of white adipose tissue. Although 
there is some evidence for ongoing leptin activity in obesity, in that a leptin antagonist 
can increase food intake and body weight in DIO mice [3], in common forms of obesity 
in humans and mice hyperleptinemia as well as administration of exogenous leptin are 
ineffective to properly mediate the hormone’s catabolic and anorexigenic effects in the 
hypothalamic arcuate nucleus (ARC), a key brain region for the regulation of energy 
homeostasis. This phenomenon was termed central leptin resistance. 
Furthermore, low grade systemic and central inflammation are associated with obesity 
[4] and increased activity of pro-inflammatory pathways in the hypothalamus has been 
linked to the development of DIO [5, 6]. By central inhibition of the inhibitor of 
nuclear factor-κB kinase β (IKKβ)/nuclear factor-κ-light-chain-enhancer of B-cells 
(NF-κB) pathway, the involvement of this pro-inflammatory pathway in the 
development of hypothalamic leptin resistance during DIO was demonstrated in mice 
[5]. A possible link between both pathways is the suppressor of cytokine signalling 3 
(SOCS3), which is a potent inhibitor of leptin signalling as well as a prominent target 
of the NF-κB signalling cascade [7]. In line with this, we showed that gene-therapeutic 
inhibition of IKKβ/NF-κB signalling in the ARC led to reduced socs3 gene expression 
[5]. Although this finding suggests that central inflammation might be a causative 
factor in the development of leptin resistance further research is required to identify the 
origin of leptin resistance. 
The occurrence of T2D correlates strongly with obesity [8]. Leptin resistance during 
DIO, a lack leptin secretion in leptin deficient patients or mice (Lepob/ob mouse) or 
mutations in the receptor (Lepdb/db mouse) is accompanied by hyperglycaemia and 
hyperinsulinemia. In certain cases leptin can be used as a replacement therapy for 
insulin and leptin is more potent at regulating glucose homeostasis than at regulating 
body weight [9]. In a leptin deficient patient it could be demonstrated that leptin 
replacement re-established insulin function in the hypothalamus [10]. Collectively, 
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these findings provide evidence that functional leptin action is crucial for functional 
insulin signalling.  
Molecularly, leptin administration leads to elevated activation of insulin receptor 
substrate 1 (IRS1) and we could show that it alters phosphorylation of IRS1 at Ser612 
and Ser307 [11], resulting in activation of the phosphoinositide 3-kinases (PI3K) - 
protein kinase B (AKT) pathway. Interestingly, pharmacological inhibition of 
hypothalamic GSK3β was shown to have similar effects on the activation of 
intracellular PI3K-AKT signalling [12]. GSK3β is a key enzyme of the WNT pathway, 
which was recently shown to play an important role in the neuroendocrine control of 
energy metabolism [13-15]. Canonical WNT signal transduction leads to the 
inactivation of GSK3β [16]. Leptin injections in rodents were indeed shown to activate 
the WNT pathway and inhibit GSK3β in leptin-deficient obese mice [14, 17]. GSK3β is 
a potent inhibitor of insulin signal transduction. Therefore, the inhibition of GSK3β by 
leptin possibly via the WNT pathway might be the explanation for leptin-induced 
sensitisation of insulin signalling. The disruption of insulin signalling in the brain, 
which is essential for the regulation of glucose homeostasis, leads to central insulin 
resistance and ultimately results in the development of T2D [18]. T2D is characterized 
by chronically elevated blood glucose concentrations, attenuated insulin sensitivity and 
hyperinsulinemia in the early stages, leading to the death of pancreatic β-cells during 
the manifestation of the disease [19]. Common complications in many patients 
suffering from T2D involve neuropathy due to pathologically elevated blood glucose as 
well as neurodegeneration. In this regard, midlife obesity as well as pathological 
changes in the brain, such as central insulin resistance and central inflammation, moved 
into the focus of AD research as risk factors for the development of sporadic AD (90% 
or more cases of AD). 
 
b) Neuroendocrine Disruptions in the Development of Alzheimer’s Disease 
AD is the most common cause of dementia. Underlying the pathology of AD are the 
progressive loss of synapses and neuronal death, resulting in cognitive decline and 
memory loss. Extracellular amyloid plaques (Aβ), caused by alternative severing of the 
amyloid precursor protein (APP) by the enzymes β-secretase 1 (BACE1) and γ-
secretase, as well as intraneuronal neurofibrillary tangles (NFTs) consisting of hyper-
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phosphorylated and aggregated tau protein, are the two traditional hallmarks of this 
disease [20]. 
Leptin was shown to exhibit neuroprotective and neurotrophic properties in different 
AD mouse models. In primary neuronal cultures as well as in APP/PS1 mice leptin was 
able to reduce tau phosphorylation and improve Aβ related pathologies [21, 22]. 
Additionally, subcutaneous leptin supplementation for 8 weeks reduced total brain Aβ 
in a transgenic mouse model of AD [23]. In line with deteriorated leptin signal 
transduction in DIO, impaired learning and memory performances and compromised 
working memory was demonstrated in DIO rodent models shortly after their diet was 
switched to a high-fat diet with 60% kcal from fat (HFD) [24]. High levels of 
cholesterol, present in obesity, further stimulate the alternative processing of APP and 
thus promote Aβ production and aggregation in vivo and in vitro [25].  
Another common feature of both DIO and AD is central inflammation, contributing to 
both pathologies in manifold ways [26]. In this regard, TLR-4-mediated 
PTEN/PI3K/AKT/NF-κB signalling was proposed as a link between DIO, T2D and AD 
[27, 28]. Basal NF-κB signalling can promote neuronal survival and regeneration, 
whereas sustained inflammation is associated with increased Aβ deposition and 
pathological tissue damage [27, 28]. 
Highlighting the profound role of impaired insulin signalling in the development and 
progression of AD, the term type 3 diabetes was proposed by Steen and colleagues in 
2005 [29]. Insulin receptors (IR) are expressed in many brain areas by neurons and glial 
cells with high abundance in the hypothalamus and hippocampus, where they regulate 
neuronal survival and differentiation, cytoskeletal rearrangements, neuronal plasticity, 
neurotransmitter release, gene expression, protein synthesis as well as central and 
whole-body energy homeostasis [30]. Ex vivo studies in post-mortem brains from non-
diabetic elderly with and without AD provided strong evidence for central insulin 
resistance as a prominent feature of the neurodegenerative disease. Talbot and 
colleagues stimulated post-mortem hippocampal tissue samples with physiological 
doses of insulin and revealed a reduced phosphorylation of IR, IRS1, AKT and GSK3β 
in AD patients in comparison to age-matched healthy controls, indicating a decreased 
action of the hormone [31]. Furthermore, these aberrations were correlated positively 
with Aβ load and the extent of tau phosphorylation as well as negatively with cognition 
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and memory scores of patients [31]. Additionally, decreases in gene expression and 
protein levels of insulin pathway molecules such as insulin, IR and IRS1 were observed 
[29]. Furthermore, insulin signal transduction was shown to be negatively correlated 
with aging and the pathogenesis of AD due to declining hormone levels in the CSF and 
decreased binding capacity of insulin to its receptor [32]. In line with those results, 
insulin-mediated gene expression declines with AD progression.  
Since glucose is the main energy source of the brain, the disturbances in glucose 
homeostasis caused by deteriorated central insulin signalling lead to a “starvation state” 
of the brain and thus to oxidative stress and cell death. Even though the uptake of 
glucose into the brain and into neurons is mediated by insulin-independent GLUT-3 
and GLUT-1 glucose transporters, respectively, a direct association between insulin 
resistance and a reduction in brain glucose metabolism was demonstrated by 
fluorodeoxyglucose (FDG) positron emission tomography (PET) in AD patients [33]. 
Accordingly, reduced glucose uptake in the brain measured by PET is an early and 
accurate indicator of neurodegeneration in humans and goes along with the severity of 
cognitive decline and memory impairments. Age-dependent impairments in central 
glucose homeostasis can also be observed in mouse models of AD [34]. Here, 
decreased brain glucose levels are associated with accelerated disease progression and 
GLUT-1 deficiency in endothelial cells was shown to enhance neuronal atrophy, Aβ 
plaque formation and cognitive impairments. In turn, overexpression of GLUT-1 
improved neurodegeneration and behavioural alterations in a fruit fly model of AD 
[35]. 
However, the negative effects of diminished insulin pathway activation are not only 
due to direct effects on energy metabolism, but also to changes in the regulation of 
important downstream pathways and molecules. A direct link between central insulin 
action and cognitive function was demonstrated by studies that depleted insulin 
receptors in the brain or inhibited central insulin signalling in rodents, causing profound 
cognitive impairments and AD-like molecular and biochemical changes [36, 37]. 
Insulin exhibits anti-apoptotic and anti-inflammatory properties via inhibition of 
Forkhead box O (FOXO), Bcl-2-associated death promoter (BAD), GSK3β and NF-κB 
pathways. In the case of insulin deficiency, these detrimental pathways remain 
activated, causing central inflammation and apoptosis. Moreover, the formation of 
cytotoxic Aβ plaques and of hyperphosphorylated tau aggregates is promoted on 
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different levels. On a transcriptional level, insulin is involved in the regulation of tau 
and APP expression, causing elevated levels of APP and decreased levels of tau mRNA 
in post-mortem AD brains [29]. Since functional insulin signalling is also essential for 
the trafficking of Aβ peptides from their production site in the trans-Golgi network to 
the plasma membrane, for secretion and degradation via insulin-degrading enzymes 
(IDE), disturbed insulin signalling leads to reduced Aβ clearance [38]. IDE expression 
and membrane localisation are induced by insulin stimulation in cultured astrocytes, 
where insulin facilitates the degradation of exogenous Aβ [39]. In turn, Aβ oligomers 
inhibit IRS1 through activation of the JNK pathway, decrease the binding affinity of 
insulin, reduce IR surface expression and interfere with PI3K-mediated activation of 
AKT, thereby exacerbating insulin signal transduction [40].  
Furthermore, GSK3β, which is inhibited by the insulin pathway, can phosphorylate tau 
at multiple sites, promoting the aggregation of hyper-phosphorylated tau and causing 
the formation of NFTs [41]. Eventually, this leads to a disruption of intraneuronal 
transport mechanisms, the collapse of the cytoskeletal structures, neurite retraction and 
the loss of synaptic connections.  
 
c) Antidiabetic Drugs in the Treatment of Alzheimer’s Disease 
Based on the shared features between T2D and AD, it is not surprising that antidiabetic 
drugs not only improve symptoms of T2D but also exhibit positive effects in AD 
patients. Recent studies showed promising results in rodent models and several drugs 
have been tested in clinical trials in AD patients. The most prominent treatment linking 
T2D to AD is intranasally administered insulin. In patients with mild cognitive 
impairment and AD, both acute and chronic treatment improved memory and plasma 
Aβ 40/42 ratio [42, 43]. Various other diabetes medications were tested in animal 
models of AD. Promising results were demonstrated for glucagon-like peptide-1 
receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors, metformin and 
thiazolidinediones. Systemic GLP-1RA administration in rodents and non-human 
primates, for instance, greatly improved numerous markers of memory function, 
neuronal survival, insulin signalling and inflammation. Additionally, hippocampal Aβ 
load and tau pathology were reduced [44-46]. So far, only a limited number of 
controlled studies with yet inconclusive outcomes were conducted in humans. 
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The Circadian Clock in Health and Disease 
a) Reciprocal Regulation of the Circadian Clock and Energy Metabolism 
The importance of the circadian clock in the control of whole body energy metabolism 
has been demonstrated in numerous studies over the last decade [47]. Considerable 
progress in this field has derived from lesions of the suprachiasmatic nucleus (SCN) 
and studies conducted in transgenic rodent models. For example, SCN-lesioning in 
mice leads to the absence of a circadian rhythmicity in oxygen consumption, food 
intake and activity, together with an increase in body weight and fat mass, as well as 
hepatic insulin resistance [48]. Furthermore, a missense mutation in the murine clock 
gene evokes loss of rhythmic expression of key metabolic genes in liver, skeletal 
muscle and pancreas, resulting in disruption of glucose and lipid homeostasis and an 
obese phenotype [49, 50]. Deletion of the bmal1 gene in pancreatic β-cells results in a 
diabetic phenotype with insulin deficiency, impaired glucose tolerance and 
hyperglycemia [49].  
In humans, chronic circadian misalignment has been shown to evoke symptoms of 
metabolic syndrome. Continuous shift-work and social jet lag lead to decreased insulin 
sensitivity and impaired glucose tolerance, both indicators of type 2 diabetes, as well as 
increased body mass index and symptoms of cardiovascular disease [51-53]. Mice 
exposed to chronic circadian disruptions in the form of repeated jet lags display 
reduced hypothalamic leptin sensitivity and increased body weight [54], illustrating a 
potential explanation for the eminent correlation between circadian misalignment and 
the development of obesity as described in humans and rodents.  
Circadian rhythms and clock gene expression are altered simultaneously in states of 
metabolic derailment. DIO leads to arrhythmic patterns of locomotor activity, food 
intake and clock gene expression [55, 56]. One possible explanation for the correlation 
of circadian misalignments and obesity derives from the close interplay between 
circadian and inflammatory processes. For instance cytokines and other immune 
mediators are under direct control of circadian rhythms in a broad variety of tissues [57, 
58]. CRY ablation leads to constitutive activation of the pro-inflammatory transcription 
factor NF-κB [59], whereas the heterodimerisation of CLOCK and BMAL-1 results in 
rhythmic repression of pro-inflammatory gene expression [60]. Thus, altered 
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inflammatory activity as a consequence of disrupted circadian clock rhythms might be 
a crucial factor for obesity and related co-morbidities. 
A unique involvement of the ARC in the generation of feeding rhythms has been 
demonstrated by ARC-targeted ablation of leptin sensitive neurons in rats, resulting in 
an obese phenotype as well as impaired feeding rhythms, whereas this was not the case 
in other hypothalamic areas [61]. Recently, hypothalamic AgRP/NPY neurons were 
identified to be a crucial component of an SCN-independent, food-entrained oscillator 
[62]. 
The interaction between circadian rhythmicity and energy metabolism is further 
highlighted by the finding that rhythmic genomic binding and thus transcriptional 
activity of the CLOCK/BMAL1 complex is directly regulated by the cellular energy 
status. The reduced forms of the nicotinamide adenine dinucleotide (NAD) redox 
cofactors, NAD(H) and NADP(H), enhance the DNA binding of the heterodimeric 
complex, whereas the oxidised forms, NAD(+) and NADP(+), inhibit its binding [63]. 
Furthermore, rhythmic levels of NAD(+) activate the NAD(+)-dependent protein 
deacetylase sirtuin 1 (SIRT1), which oscillates and binds CLOCK/BMAL1 
heterodimers in a circadian manner, thereby facilitating the degradation of PER2 and 
directly regulating circadian output [64]. These results demonstrate how cellular energy 
metabolism directly regulates the circadian clockwork machinery.  
 
b) Circadian Disruptions in Alzheimer’s Disease 
Beside metabolic derangements, disruptions in circadian rhythms are associated with a 
number of different diseases such as cancer, mood disorders and also AD. In fruit fly 
and rodent models, mutations or knock-outs of the clock genes bmal1 and period cause 
an accelerated aging phenotype characterised by an earlier decline in cognitive 
functions, a high rate of oxidative tissue damage and an overall shorter life-span [65, 
66].  
 
The influence of the pathology of AD on circadian rhythms was already observed 
decades ago. More recently it became clear that circadian disturbances are one of the 
earliest symptoms of AD and often they precede the onset of cognitive and motor 
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symptoms by years [67]. AD patients exhibit abnormal behavioural rhythms such as 
disturbed sleep/wake cycles and emotional imbalances. While nocturnal sleep becomes 
more and more fragmented, night-time activity and daytime sleepiness intensify in 
these patients [68, 69]. This is accompanied by the ‘sundown syndrome’ that describes 
a state of increased distress, emotional volatility and aggression in the evening. 
Physiological and biochemical processes such as hormone release patterns or anti-
oxidative defence rhythms are also changed [70]. The hormone melatonin, which is 
produced by the pineal gland, is involved in the entrainment of circadian rhythms in the 
SCN and acts as an effective free radical scavenger. In healthy individuals its release 
peaks during night-time and is suppressed by daylight. However, in AD patients and 
individuals with pre-clinical cognitive symptoms of dementia melatonin levels are 
reduced and its rhythmic oscillation is flattened [70, 71]. Further circadian 
abnormalities were detected in the core body temperature rhythm, which is delayed and 
its amplitude decreased [72]. In line with these results, post-mortem AD brains display 
a severe loss of hypothalamic tissue, including SCN cells and lowered melatonin 
receptor (MT1) levels [73]. 
Recent studies in animal models of AD indicate changes in the rhythmic expression 
patterns of the clock genes bmal1, per1 and cry1 in the brain. Although bmal1 
expression remains rhythmic in several brain regions and peripheral tissues, the 
temporal phase relationship between different areas seems to vary in comparison to 
healthy controls [69]. Additionally, the bmal1, per1 and cry1 mRNA rhythmicity is lost 
in cells of the pineal gland [74]. Regarding the pathology of AD, presilin-2 expression 
is regulated by CLOCK/BMAL1 heterodimers on a transcriptional and post-
transcriptional level in peripheral tissue [75]. Mutations in presilin-2 are associated 
with the development and Aβ pathology of familial, early-onset AD.  
A direct link between desynchronised body clocks and the Aβ pathology was recently 
shown in different cell culture and mouse models. The treatment of human skin 
fibroblast, human A172 glioma cells as well as primary cortical and hippocampal 
mouse neurons with physiological concentrations of Aβ1–42 peptides caused a 
dampening in metabolic ATP level oscillations and mitochondrial respiration rhythms 
leading to increased oxidative stress in those cells [76]. In turn, the disruption of 
circadian rhythmicity either globally or locally in the brain, achieved by the deletion of 
the clock gene bmal1 in a β-amyloidosis mouse model, exposed a direct effect of 
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central circadian disruptions on daily Aβ fluctuations in the hippocampal interstitial 
fluid, promoting Aβ plaques deposition [77]. Furthermore, a global bmal1 deletion 
resulted in elevated apoe expression in the brain parenchyma and the formation of 
fibrillary plaques [77]. 
The number of circadian abnormalities in AD and metabolic syndrome leads inevitably 
to the question whether circadian disruptions are the cause or consequence of the 
pathogenesis of AD and other neurodegenerative diseases. So far, this question cannot 
be answered easily even though there is some evidence that changes in the master clock 
deteriorate rather than initiate pathological processes in AD [78].  
 
c) Time-Restricted Feeding as a Therapeutic Intervention to Combat 
Circadian Disruptions and Metabolic Diseases 
Considering the close relationship between circadian clocks and energy homeostasis, 
behavioural interventions, such as fasting regimens, to combat the consequences of 
disrupted rhythms and metabolism appear as a favourable tool. Intriguingly, fasting and 
caloric restriction (CR) protocols increase SIRT1 activity in the hypothalamus as well 
as the periphery [79]. SIRT1 possesses potent anti-inflammatory capacities and was 
shown to improve metabolic health by its ability to interact with a variety of 
transcription factors that control energy homeostasis [79]. These findings offer an 
explanation for the beneficial effects of intermittent fasting (IF) and time-restricted 
feeding (TRF) on the detrimental consequences of DIO and related metabolic disorders. 
TRF is a form of IF wherein food intake is restricted to specified hours each day. In a 
broad variety of species from fruit flies to mice and humans, CR and TRF lead to an 
extension of lifespan, promote weight loss, prevent the development of metabolic 
diseases and/or reduce levels of pro-inflammatory cytokines [80-82]. Recent studies 
suggest that the beneficial effects of TRF strongly depend on the timing of food intake. 
Time-restricted access to HFD during the active (dark) phase of mice prevents body 
weight gain, hyperinsulinemia, glucose intolerance and systemic inflammation, 
whereas mice with access to HFD both ad libitum and exclusively during their inactive 
(light) phase develop metabolic disorders, even when caloric intake is identical [56, 
81]. Timing of food intake is such a strong circadian entrainment cue that TRF of HFD 
can restore the expression phase of the hepatic clock genes Clock and Cry1 and phase-
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advance the expression of Bmal1, Per1/2, Cry2, amongst others, compared with mice 
fed HFD ad libitum [83]. These findings suggest that TRF can be employed as a 
behavioural intervention strategy to counteract the detrimental effects of obesity and/or 
circadian disruptions.  
In line with this, circadian-focussed therapies were suggested to improve the symptoms 
of AD. These interventions, including bright light therapy and timed administration of 
melatonin resulted in inconsistent outcomes, thus their benefit is still controversial [84-
87]. Studies to determine the therapeutic effects of food as a time cue to resynchronise 
peripheral clocks are underway. Restricting meal times to certain hours of the day may 
be a promising long-term strategy to combat metabolic disease. 
 
Conclusion 
The brain plays a crucial role in the development of obesity, T2D and AD and 
disruptions of neuroendocrine signalling cascades deteriorate metabolic health. Central 
insulin resistance, altered GSK3β signalling and an increase in inflammatory processes 
are shared hallmarks of these metabolic diseases. The development of one of these 
disorders can therefore facilitate further metabolic derangement. Furthermore, the close 
regulatory relationship between energy metabolism as well as cognitive health and the 
circadian clock identifies circadian disruptions as a major risk factor in the 
development of obesity, T2D and AD. Accordingly, TRF regimens are an efficient 
therapeutic intervention to re-entrain disrupted circadian rhythms as well as metabolic 
health. 
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Appendix 
The pathogenesis of Alzheimer´s disease 
Clinically, Alzheimer´s disease (AD) is characterised by an initially mild impairment in 
memory, especially concerning word- and recent event recollection. With the 
progression of AD symptoms worsen gradually and individuals undergo a severe 
decline in cognitive abilities accompanied by neurological symptoms and behavioural 
changes. These range from difficulties to complete familiar tasks to pronounced 
disorientation and confusion about time, location and events and difficulties to speak, 
swallow or walk [88]. 
The brains of AD patients are characterised by manifold histopathological changes. The 
most prominent and most studied features are amyloid β plaques and neurofibrillary 
tangles, which have been the gold standard for diagnosis for decades [20]. Aβ peptides 
originate from the alternative processing of the amyloid precursor protein (APP) by β- 
and γ-secretases, yielding in 38-43 amino acid long, hydrophobic peptides, which are 
prone to aggregation into soluble Aβ oligomers or extracellular amyloid plaques [20]. 
The isoforms Aβ40 and Aβ42 are most common in AD, whereas Aβ42 is considered to 
have the highest hydrophobicity and toxicity. Since Aβ42 production is enhanced on 
the expenses of Aβ40 synthesis, the plasma Aβ42/Aβ40 ratio serves as a reliable 
biomarker to predict brain depositions [89]. The brain Aβ load is further increased in 
AD by a reduction in Aβ degrading enzymes, a decrease in the brain clearing rate and 
an increase in the brain uptake of soluble Aβ oligomers via multi-ligand advanced 
glycation end products receptors (RAGE). Additionally, interaction of RAGE with Aβ 
causes activation of pro-inflammatory signalling in endothelial cells of the blood-brain-
barrier, which in turn leads to endothelial apoptosis and a decrease in cerebral blood 
flow rate [90]. This effect of Aβ might contribute to the neurovascular changes 
overserved in AD. The second prominent pathological feature of the brain in AD are 
intracellular neurofibrillary tangles, consisting of abnormal phosphorylated tau protein. 
Tau phosphorylation in different sites is thereby mediated by a variety of kinases 
involved in manifold pathways such as GSK3β [20]. Hyper-phosphorylation of tau 
causes its translocation into the somatodendritic area and its aggregation, thus, causing 
the break-down of cytoskeletal structures and a disruption of intracellular transport and 
signal transduction in neurons [20]. Further pathological brain features are oxidative 
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stress due to excessive reactive oxygen species (ROS) production, a disturbed calcium 
homeostasis and alterations in neurotransmitter signalling caused by changes in 
neurotransmitter release, its clearing from the synaptic cleft and receptor expression. 
All these molecular alterations lead to a loss of synapses and finally to neuronal death 
[91]. 
Interestingly, histopathological changes in the brain precede cognitive symptoms by 
decades, emphasizing the importance for new screening methods to detect early 
molecular changes. Currently, diagnoses are made by clinical and neuropsychological 
tests. Neuroimaging in form of computer tomography (CT) and magnetic resonance 
imaging (MRI) is not sufficient to diagnose AD and can only be used to exclude other 
brain diseases such as strokes or tumours. Therefore, there is a need for new imaging 
techniques to diagnose AD. Amyloid-β positron-emission tomography (PET) imaging 
and the measurement of amyloid-β in cerebrospinal fluid can estimate the Aβ burden of 
a patient, however these techniques are very expensive and laborious [92]. Recently 
structural and functional MRI and PET studies measuring cerebral metabolism 
provided promising results even in pre-symptomatic stages of AD [33]. A new blood 
test developed by Nakamura and colleagues, measuring the APP/Aβ42 and the 
Aβ40/Aβ42 ratios in blood, still in preliminary stages, may provide a feasible and less 
expensive alternative to neuroimaging [93]. 
 
Type 3 diabetes 
Central insulin resistance can have a high impact on the histopathological changes seen 
in AD brains due to impaired glucose uptake and utilisation and altered signal 
transduction as described in the main text. Accordingly, patients suffering from T2D 
have a 50-65% higher risk to develop AD and other forms of dementia [94]. 
Emphasising the similarities between both diseases, the term type 3 diabetes was 
coined for patients suffering from both medical conditions, T2D and AD/dementia. 
Common molecular features of both diseases, beside central insulin resistance, are the 
occurrence of amyloidogenic protein aggregates in the brain and/or pancreas, increased 
pro-inflammatory signalling, severe oxidative stress, neurodegeneration, microvascular 
changes and an advanced production of glycation end-products. 
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Glossary 
 Circadian rhythms: endogenously generated rhythms with a free-running period of 
approximately 24 hours, meaning they persist under constant conditions. Circadian 
rhythms are entrainable by external cues (“Zeitgebers”). In mammals, light is the 
primary Zeitgeber, resulting in a 24-hour oscillation of physiological and 
behavioural rhythms. Time of food intake is another prominent Zeitgeber. 
 Glycogen synthase kinase 3β (GSK3β): GSK3β is a proline-directed 
serine/threonine protein kinase that is ubiquitously expressed and constitutively 
active. GSK3β activity is controlled by phosphorylation at different sites. The major 
inhibitory phosphorylation site is Ser9. This inhibitory phosphorylation is mediated 
by different kinases and pathways amongst which the insulin pathway-related kinase 
AKT is most prominent. GSK3β is also involved in the regulation of oxidative 
stress, apoptosis and gene transcription. The latter is mediated by the GSK3β 
regulation of diverse co-/transcription factors such as NF-κB, STAT3 or β-catenin. 
An over-activation of GSK3β is implicated in several diseases, including T2D, AD 
and other neurodegenerative disorders, inflammation, cancer and cardiovascular 
diseases. 
 Suprachiasmatic nucleus: Located in the anterior hypothalamus, the SCN is the 
central master pacemaker of mammalian circadian rhythms. The main role of the 
SCN is the synchronisation of peripheral circadian clocks, which are present in 
virtually all tissues, to ensure a tranquil coordination between physiological and 
behavioural processes.   
 Time-restricted feeding: A feeding regimen in which food intake is restricted to a 
specified period each day, followed by an extended period of food deprivation. TRF 
does not necessarily imply a reduction in caloric intake, but beneficial outcomes on 
metabolic health are dependent on the circadian timing of caloric intake. 
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Trends 
 On the molecular level obesity, T2D and AD share common features such as 
central insulin resistance, chronic low-grade inflammation and altered GSK3 
signalling.  
 Several antidiabetic drugs showed positive effects in AD patients underpinning 
the molecular similarities of both diseases.  
 Recent studies emphasize the circadian clock as an important player in whole 
body energy metabolism. Circadian rhythms and clock gene expression are 
altered in states of metabolic derailment and disruptions in circadian rhythms 
are associated with a number of different diseases including T2D and AD 
 Considering the close relationship between circadian clocks and energy 
homeostasis, behavioural interventions, such as fasting regimens, to combat the 
consequences of disrupted rhythms and metabolism appear as a favourable tool 
 
Outstanding Questions 
 How important is the timing of meals for the synchronization of the master 
clock and do abnormal eating patterns lead to a disruption of circadian rhythms?  
 Are neuroendocrine pathways, which control energy metabolism, regulated in a 
circadian manner in the brain? 
 Are central insulin resistance, altered GSK3 signalling and chronic low-grade 
inflammation accompanying symptoms of a disrupted clock?   
 Are circadian disruptions the cause or consequence of the pathogenesis of AD 
and other neurodegenerative diseases? Recent evidence suggests that circadian 
disruptions deteriorate rather than initiate pathological processes in AD but little 
is known about the underlying mechanisms. 
 Can IF/TRF restore a misalignment of the circadian clock and thereby 
alleviate/reverse metabolic derangements and what are the molecular 
mechanisms?  
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Figure 1. Insulin and leptin signalling in the brain. Insulin, secreted by pancreatic β-
cells, crosses the blood brain barrier and binds to IR expressed by neurons. Upon 
binding of insulin to IR its intrinsic tyrosine kinase domain phosphorylates IRS1. 
Activated IRS1 phosphorylates PI3K leading to downstream activation of AKT. 
Activated AKT exhibits pleiotropic effects, most importantly controlling FOXO and 
GSK3β thereby regulating key processes such as cell survival, proliferation and 
metabolic adaptions. The adipokine leptin controls energy homeostasis and body 
weight primarily by targeting orexigenic as well as anorexigenic neurons in the 
hypothalamus. Binding of leptin to LepRb leads to an activation of JAK2 resulting in a 
phosphorylation of the three intracellular receptor tyrosine residues Tyr985, Tyr1077 and 
Tyr1138. The phosphorylation of Tyr1138 causes the recruitment of STAT3. STAT3 is 
subsequently phosphorylated by JAK2 at the phosphorylation site Tyr705, which leads 
to homodimerization and nuclear translocation of STAT3. In the nucleus, STAT3 acts 
as a transcription factor and induces target gene expression, including SOCS3. SOCS3 
initiates a negative feedback loop inhibiting JAK2 activation thereby decreasing leptin 
action. In addition to its fundamental effects on body weight via the JAK2/STAT3 
pathway, leptin also inactivates GSK3β, linking leptin signalling to various metabolic 
processes. Glycogen synthase kinase 3β (GSK3β), insulin receptor (IR), insulin 
receptor substrate 1 (IRS1), Janus kinase 2 (JAK2), phosphoinositide 3-kinases (PI3K), 
protein kinase B (AKT), signal transducer and activator of transcription 3 (STAT3), 
suppressor of cytokine signalling 3 (SOCS3). 
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Figure 2. Regulation of cell autonomous circadian rhythms. The master pacemaker 
of circadian rhythm is the central circadian clock that resides in the SCN of the 
hypothalamus and synchronizes peripheral clocks in the body. On the molecular level, 
circadian rhythms are driven by a cell autonomous transcriptional translational 
feedback loop that occurs in virtually all cells. The positive arm of the mammalian 
circadian clock consists of the clock proteins CLOCK and BMAL1, which 
heterodimerize and bind to E-box regions in promotors of the clock genes cry 1/2 and 
per 1-3 initiating their transcription. Additionally, CLOCK/BMAL1 induces rev-erbα 
and rorα/β gene expression. The negative arm is represented by CRY, PER and REV-
ERBα. CRY/PER heterodimers, translocate into the nucleus and repress the binding of 
the CLOCK/BMAL1 complex to target promotor regions thereby inhibiting their own 
transcription. Furthermore, REV-ERBα negatively regulates bmal1 expression, while 
RORα/β induces its expression. CLOCK/BMAL1 is directly regulated by NAD(H) and 
NADP(H), which enhance the transcriptional activity of the complex. Their oxidised 
forms, NAD(+) and NADP(+), inhibit CLOCK/BMAL1 binding to the DNA. 
Furthermore, SIRT1 oscillates and binds CLOCK/BMAL1 heterodimers in a circadian 
manner, facilitating the degradation of PER2 and directly regulating circadian rhythms. 
Another regulatory mechanism for this rhythmic machinery is represented by the 
cytosolic enzymes CK1 and GSK3β, which label CRY and PER for degradation. This 
transcriptional translational feedback loop is repeated approximately once every 24 
hours. Brain and muscle ARNT-like protein 1 (BMAL1), casein kinases (CK1), 
circadian locomotor output cycles kaput (CLOCK), cryptochrome (CRY), glycogen 
synthase kinase 3β (GSK3β), nicotinamide adenine dinucleotide redox cofactors 
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(NAD/NADP), period (PER), reverse erythoblastoma (REV-ERB), retinoid orphan 
receptor (ROR), suprachiasmatic nucleus (SCN), sirtuin 1 (SIRT1). 
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Figure 3 (Key Figure). Obesity, type 2 diabetes and Alzheimer´s disease are tightly 
linked disorders with obesity being a major risk factor for the development of T2D and 
AD. Impaired glucose homeostasis in T2D also increases the risk for the development 
of sporadic AD. Pathological changes such as insulin resistance, altered GSK3β 
signalling and central inflammation are common features of all three diseases. Recent 
research could also provide evidence, that a disruption of the circadian clock can 
further promote the progression of all three disorders. Alzheimer´s disease (AD), 
glycogen synthase kinase 3β (GSK3β), type 2 diabetes (T2D). 
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